{
 "cells": [
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Data Scraping through Tweepy"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [
    {
     "ename": "KeyboardInterrupt",
     "evalue": "",
     "output_type": "error",
     "traceback": [
      "\u001b[0;31m---------------------------------------------------------------------------\u001b[0m",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m                         Traceback (most recent call last)",
      "\u001b[0;32m<ipython-input-62-fdb11fc0c829>\u001b[0m in \u001b[0;36m<module>\u001b[0;34m\u001b[0m\n\u001b[1;32m     27\u001b[0m     \u001b[0mauth\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mset_access_token\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0maccess_token\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0maccess_token_secret\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m     28\u001b[0m     \u001b[0mstream\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mStream\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mauth\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0ml\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m---> 29\u001b[0;31m     \u001b[0mstream\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mfilter\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mtrack\u001b[0m\u001b[0;34m=\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'#AACR20'\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m",
      "\u001b[0;32m~/.local/lib/python3.7/site-packages/tweepy/streaming.py\u001b[0m in \u001b[0;36mfilter\u001b[0;34m(self, follow, track, is_async, locations, stall_warnings, languages, encoding, filter_level)\u001b[0m\n\u001b[1;32m    472\u001b[0m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mbody\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m'filter_level'\u001b[0m\u001b[0;34m]\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mfilter_level\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mencode\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mencoding\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    473\u001b[0m         \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msession\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mparams\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;34m{\u001b[0m\u001b[0;34m'delimited'\u001b[0m\u001b[0;34m:\u001b[0m \u001b[0;34m'length'\u001b[0m\u001b[0;34m}\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 474\u001b[0;31m         \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_start\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mis_async\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    475\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    476\u001b[0m     def sitestream(self, follow, stall_warnings=False,\n",
      "\u001b[0;32m~/.local/lib/python3.7/site-packages/tweepy/streaming.py\u001b[0m in \u001b[0;36m_start\u001b[0;34m(self, is_async)\u001b[0m\n\u001b[1;32m    387\u001b[0m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_thread\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mstart\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    388\u001b[0m         \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 389\u001b[0;31m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_run\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    390\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    391\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0mon_closed\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mresp\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/.local/lib/python3.7/site-packages/tweepy/streaming.py\u001b[0m in \u001b[0;36m_run\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    287\u001b[0m                     \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msnooze_time\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0msnooze_time_step\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    288\u001b[0m                     \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mlistener\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mon_connect\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 289\u001b[0;31m                     \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_read_loop\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mresp\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    290\u001b[0m             \u001b[0;32mexcept\u001b[0m \u001b[0;34m(\u001b[0m\u001b[0mTimeout\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mssl\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mSSLError\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mas\u001b[0m \u001b[0mexc\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    291\u001b[0m                 \u001b[0;31m# This is still necessary, as a SSLError can actually be\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/.local/lib/python3.7/site-packages/tweepy/streaming.py\u001b[0m in \u001b[0;36m_read_loop\u001b[0;34m(self, resp)\u001b[0m\n\u001b[1;32m    337\u001b[0m             \u001b[0mlength\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;36m0\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    338\u001b[0m             \u001b[0;32mwhile\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0mresp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mraw\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mclosed\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 339\u001b[0;31m                 \u001b[0mline\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mbuf\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mread_line\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    340\u001b[0m                 \u001b[0mstripped_line\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mline\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mstrip\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;32mif\u001b[0m \u001b[0mline\u001b[0m \u001b[0;32melse\u001b[0m \u001b[0mline\u001b[0m \u001b[0;31m# line is sometimes None so we need to check here\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    341\u001b[0m                 \u001b[0;32mif\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0mstripped_line\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m~/.local/lib/python3.7/site-packages/tweepy/streaming.py\u001b[0m in \u001b[0;36mread_line\u001b[0;34m(self, sep)\u001b[0m\n\u001b[1;32m    198\u001b[0m             \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    199\u001b[0m                 \u001b[0mstart\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mlen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_buffer\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 200\u001b[0;31m             \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_buffer\u001b[0m \u001b[0;34m+=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_stream\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mread\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_chunk_size\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    201\u001b[0m         \u001b[0;32mreturn\u001b[0m \u001b[0msix\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mb\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m''\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    202\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/usr/lib/python3/dist-packages/urllib3/response.py\u001b[0m in \u001b[0;36mread\u001b[0;34m(self, amt, decode_content, cache_content)\u001b[0m\n\u001b[1;32m    442\u001b[0m             \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    443\u001b[0m                 \u001b[0mcache_content\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;32mFalse\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 444\u001b[0;31m                 \u001b[0mdata\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_fp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mread\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mamt\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    445\u001b[0m                 \u001b[0;32mif\u001b[0m \u001b[0mamt\u001b[0m \u001b[0;34m!=\u001b[0m \u001b[0;36m0\u001b[0m \u001b[0;32mand\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0mdata\u001b[0m\u001b[0;34m:\u001b[0m  \u001b[0;31m# Platform-specific: Buggy versions of Python.\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    446\u001b[0m                     \u001b[0;31m# Close the connection when no data is returned\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/usr/lib/python3.7/http/client.py\u001b[0m in \u001b[0;36mread\u001b[0;34m(self, amt)\u001b[0m\n\u001b[1;32m    455\u001b[0m             \u001b[0;31m# Amount is given, implement using readinto\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    456\u001b[0m             \u001b[0mb\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mbytearray\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mamt\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 457\u001b[0;31m             \u001b[0mn\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mreadinto\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mb\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    458\u001b[0m             \u001b[0;32mreturn\u001b[0m \u001b[0mmemoryview\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mb\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m[\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0mn\u001b[0m\u001b[0;34m]\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mtobytes\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    459\u001b[0m         \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/usr/lib/python3.7/http/client.py\u001b[0m in \u001b[0;36mreadinto\u001b[0;34m(self, b)\u001b[0m\n\u001b[1;32m    489\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    490\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mchunked\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 491\u001b[0;31m             \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_readinto_chunked\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mb\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    492\u001b[0m \u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    493\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mlength\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/usr/lib/python3.7/http/client.py\u001b[0m in \u001b[0;36m_readinto_chunked\u001b[0;34m(self, b)\u001b[0m\n\u001b[1;32m    584\u001b[0m         \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    585\u001b[0m             \u001b[0;32mwhile\u001b[0m \u001b[0;32mTrue\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 586\u001b[0;31m                 \u001b[0mchunk_left\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_get_chunk_left\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    587\u001b[0m                 \u001b[0;32mif\u001b[0m \u001b[0mchunk_left\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    588\u001b[0m                     \u001b[0;32mreturn\u001b[0m \u001b[0mtotal_bytes\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/usr/lib/python3.7/http/client.py\u001b[0m in \u001b[0;36m_get_chunk_left\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    552\u001b[0m                 \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_safe_read\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;36m2\u001b[0m\u001b[0;34m)\u001b[0m  \u001b[0;31m# toss the CRLF at the end of the chunk\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    553\u001b[0m             \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 554\u001b[0;31m                 \u001b[0mchunk_left\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_read_next_chunk_size\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    555\u001b[0m             \u001b[0;32mexcept\u001b[0m \u001b[0mValueError\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    556\u001b[0m                 \u001b[0;32mraise\u001b[0m \u001b[0mIncompleteRead\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34mb''\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/usr/lib/python3.7/http/client.py\u001b[0m in \u001b[0;36m_read_next_chunk_size\u001b[0;34m(self)\u001b[0m\n\u001b[1;32m    512\u001b[0m     \u001b[0;32mdef\u001b[0m \u001b[0m_read_next_chunk_size\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mself\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    513\u001b[0m         \u001b[0;31m# Read the next chunk size from the file\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 514\u001b[0;31m         \u001b[0mline\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mfp\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mreadline\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0m_MAXLINE\u001b[0m \u001b[0;34m+\u001b[0m \u001b[0;36m1\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    515\u001b[0m         \u001b[0;32mif\u001b[0m \u001b[0mlen\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mline\u001b[0m\u001b[0;34m)\u001b[0m \u001b[0;34m>\u001b[0m \u001b[0m_MAXLINE\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    516\u001b[0m             \u001b[0;32mraise\u001b[0m \u001b[0mLineTooLong\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m\"chunk size\"\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/usr/lib/python3.7/socket.py\u001b[0m in \u001b[0;36mreadinto\u001b[0;34m(self, b)\u001b[0m\n\u001b[1;32m    587\u001b[0m         \u001b[0;32mwhile\u001b[0m \u001b[0;32mTrue\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    588\u001b[0m             \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 589\u001b[0;31m                 \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_sock\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mrecv_into\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mb\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    590\u001b[0m             \u001b[0;32mexcept\u001b[0m \u001b[0mtimeout\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    591\u001b[0m                 \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_timeout_occurred\u001b[0m \u001b[0;34m=\u001b[0m \u001b[0;32mTrue\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/usr/lib/python3.7/ssl.py\u001b[0m in \u001b[0;36mrecv_into\u001b[0;34m(self, buffer, nbytes, flags)\u001b[0m\n\u001b[1;32m   1069\u001b[0m                   \u001b[0;34m\"non-zero flags not allowed in calls to recv_into() on %s\"\u001b[0m \u001b[0;34m%\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1070\u001b[0m                   self.__class__)\n\u001b[0;32m-> 1071\u001b[0;31m             \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mread\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mnbytes\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mbuffer\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m   1072\u001b[0m         \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m   1073\u001b[0m             \u001b[0;32mreturn\u001b[0m \u001b[0msuper\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mrecv_into\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mbuffer\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mnbytes\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mflags\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;32m/usr/lib/python3.7/ssl.py\u001b[0m in \u001b[0;36mread\u001b[0;34m(self, len, buffer)\u001b[0m\n\u001b[1;32m    927\u001b[0m         \u001b[0;32mtry\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    928\u001b[0m             \u001b[0;32mif\u001b[0m \u001b[0mbuffer\u001b[0m \u001b[0;32mis\u001b[0m \u001b[0;32mnot\u001b[0m \u001b[0;32mNone\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0;32m--> 929\u001b[0;31m                 \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_sslobj\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mread\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mlen\u001b[0m\u001b[0;34m,\u001b[0m \u001b[0mbuffer\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[0m\u001b[1;32m    930\u001b[0m             \u001b[0;32melse\u001b[0m\u001b[0;34m:\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n\u001b[1;32m    931\u001b[0m                 \u001b[0;32mreturn\u001b[0m \u001b[0mself\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0m_sslobj\u001b[0m\u001b[0;34m.\u001b[0m\u001b[0mread\u001b[0m\u001b[0;34m(\u001b[0m\u001b[0mlen\u001b[0m\u001b[0;34m)\u001b[0m\u001b[0;34m\u001b[0m\u001b[0;34m\u001b[0m\u001b[0m\n",
      "\u001b[0;31mKeyboardInterrupt\u001b[0m: "
     ]
    }
   ],
   "source": [
    "###Python scraping\n",
    "from tweepy.streaming import StreamListener\n",
    "from tweepy import OAuthHandler\n",
    "from tweepy import Stream\n",
    "\n",
    "access_token = \"yourAccesToken\"\n",
    "access_token_secret= \"access_token_secret\"\n",
    "consumer_key = \"consumer_key\"\n",
    "consumer_secret = \"consumer_s\"\n",
    "\n",
    "\n",
    "class StdOutListener(StreamListener):\n",
    "    def on_data(self, data):\n",
    "        try:\n",
    "            with open('umairBhai.json', 'a') as f:\n",
    "                f.write(data)\n",
    "                return True\n",
    "        except BaseException as e:\n",
    "            print(\"error on data: %s\" % str(e))\n",
    "        return True\n",
    "    def on_error(self, status):\n",
    "        print (status)\n",
    "\n",
    "if __name__=='__main__':\n",
    "    l = StdOutListener()\n",
    "    auth = OAuthHandler(consumer_key, consumer_secret)\n",
    "    auth.set_access_token(access_token, access_token_secret)\n",
    "    stream = Stream(auth, l)\n",
    "    stream.filter(track=['#AACR20'])"
   ]
  },
  {
   "cell_type": "markdown",
   "metadata": {},
   "source": [
    "### Converting the scraped data into the csv file"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "import json\n",
    "\n",
    "data = []\n",
    "with open('bjp.json') as f:\n",
    "    for line in f:\n",
    "        data.append(json.loads(line))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {
    "scrolled": false
   },
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'created_at': 'Tue Apr 28 19:47:18 +0000 2020',\n",
       " 'id': 1255222074144108546,\n",
       " 'id_str': '1255222074144108546',\n",
       " 'text': 'Tertiary Lymphoid Structures as biomarkers of response to immunotherapy, live now #AACR20 ! https://t.co/MTsmp8ezB4',\n",
       " 'display_text_range': [0, 91],\n",
       " 'source': '<a href=\"https://mobile.twitter.com\" rel=\"nofollow\">Twitter Web App</a>',\n",
       " 'truncated': False,\n",
       " 'in_reply_to_status_id': None,\n",
       " 'in_reply_to_status_id_str': None,\n",
       " 'in_reply_to_user_id': None,\n",
       " 'in_reply_to_user_id_str': None,\n",
       " 'in_reply_to_screen_name': None,\n",
       " 'user': {'id': 1071028411567652865,\n",
       "  'id_str': '1071028411567652865',\n",
       "  'name': 'Florent Petitprez',\n",
       "  'screen_name': 'petitprez_f',\n",
       "  'location': 'Paris, France',\n",
       "  'url': 'https://florentpetitprez.netlify.com/',\n",
       "  'description': 'Cancer genomics research scientist @programmeCIT, interested in Immuno-oncology bioinformatics.',\n",
       "  'translator_type': 'none',\n",
       "  'protected': False,\n",
       "  'verified': False,\n",
       "  'followers_count': 196,\n",
       "  'friends_count': 202,\n",
       "  'listed_count': 0,\n",
       "  'favourites_count': 151,\n",
       "  'statuses_count': 120,\n",
       "  'created_at': 'Fri Dec 07 13:07:26 +0000 2018',\n",
       "  'utc_offset': None,\n",
       "  'time_zone': None,\n",
       "  'geo_enabled': False,\n",
       "  'lang': None,\n",
       "  'contributors_enabled': False,\n",
       "  'is_translator': False,\n",
       "  'profile_background_color': '000000',\n",
       "  'profile_background_image_url': 'http://abs.twimg.com/images/themes/theme1/bg.png',\n",
       "  'profile_background_image_url_https': 'https://abs.twimg.com/images/themes/theme1/bg.png',\n",
       "  'profile_background_tile': False,\n",
       "  'profile_link_color': '1B95E0',\n",
       "  'profile_sidebar_border_color': '000000',\n",
       "  'profile_sidebar_fill_color': '000000',\n",
       "  'profile_text_color': '000000',\n",
       "  'profile_use_background_image': False,\n",
       "  'profile_image_url': 'http://pbs.twimg.com/profile_images/1072084753162084353/fUjq-Gc9_normal.jpg',\n",
       "  'profile_image_url_https': 'https://pbs.twimg.com/profile_images/1072084753162084353/fUjq-Gc9_normal.jpg',\n",
       "  'profile_banner_url': 'https://pbs.twimg.com/profile_banners/1071028411567652865/1571384249',\n",
       "  'default_profile': False,\n",
       "  'default_profile_image': False,\n",
       "  'following': None,\n",
       "  'follow_request_sent': None,\n",
       "  'notifications': None},\n",
       " 'geo': None,\n",
       " 'coordinates': None,\n",
       " 'place': None,\n",
       " 'contributors': None,\n",
       " 'is_quote_status': False,\n",
       " 'quote_count': 0,\n",
       " 'reply_count': 0,\n",
       " 'retweet_count': 0,\n",
       " 'favorite_count': 0,\n",
       " 'entities': {'hashtags': [{'text': 'AACR20', 'indices': [82, 89]}],\n",
       "  'urls': [],\n",
       "  'user_mentions': [],\n",
       "  'symbols': [],\n",
       "  'media': [{'id': 1255221932565430272,\n",
       "    'id_str': '1255221932565430272',\n",
       "    'indices': [92, 115],\n",
       "    'media_url': 'http://pbs.twimg.com/media/EWtxsnzXgAAY-6y.jpg',\n",
       "    'media_url_https': 'https://pbs.twimg.com/media/EWtxsnzXgAAY-6y.jpg',\n",
       "    'url': 'https://t.co/MTsmp8ezB4',\n",
       "    'display_url': 'pic.twitter.com/MTsmp8ezB4',\n",
       "    'expanded_url': 'https://twitter.com/petitprez_f/status/1255222074144108546/photo/1',\n",
       "    'type': 'photo',\n",
       "    'sizes': {'medium': {'w': 1200, 'h': 753, 'resize': 'fit'},\n",
       "     'thumb': {'w': 150, 'h': 150, 'resize': 'crop'},\n",
       "     'large': {'w': 1335, 'h': 838, 'resize': 'fit'},\n",
       "     'small': {'w': 680, 'h': 427, 'resize': 'fit'}}}]},\n",
       " 'extended_entities': {'media': [{'id': 1255221932565430272,\n",
       "    'id_str': '1255221932565430272',\n",
       "    'indices': [92, 115],\n",
       "    'media_url': 'http://pbs.twimg.com/media/EWtxsnzXgAAY-6y.jpg',\n",
       "    'media_url_https': 'https://pbs.twimg.com/media/EWtxsnzXgAAY-6y.jpg',\n",
       "    'url': 'https://t.co/MTsmp8ezB4',\n",
       "    'display_url': 'pic.twitter.com/MTsmp8ezB4',\n",
       "    'expanded_url': 'https://twitter.com/petitprez_f/status/1255222074144108546/photo/1',\n",
       "    'type': 'photo',\n",
       "    'sizes': {'medium': {'w': 1200, 'h': 753, 'resize': 'fit'},\n",
       "     'thumb': {'w': 150, 'h': 150, 'resize': 'crop'},\n",
       "     'large': {'w': 1335, 'h': 838, 'resize': 'fit'},\n",
       "     'small': {'w': 680, 'h': 427, 'resize': 'fit'}}}]},\n",
       " 'favorited': False,\n",
       " 'retweeted': False,\n",
       " 'possibly_sensitive': False,\n",
       " 'filter_level': 'low',\n",
       " 'lang': 'en',\n",
       " 'timestamp_ms': '1588103238031'}"
      ]
     },
     "execution_count": 46,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "data[19]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {
    "scrolled": true
   },
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "1\n",
      "-----\n",
      "Promising research for #braincancer #coloncancer treatment! .@amritasule presented study results at #AACR20 showing #PARP and #ATR #DNA repair inhibitors together are more effective than a PARP inhibitor alone. @RanjitBindra @SmilowCancer @YaleMed @YNHH   https://t.co/XFB6b6peoz https://t.co/qfzig30WOb\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "2\n",
      "-----\n",
      "#OncoAlert #AACR20 Chemotherapy within the past 3 months correlated with more severe clinical course. I suspect risk will vary by specific regimen though. Added risk not really seen with targeted therapy / TKI or immunotherapy though numbers are small. https://t.co/TY93m1fU0r\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "3\n",
      "-----\n",
      "#AACR20 🩸🧬🧪ability to predict PFS. With the short t-1/2, of great value to consider. #LiquidBiopsies #ctDNA https://t.co/op3g36bnUr\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "4\n",
      "-----\n",
      "Live #AACR20 Tweet by @LizCancerHealth  \"Hongbing Cai, Wuhan University: People with #cancer appear to have higher risk of severe #COVID19 outcomes\" @OncoAlert 🚨\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "5\n",
      "-----\n",
      "#AACR20 💭I think integrating #ctDNA #liquidbiopsies is going to be the new paradigm shift in more efficient trial designs. If you chose 🩸🧬MRD➕subset of patients, especially for these adjuvant studies, sample size required would be a lot lower since event rate will be high📈. https://t.co/ltbTc4pISo\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "6\n",
      "-----\n",
      "#OncoAlert #AACR20 In the Liang report from @TheLancetOncol, we saw 1% of #COVID19 patients had cancer. In this Wuhan report from 3 hospitals (1/13/20-2/26/20), it was 2.2% (25% lung, 14% esophageal, 11% breast), 30% stage IV. 60/40 split male/female. 71% community acquired. https://t.co/PF7pTJn9nn\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "7\n",
      "-----\n",
      "#AACR20 💭I think integrating #ctDNA #liquidbiopsies is going to be the new paradigm shift in more efficient trial designs. If you chose 🩸🧬MRD➕subset of patients, especially for these adjuvant studies, sample size required would be a lot lower since event rate will be high📈. https://t.co/ltbTc4pISo\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "8\n",
      "-----\n",
      "It’s day two of #AACR20. Today at 520 pm ET, @theNCI’s Deputy Director for Scientific Strategy and Development, Dr. Dinah Singer will present a special session, “NCI Activities: #COVID-19 and #CancerResearch.” Be sure to tune in. https://t.co/Axx9XlL1xs https://t.co/zFQODE0ezB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "9\n",
      "-----\n",
      "Promising research for #braincancer #coloncancer treatment! .@amritasule presented study results at #AACR20 showing #PARP and #ATR #DNA repair inhibitors together are more effective than a PARP inhibitor alone. @RanjitBindra @SmilowCancer @YaleMed @YNHH   https://t.co/XFB6b6peoz https://t.co/qfzig30WOb\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "10\n",
      "-----\n",
      "@AnjaNitzscheB Saluti, you can read it here: @ADesaiMD: Missed #COVID19nCancer plenary in #AACR20 @AACR? Here’s a thread to catch up on all the fascinating global… https://t.co/U3ze6rz3G5 Share this if you think it's interesting. 🤖\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "11\n",
      "-----\n",
      "#OncoAlert #AACR20 In the Liang report from @TheLancetOncol, we saw 1% of #COVID19 patients had cancer. In this Wuhan report from 3 hospitals (1/13/20-2/26/20), it was 2.2% (25% lung, 14% esophageal, 11% breast), 30% stage IV. 60/40 split male/female. 71% community acquired. https://t.co/PF7pTJn9nn\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "12\n",
      "-----\n",
      "#AACR20 Virtual Annual Meeting program covers the latest discoveries across the spectrum of cancer research and highlights the work of the best minds in research and medicine from institutions all over the world. https://t.co/soarocUBoq\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "13\n",
      "-----\n",
      "This Duvelisib data from #AACR20 is quite interesting - maybe a future area for us to examine in IBC given the prominent role of M2-like macs in bad biology.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "14\n",
      "-----\n",
      "#rookie new student mistake - Forgot that North America has several different time zones 🕓, and that I have to factor that in when setting reminders for online conference meetings 🖥 @AACR #AACR20 @AcademicChatter\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "15\n",
      "-----\n",
      "#OncoAlert #AACR20 More mature data emerging from China. This review by Dr. Zhang at Tongji in Wuhan discusses patients with cancer and #COVID19. Interesting to contrast these with data from US, Italy, Spain, France, etc - some trends just reflect patient populations served. https://t.co/5nxOc3BYb2\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "16\n",
      "-----\n",
      "#AACR20 💭I think integrating #ctDNA #liquidbiopsies is going to be the new paradigm shift in more efficient trial designs. If you chose 🩸🧬MRD➕subset of patients, especially for these adjuvant studies, sample size required would be a lot lower since event rate will be high📈. https://t.co/ltbTc4pISo\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "17\n",
      "-----\n",
      "There was #cancer before the pandemic, there is cancer now, and there will be cancer after. Thankfully, some research continues. Progress toward off-the-shelf #CAR_T cells, from Shanghai #biotech, at #AACR20: https://t.co/YuVBfGVs5J\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "18\n",
      "-----\n",
      "#AACR20 💭I think integrating #ctDNA #liquidbiopsies is going to be the new paradigm shift in more efficient trial designs. If you chose 🩸🧬MRD➕subset of patients, especially for these adjuvant studies, sample size required would be a lot lower since event rate will be high📈. https://t.co/ltbTc4pISo\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "19\n",
      "-----\n",
      "Combining the immunotherapy drug durvalumab with chemotherapy achieved improved response in advanced #ovariancancer patients, according to a recent MD Anderson-led study, presented at #AACR20 by our @ShannonWestin:  https://t.co/NXUYjKX0oE #CancerMoonshot #endcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "20\n",
      "-----\n",
      "Tertiary Lymphoid Structures as biomarkers of response to immunotherapy, live now #AACR20 ! https://t.co/MTsmp8ezB4\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "21\n",
      "-----\n",
      "More results presented today at #AACR20:\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "22\n",
      "-----\n",
      "This Duvelisib data from #AACR20 is quite interesting - maybe a future area for us to examine in IBC given the prominent role of M2-like macs in bad biology.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "23\n",
      "-----\n",
      "#OncoAlert #AACR20 In 28 patients with cancer and #COVID19, 36% required mechanical ventilation, 29% mortality with 21% still hospitalized. For those discharged, median hospitalization 18.4 days. For those with severe events, median 7 days from COVID diagnosis to event. https://t.co/Gq4j4ivica\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "24\n",
      "-----\n",
      "Presentan resultados de ensayo clínico CIMAvax en congreso de Asociación para la Investigación del Cáncer en #US. Resultados alentadores de combinar dos inmunoterapias novedosas. @centro_cim @RoswellPark https://t.co/ZjU38wpVMz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "25\n",
      "-----\n",
      "There was #cancer before the pandemic, there is cancer now, and there will be cancer after. Thankfully, some research continues. Progress toward off-the-shelf #CAR_T cells, from Shanghai #biotech, at #AACR20: https://t.co/YuVBfGVs5J\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "26\n",
      "-----\n",
      "#OncoAlert #AACR20 In the Liang report from @TheLancetOncol, we saw 1% of #COVID19 patients had cancer. In this Wuhan report from 3 hospitals (1/13/20-2/26/20), it was 2.2% (25% lung, 14% esophageal, 11% breast), 30% stage IV. 60/40 split male/female. 71% community acquired. https://t.co/PF7pTJn9nn\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "27\n",
      "-----\n",
      "#AACR20 David Thiel from @MayoClinic presents at the Early Detection and ctDNA session results from the study investigating the @GrailBio cfDNA methylation signatures test. The manuscript can be found here in Annals of Oncology:  https://t.co/8OjSaWeURz https://t.co/cfEcY8pxVd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "28\n",
      "-----\n",
      "Amgen presents positive preclinical data for AMG-509, a bispecific antibody targeting STEAP1 and CD3 for the treatment of prostate cancer and Ewing sarcoma #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "29\n",
      "-----\n",
      "#AACR20 💭I think integrating #ctDNA #liquidbiopsies is going to be the new paradigm shift in more efficient trial designs. If you chose 🩸🧬MRD➕subset of patients, especially for these adjuvant studies, sample size required would be a lot lower since event rate will be high📈. https://t.co/ltbTc4pISo\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "30\n",
      "-----\n",
      "Great presentation by Dr. Padmanee Sharma of @MDAndersonNews @AACR #AACR20 on why PD-1 and PD-L1 inhibitors performed poorly in #mCRPC to date and what the next steps should be https://t.co/0vT59YkLKy\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "31\n",
      "-----\n",
      "Live #AACR20 Tweet by @LizCancerHealth  \"Hongbing Cai, Wuhan University: People with #cancer appear to have higher risk of severe #COVID19 outcomes\" @OncoAlert 🚨\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "32\n",
      "-----\n",
      "CONGRESS | #AACR20 | Caron A Jacobson, @DanaFarber, presents results from ZUMA-6: axi-cel + atezolizumab for refractory DLBCL. ORR was 75% with a 46% CR rate and no significant increase in incidence of AEs #lymsm https://t.co/nARISEHLLb\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "33\n",
      "-----\n",
      "In the \"green room\" (it's pretty grey...) ahead of the @AACR #AACR20 presentation on the @CancerResrch #TMB Harmonization Project. Excited to be representing the collaborative work of such a great group of partners! Don't forget to tune in! Presentation starts at 4:55pm! https://t.co/ILJMIVTej1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "34\n",
      "-----\n",
      "Our @OncoAlert 🚨Colleague @LeciaSequist 👩‍⚕️of @MassGeneralNews Live from #AACR20 Discussing The Geometry Study and Zenith20. #LCSM @LungCancer \n",
      "Edited: @weoncologists https://t.co/U9ZPHynuZA\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "35\n",
      "-----\n",
      "Dr Marina Garassino @marinagarassino presenting data from #TERAVOLT evaluating #COVID19 and lung cancer #LCSM \n",
      "Results overlapping with our own institutional experience recently spread via #SoMe #AACR20 @AACR @OncoAlert #OncoAlert @IASLC @gecp_org https://t.co/zcglqIyYow\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "36\n",
      "-----\n",
      "#OncoAlert #AACR20 Serial scans show #COVID19 related lung changes. Note the fibrosis emerging at day 25. Will long-term sequela impact respiratory function, quality of life? Will this vary by prior lung pathology, prior radiation, prior pneumonitis, etc? https://t.co/XrcRUiRe7e\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "37\n",
      "-----\n",
      "What we learned at #AACR20 Day 1: 1. You CAN get 48,000+ participants to register for the world’s largest webinar (can’t wait to see demographic data);\n",
      "2. KRAS is Undrugged (*yet*), not Undruggable;\n",
      "3. BRAF is the ultimate Hydra;           4. @AACR really came through👍\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "38\n",
      "-----\n",
      "Targeting #EGFR exon 20 insertion with TAK788 leads to ORR of 43% #AACR20 https://t.co/fYp5lEkShc\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "39\n",
      "-----\n",
      "New research results presented at #AACR20 show that cancer patients – especially those with #metastatic disease – are at higher risk of severe illness from #COVID19. Read more https://t.co/nrovLkZCw0\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "40\n",
      "-----\n",
      "Join us virtually at #AACR20, where we will be presenting new analyses on genomic alterations in cancer: https://t.co/x6Fx5s35gB https://t.co/gEqrivb5Im\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "41\n",
      "-----\n",
      "Talk from #TRACERx about the use ctDNA in early stage lung cancer to predict patient relapse after surgery, correlating it with minimum residual disease:\n",
      "⬆️ pre-op ctDNA shedding associated with longer MRD lead-times and shorter DFS times post-op\n",
      "#AACR20 #AACR2020 #lcsm https://t.co/eqtjL1ypV1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "42\n",
      "-----\n",
      "Talk from #TRACERx about the use ctDNA in early stage lung cancer to predict patient relapse after surgery, correlating it with minimum residual disease:\n",
      "⬆️ pre-op ctDNA shedding associated with longer MRD lead-times and shorter DFS times post-op\n",
      "#AACR20 #AACR2020 #lcsm https://t.co/eqtjL1ypV1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "43\n",
      "-----\n",
      "CONGRESS | #AACR20 | Caron A Jacobson, @DanaFarber, presents results from ZUMA-6: axi-cel + atezolizumab for refractory DLBCL. ORR was 75% with a 46% CR rate and no significant increase in incidence of AEs #lymsm https://t.co/nARISEHLLb\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "44\n",
      "-----\n",
      "Fantastic presentation discussing how co-occurring mutations in mouse models of EGFR-mutant lung cancer affect response to treatment. Such a great example of \"bench to bedside\".@GiorgiaFoggetti\n",
      "@politikaterina @Yale #AACR2020 #AACR20 #LCSM https://t.co/A888kgFUmZ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "45\n",
      "-----\n",
      "75% of cancers aren't picked up by current screening tests. Thrive conducted first-ever interventional study evaluating a liquid biopsy to detect cancer in healthy population. Results presented at #AACR20 and published today in @ScienceMagazine: https://t.co/jw1wGhHN0b #AACR20 https://t.co/IN2vR9zQ6I\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "46\n",
      "-----\n",
      "#OncoAlert #AACR20 Analyses to identify risk factors for severe events such as recent anti-cancer therapy (14d), radiographic findings. IO therapy not a clear risk. Numbers though are small and this is where large ongoing registries (such as #TERAVOLT) will help with perspective. https://t.co/XTfdNTdJqB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "47\n",
      "-----\n",
      "@DoggettJamie @akndegarcia Pharma misses the point.. If you follow the pharma twitter handles forn #aacr20, you will see they are sticking w promotional 'flyers'.. not adding value to the discussion. \n",
      "Makes me feel they  have a hard time finding their 'SoMe 'voice'..\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "48\n",
      "-----\n",
      "#OncoAlert #AACR20 TAK-788 safety: At 160mg qd, G3+ AE in 40%, 25% dose reduction, 50% interruption. G3+ diarrhea 18%. Given the history of drugs here, does dose intensity correlate with DOR? I'm interested in G2 toxicities, which are very relevant here. Any QOL data? #LCSM https://t.co/32yxkSYdLW\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "49\n",
      "-----\n",
      "FDA Grants Mobocertinib (TAK-788) Breakthrough Designation for EGFR Exon 20-Mutant NSCLC https://t.co/VbM00DvgxX #AACR20 #LCSM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "50\n",
      "-----\n",
      "New research results presented at #AACR20 show that cancer patients – especially those with #metastatic disease – are at higher risk of severe illness from #COVID19. Read more https://t.co/nrovLkZCw0\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "51\n",
      "-----\n",
      "New research results presented at #AACR20 show that cancer patients – especially those with #metastatic disease – are at higher risk of severe illness from #COVID19. Read more https://t.co/nrovLkZCw0\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "52\n",
      "-----\n",
      "Thanks @weoncologists \n",
      "Cc: @MGHThoracicOnc @EGFRResisters @Exon20Group\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "53\n",
      "-----\n",
      "#Immunotherapy #COVID19 #lockdown #cure\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "54\n",
      "-----\n",
      "#OncoAlert #AACR20 Analyses to identify risk factors for severe events such as recent anti-cancer therapy (14d), radiographic findings. IO therapy not a clear risk. Numbers though are small and this is where large ongoing registries (such as #TERAVOLT) will help with perspective. https://t.co/XTfdNTdJqB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "55\n",
      "-----\n",
      "Thank you to everyone who participated in day one of #AACR20 Virtual Meeting I. We loved reading all of your tweets throughout the day, here are the highlights: https://t.co/7yW5Nen5Yl\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "56\n",
      "-----\n",
      "Study results presented at #AACR20 on Tuesday suggest progress for an experimental blood test meant to catch cancer early, when it might be easier to treat. https://t.co/S4y7UMBZvC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "57\n",
      "-----\n",
      "Very important for medical &amp; scientific writing #MedTwitter\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "58\n",
      "-----\n",
      "@chuynhMDCM 🔑 to integrating #MRD in practice and/or ongoing #clinicaltrials is to get your #surgery colleagues involved. They often would see the patient before medical oncology would see them. For the #TumorINFORMED #ctDNA assays, you’d want the tissue sent out ASAP. #AACR20🩸🧬🧪\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "59\n",
      "-----\n",
      "#AACR20 Reminder that #WordsMatter. Just heard \"Many of our pts are metastatic.\" Pts don't metastasize. Tumors do. Pts are not their disease so: \"Many of our pts have metastatic dz.\" See our lang of respect guide for all speakers at #ASCO20: https://t.co/ne7tIMJLDC #advocacy https://t.co/ZmDYDXNbIP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "60\n",
      "-----\n",
      "Tertiary lymphoid structure (TLS) formation in NSCLC may predict response to immunotherapy (durvalumab) thru interaction with tumor micro-environment. Dr. Sriram Sridhar from AstraZeneca #AACR2020 #AACR20 #LCSM https://t.co/ywMmlw63gL\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "61\n",
      "-----\n",
      "Tertiary Lymphoid Structures as biomarkers of response to immunotherapy, live now #AACR20 ! https://t.co/MTsmp8ezB4\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "62\n",
      "-----\n",
      "Dr Zhao discusses Skp2 as a  target in #SCLC. Data showing Skp2 pathway is a promising therapeutic strategy to reactivate RB1 and TP53 #AACR20 #LCSM https://t.co/4fvzbujiKH\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "63\n",
      "-----\n",
      "Toni Ribas just announced a dedicated symposium on #COVID19nCancer in July by @AACR. \n",
      "#AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "64\n",
      "-----\n",
      "There was #cancer before the pandemic, there is cancer now, and there will be cancer after. Thankfully, some research continues. Progress toward off-the-shelf #CAR_T cells, from Shanghai #biotech, at #AACR20: https://t.co/YuVBfGVs5J\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "65\n",
      "-----\n",
      "Missed #COVID19nCancer plenary in #AACR20 @AACR?\n",
      "Here’s a thread to catch up on all the fascinating global research presented by:\n",
      "@AACR @AACRPres #AntoniRibas #LiZhang @marinagarassino @barlesi #CarlosGomez #LouisVoigt #HongbingCai cc:@OncoAlert @COVID19nCCC @ASCO @ASH_hematology\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "66\n",
      "-----\n",
      "Find out what the Editors of @OncologyCentral, @MyBioTechniques and @NanomedZone thought of day 1 #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "67\n",
      "-----\n",
      "Read the Clinical Trials collection - newly released for the #AACR20 Virtual Annual Meeting I! https://t.co/TCMvqxZcxC https://t.co/UEmZK1wAGW\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "68\n",
      "-----\n",
      "#NewsInBrief: Triple Therapy Better for Advanced Melanoma. https://t.co/81bRv6tvWV #AACR20 https://t.co/EI1HmRu1Tc\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "69\n",
      "-----\n",
      "Outstanding summary for recent data discussing COVID-19 infection in cancer patients.@ADesaiMD #Covid_19 #AACR #cancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "70\n",
      "-----\n",
      "Predictive biomarker for #immunotherapy in #NSCLC #LCSM #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "71\n",
      "-----\n",
      "CONGRESS | #AACR20 | Caron A Jacobson, @DanaFarber, presents results from ZUMA-6: axi-cel + atezolizumab for refractory DLBCL. ORR was 75% with a 46% CR rate and no significant increase in incidence of AEs #lymsm https://t.co/nARISEHLLb\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "72\n",
      "-----\n",
      "More on #ctDNA 🩸🧬🧪#AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "73\n",
      "-----\n",
      ".@Amgen strives to address the unmet need for #prostatecancer patients. This includes investigating potential therapeutic targets such as STEAP1 which is over-expressed in more than 80 percent of prostate cancers. See data presented earlier today at #AACR20 https://t.co/9eGGWlLpM6\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "74\n",
      "-----\n",
      "Many thanks to LUNGevity for funding this work, would not be possible without this support.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "75\n",
      "-----\n",
      "Missed #COVID19nCancer plenary in #AACR20 @AACR?\n",
      "Here’s a thread to catch up on all the fascinating global research presented by:\n",
      "@AACR @AACRPres #AntoniRibas #LiZhang @marinagarassino @barlesi #CarlosGomez #LouisVoigt #HongbingCai cc:@OncoAlert @COVID19nCCC @ASCO @ASH_hematology\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "76\n",
      "-----\n",
      "Predictive Biomarkers offer a noninvasive approach for prediction of therapeutic benefit from immune checkpoint inhibition in #lungcancer, per #AACR20 presentation by @max_diehn @AshAlizadeh on @SU2C @LUNGevity @LungAssociation #LungCancer Dream Team\n",
      "https://t.co/6tRnpjoAIl\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "77\n",
      "-----\n",
      "Thread by @ADesaiMD: Missed #COVID19nCancer plenary in #AACR20 @AACR? Here’s a thread to catch up on all the fascinating global research presy: @AACR @AACRPres #AntoniRibas #LiZhang @marinagarassino @barlesi #CarlosGomez #LouisVoigt #HongbingCai cc:@Onco… https://t.co/jiRO4nRWCM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "78\n",
      "-----\n",
      "@HornLeora and @marinagarassino describe the impact of their #lungcancer  / #COVID19 TERAVOLT initial data\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "79\n",
      "-----\n",
      "Nice presentation by Dr Sridhar (AstraZeneca) showing that tertiary lymphoid structures (assessed by gene signatures expression) are associated with response to anti-PD-L1 durvalumab in #NSCLC and UC, extending the results from soft tissue sarcoma and melanoma. #AACR20 https://t.co/uFPyA5EFzV\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "80\n",
      "-----\n",
      "Atezolizumab + enzalutamide not increasing OS or PFS (vs Enza alone) in prostate cancer (CRPC) - HR1.12. No subgroup appears to benefit and no long-term progressors. This seriously questions any role for ICIs in prostate cancer #AACR20 #prostatecancer https://t.co/VBx5PDu0bO\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "81\n",
      "-----\n",
      "Outstanding thread from @ADesaiMD #COVID19 #AACR20 @COVID19nCCC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "82\n",
      "-----\n",
      "I’m watching some excellent #AACR20 presentations and still catching the inspiration - thank you @AACR for making it happen.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "83\n",
      "-----\n",
      "Promising research for #braincancer #coloncancer treatment! .@amritasule presented study results at #AACR20 showing #PARP and #ATR #DNA repair inhibitors together are more effective than a PARP inhibitor alone. @RanjitBindra @SmilowCancer @YaleMed @YNHH   https://t.co/XFB6b6peoz https://t.co/qfzig30WOb\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "84\n",
      "-----\n",
      "Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "85\n",
      "-----\n",
      "Join #AACR20 presentation \"A multicenter randomized phase 2 trial of atezolizumab as monotherapy or in combination with cobimetinib in biliary tract cancers\", at 2:25 - 2:35 PM April 28, 2020 @AACR virtual annual meeting, #ETCTN @hopkinskimmel Learn more: https://t.co/knKhZKyZIW https://t.co/H9jMSUDuRi\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "86\n",
      "-----\n",
      ".@Amgen strives to address the unmet need for #prostatecancer patients. This includes investigating potential therapeutic targets such as STEAP1 which is over-expressed in more than 80 percent of prostate cancers. See data presented earlier today at #AACR20 https://t.co/9eGGWlLpM6\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "87\n",
      "-----\n",
      "#Covid19: First results from TERAVOLT registry for thoracic cancers show high mortality rate of COVID-19 in pats w/ thoracic malignancies. Mortality rate of COVID-19 in this group does not appear 2 b linked to specific treatmt/comorbidity. Video: https://t.co/QlXez9T5FB #AACR20 https://t.co/wPkHD6ouqF\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "88\n",
      "-----\n",
      "Fighting stigma —  #AACR20: Early data suggest Novartis' Incyte-discovered MET inhibitor helps lung cancer patients ...: Data from the mid-stage GEOMETRY mono-1 study showed that 7 of the 13 ... The overall response rate — the study's main goal — was… https://t.co/djLzhqhagk\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "89\n",
      "-----\n",
      "#AACR20 Reminder that #WordsMatter. Just heard \"Many of our pts are metastatic.\" Pts don't metastasize. Tumors do. Pts are not their disease so: \"Many of our pts have metastatic dz.\" See our lang of respect guide for all speakers at #ASCO20: https://t.co/ne7tIMJLDC #advocacy https://t.co/ZmDYDXNbIP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "90\n",
      "-----\n",
      "ctDNA measurement thru liquid biopsy over time (frm FLAURA study) predicts progression-free survival &amp; correlates w/ tumor size in EGFR-mutant NSCLC tx w/ osimertinib. Possibility fr monitoring during #COVID19? Dr. Martin Johnson frm Astra Zeneca #AACR2020 #AACR20 #LCSM https://t.co/5utKOMIMZc\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "91\n",
      "-----\n",
      "👇🏼🩸🧪🧬 #ctDNA #LiquidBiopsies #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "92\n",
      "-----\n",
      "Our @OncoAlert 🚨Colleague @LeciaSequist 👩‍⚕️of @MassGeneralNews Live from #AACR20 Discussing The Geometry Study and Zenith20. #LCSM @LungCancer \n",
      "Edited: @weoncologists https://t.co/U9ZPHynuZA\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "93\n",
      "-----\n",
      "$IOVA off 8%. Surely it’s time for the loonies to start accusing the #AACR20 discussant of being a filthy short seller.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "94\n",
      "-----\n",
      "Presentan resultados de ensayo clínico CIMAvax en congreso de Asociación para la Investigación del Cáncer en #US. Resultados alentadores de combinar dos inmunoterapias novedosas. @centro_cim @RoswellPark\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "95\n",
      "-----\n",
      "Dr Zhao discusses Skp2 as a  target in #SCLC. Data showing Skp2 pathway is a promising therapeutic strategy to reactivate RB1 and TP53 #AACR20 #LCSM https://t.co/4fvzbujiKH\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "96\n",
      "-----\n",
      "Nice presentation by Dr Sridhar (AstraZeneca) showing that tertiary lymphoid structures (assessed by gene signatures expression) are associated with response to anti-PD-L1 durvalumab in #NSCLC and UC, extending our results from soft tissue sarcoma and melanoma. #AACR20 https://t.co/ZWZ30ATRIF\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "97\n",
      "-----\n",
      "David Huntsman discusses role of ctDNA/liquid biopsies &amp; interestingly the potential benefits of the uses are greatly increased due to #COVID19. #AACR20 #LCSM https://t.co/VofP7CmZXH\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "98\n",
      "-----\n",
      "Dear #AACR20 We're #OncoAlert ⚕️: @CharuAggarwalMD @Alfdoc2 @Tony_Calles @agrothey @JTrentMDPhD @ChristianRolfo @TiansterZhang @StephenVLiu @guiperini @prat_aleix @marklewismd @FAndreMD @weldeiry @BK_radiation @sharp_lena @DrSGraff @DrDanielHeng @MKnoll_MD @marinagarassino\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "99\n",
      "-----\n",
      "Those $IOVA durable complete responses DEFINITELY, DEFINITELY DO NOT have anything to do with Opdivo #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "100\n",
      "-----\n",
      "#OncoAlert #AACR20 In patients with #EGFRex20 #NSCLC treated with TAK-788 at 160mg, RR was 43% (n=28) including ASV mutations and NPH insertions. mPFS 7.3 months. Responses independent of prior therapy. Certainly encouraging - need more numbers, longer f/u, full dataset. #LCSM https://t.co/7TItSqO3W2\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "101\n",
      "-----\n",
      "Talk from #TRACERx about the use ctDNA in early stage lung cancer to predict patient relapse after surgery, correlating it with minimum residual disease:\n",
      "⬆️ pre-op ctDNA shedding associated with longer MRD lead-times and shorter DFS times post-op\n",
      "#AACR20 #AACR2020 #lcsm https://t.co/eqtjL1ypV1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "102\n",
      "-----\n",
      "Baller co-fellow, physician-scientist, and desk neighbor @JZimmermanMDPhD presents her work at #AACR20 virtually:\n",
      "''miR-21 inhibition in mice models of pancreatic cancer''\n",
      "\n",
      "She talks organoids, I talk OCM, @jaffeejaffee/ @laherda mentor both. Incredible to be at @hopkinskimmel! https://t.co/om7WtTTHj2\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "103\n",
      "-----\n",
      "#AACR20 #TwitterPoll👇🏼\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "104\n",
      "-----\n",
      "Talk from #TRACERx about the use ctDNA in early stage lung cancer to predict patient relapse after surgery, correlating it with minimum residual disease:\n",
      "⬆️ pre-op ctDNA shedding associated with longer MRD lead-times and shorter DFS times post-op\n",
      "#AACR20 #AACR2020 #lcsm https://t.co/eqtjL1ypV1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "105\n",
      "-----\n",
      "ctDNA measurement thru liquid biopsy over time (frm FLAURA study) predicts progression-free survival &amp; correlates w/ tumor size in EGFR-mutant NSCLC tx w/ osimertinib. Possibility fr monitoring during #COVID19? Dr. Martin Johnson frm Astra Zeneca #AACR2020 #AACR20 #LCSM https://t.co/5utKOMIMZc\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "106\n",
      "-----\n",
      "#AACR20 💭I think integrating #ctDNA #liquidbiopsies is going to be the new paradigm shift in more efficient trial designs. If you chose 🩸🧬MRD➕subset of patients, especially for these adjuvant studies, sample size required would be a lot lower since event rate will be high📈. https://t.co/ltbTc4pISo\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "107\n",
      "-----\n",
      "#AACR20 delighted to share that my small observation/formula➗is now published.💡Small but novel finding. \n",
      "\n",
      "👉🏼What if you could calculate the 🔢CA-19-9/CEA ratio &amp; it could identify 🧬BRAFV600E MSS 🆚 MSI-High 🆚 Others. Simple, rapid, &amp; cheap. \n",
      "\n",
      "#CRCSM 📃https://t.co/7j0v23E2pq https://t.co/t359VmAK1n\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "108\n",
      "-----\n",
      "Metabolomic adaptations and correlates of survival to immune checkpoint blockade: https://t.co/bGMKiJQ75L\n",
      "\n",
      "#AACR20 #biomarkers https://t.co/GFaoBgO9kx\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "109\n",
      "-----\n",
      "#OncoAlert #AACR20 Analyses to identify risk factors for severe events such as recent anti-cancer therapy (14d), radiographic findings. IO therapy not a clear risk. Numbers though are small and this is where large ongoing registries (such as #TERAVOLT) will help with perspective. https://t.co/XTfdNTdJqB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "110\n",
      "-----\n",
      "#OncoAlert #AACR20 Serial scans show #COVID19 related lung changes. Note the fibrosis emerging at day 25. Will long-term sequela impact respiratory function, quality of life? Will this vary by prior lung pathology, prior radiation, prior pneumonitis, etc? https://t.co/XrcRUiRe7e\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "111\n",
      "-----\n",
      "#OncoAlert #AACR20 In 28 patients with cancer and #COVID19, 36% required mechanical ventilation, 29% mortality with 21% still hospitalized. For those discharged, median hospitalization 18.4 days. For those with severe events, median 7 days from COVID diagnosis to event. https://t.co/Gq4j4ivica\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "112\n",
      "-----\n",
      "Now @marinagarassino presents data from the TERAVOLT Registry, an impressive international collaboration of COVID19 in patients with lung cancer, led by oncology researchers around the world (also led b y @HornLeora) #AACR20 #LCSM https://t.co/f07FM0Nbip\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "113\n",
      "-----\n",
      "Thank you to the #brainmets working group: @tmprowell, @nlinmd, @EdKimMDLCI, @ASCO, @CancerResrch\n",
      "\n",
      "Esp important is the rec to incl those vulnerable #patients w/ lepto (LMD) in #ClinicalTrials as a separate cohort. \n",
      "\n",
      "Now - how to enforce these guidelines?!\n",
      "\n",
      "#BCSM #LCSM #MelSM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "114\n",
      "-----\n",
      "#AACR20 🆕#ClinicalTrials 📝 👇🏼\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "115\n",
      "-----\n",
      "#OncoAlert #AACR20 Long awaited data from TAK-788 (now mobocertinib) in #EGFR exon 20 #NSCLC - this is clearly an unmet need with poor outcomes achieved using standard EGFR TKIs or immunotherapy. TAK-788 has some promising features to help in this setting #LCSM https://t.co/43HKq137Sr\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "116\n",
      "-----\n",
      "#AACR20 Reminder that #WordsMatter. Just heard \"Many of our pts are metastatic.\" Pts don't metastasize. Tumors do. Pts are not their disease so: \"Many of our pts have metastatic dz.\" See our lang of respect guide for all speakers at #ASCO20: https://t.co/ne7tIMJLDC #advocacy https://t.co/ZmDYDXNbIP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "117\n",
      "-----\n",
      "There was #cancer before the pandemic, there is cancer now, and there will be cancer after. Thankfully, some research continues. Progress toward off-the-shelf #CAR_T cells, from Shanghai #biotech, at #AACR20: https://t.co/YuVBfGVs5J\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "118\n",
      "-----\n",
      "Durable Immunotherapy Response Estimation by immune profiling and ctDNA-On-treatment (DIRECT-On assay) is a simple blood test that can predict which pts respond to immunotherapy within first 6 months of starting immunotherapy @Barzin_ @Stanford @max_diehn #AACR2020 #AACR20 #LCSM https://t.co/9E8gRBzV8D\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "119\n",
      "-----\n",
      "Thank you to the #brainmets working group: @tmprowell, @nlinmd, @EdKimMDLCI, @ASCO, @CancerResrch\n",
      "\n",
      "Esp important is the rec to incl those vulnerable #patients w/ lepto (LMD) in #ClinicalTrials as a separate cohort. \n",
      "\n",
      "Now - how to enforce these guidelines?!\n",
      "\n",
      "#BCSM #LCSM #MelSM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "120\n",
      "-----\n",
      ".@LocasaleLab, @WellenLab, and @ThalesPapaG gather on Zoom to discuss the links between diet, extracellular nutrient availability, and cellular tumor metabolism.\n",
      "\n",
      "https://t.co/kipDU8ttyb #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "121\n",
      "-----\n",
      "It’s day two of #AACR20. Today at 520 pm ET, @theNCI’s Deputy Director for Scientific Strategy and Development, Dr. Dinah Singer will present a special session, “NCI Activities: #COVID-19 and #CancerResearch.” Be sure to tune in. https://t.co/Axx9XlL1xs https://t.co/zFQODE0ezB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "122\n",
      "-----\n",
      "Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "123\n",
      "-----\n",
      "A lot of toxicity observed with MEK mono-therapy - James Cleary on Binimetinib #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "124\n",
      "-----\n",
      "Presentan resultados de ensayo clínico CIMAvax en congreso de Asociación para la Investigación del Cáncer en #US. Resultados alentadores de combinar dos inmunoterapias novedosas. @centro_cim @RoswellPark https://t.co/ZjU38wpVMz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "125\n",
      "-----\n",
      "Toxicity of capmatinib is generally pretty mild, and not dissimilar from with crizotinib.  We gain CNS efficacy without cost in the form of toxicity.  Hopefully patients will have access to this agent soon. It is currently under priority review at the FDA #AACR20 #LCSM https://t.co/s4f8Gble9o\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "126\n",
      "-----\n",
      "Dog does not like competing with #AACR20 webinar about P13K and PD1 inhibition. https://t.co/3Y1k3WQTuk\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "127\n",
      "-----\n",
      "Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "128\n",
      "-----\n",
      "Next up at #AACR20 a study of poziotinib in patients with EGFR Exon  20 insertions presented by Dr Le.  This variant of EGFR mutated NSCLC tends to be nonresponsive to traditional EGFR TKI's, as is shown dramatically in this KM survival curve. #LCSM https://t.co/fiKlplLPBM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "129\n",
      "-----\n",
      "Tuned back into #AACR20 &amp; immediately learned something: \n",
      "Q: \"How do you determine cfDNA-shedder from cfDNA-non-shedder if without in-situ tumor data?\"\n",
      "A: \"It may not be a shedder/non-shedder question, it may be level of sensitivity of the test.\" \n",
      "cc: #lcsm #bcsm #crcsm #gyncsm\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "130\n",
      "-----\n",
      "Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "131\n",
      "-----\n",
      "Promising research for #braincancer #coloncancer treatment! .@amritasule presented study results at #AACR20 showing #PARP and #ATR #DNA repair inhibitors together are more effective than a PARP inhibitor alone. @RanjitBindra @SmilowCancer @YaleMed @YNHH   https://t.co/XFB6b6peoz https://t.co/qfzig30WOb\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "132\n",
      "-----\n",
      "#AACR20 Reminder that #WordsMatter. Just heard \"Many of our pts are metastatic.\" Pts don't metastasize. Tumors do. Pts are not their disease so: \"Many of our pts have metastatic dz.\" See our lang of respect guide for all speakers at #ASCO20: https://t.co/ne7tIMJLDC #advocacy https://t.co/ZmDYDXNbIP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "133\n",
      "-----\n",
      "Great discussion by @AbboshChris on using ctDNA to measure minimum residual disease (MRD) in adjuvant trials for early-stage lung cancer - to predict which pts will relapse after surgery. Results frm TRACERx @SwantonLab @SU2Cscience @LungAssociation #AACR2020 #AACR20 #LCSM https://t.co/DToCKYUfKg\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "134\n",
      "-----\n",
      "David Hong on \"Efficacy and safety of larotrectinib in patients with cancer and NTRK gene fusions or other alterations\" #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "135\n",
      "-----\n",
      "#AACR20 Virtual Annual Meeting I: Early Detection and ctDNA Session. Chris Abbosh presents: Phylogenetic tracking and minimal residual disease detection using ctDNA in early-stage NSCLC: A lung TRACERx study. https://t.co/dmVDkxM9tt\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "136\n",
      "-----\n",
      "Durable Immunotherapy Response Estimation by immune profiling and ctDNA-On-treatment (DIRECT-On assay) is a simple blood test that can predict which pts respond to immunotherapy within first 6 months of starting immunotherapy @Barzin_ @Stanford @max_diehn #AACR2020 #AACR20 #LCSM https://t.co/9E8gRBzV8D\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "137\n",
      "-----\n",
      "#AACR20 #ctDNA #LiquidBiopsies key is that if fusions are detected is helpful - ⛔️doesn’t exclude its presence. Interpret with disease context. #OncoAlert\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "138\n",
      "-----\n",
      "ICYMI earlier, a look at #liquidbiopsy data at #AACR20:\n",
      "Thrive, chasing Grail with a #cancer blood test, finds tumors in seemingly healthy women https://t.co/BIZLvIZSk3\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "139\n",
      "-----\n",
      "#OncoAlert #AACR20 Serial scans show #COVID19 related lung changes. Note the fibrosis emerging at day 25. Will long-term sequela impact respiratory function, quality of life? Will this vary by prior lung pathology, prior radiation, prior pneumonitis, etc? https://t.co/XrcRUiRe7e\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "140\n",
      "-----\n",
      "#COVID19 #AACR20 #LCSM\n",
      "TERAVOLT preliminary results by @marinagarassino. An amazing international effort to improve knowledge about #lungcancer &amp; COVID19.\n",
      "198 pts evaluated with 34.6% of death rate.\n",
      "Not specific anti-cancer treatment was associated w/ higher mortality #OncoAlert https://t.co/dWUKuoU1qi\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "141\n",
      "-----\n",
      "Today at 3:50pm tune in to #AACR20's minisymposium \"Evaluating #Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease,\" to hear from @KellyLBolton on \"Oncologic therapy shapes the fitness landscape of #ClonalHematopoiesis.\" https://t.co/OGd2f4qvSM https://t.co/PF7CXsVcvq\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "142\n",
      "-----\n",
      "Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "143\n",
      "-----\n",
      "#Covid19: First results from TERAVOLT registry for thoracic cancers show high mortality rate of COVID-19 in pats w/ thoracic malignancies. Mortality rate of COVID-19 in this group does not appear 2 b linked to specific treatmt/comorbidity. Video: https://t.co/QlXez9T5FB #AACR20 https://t.co/wPkHD6ouqF\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "144\n",
      "-----\n",
      "ICYMI earlier, a look at #liquidbiopsy data at #AACR20:\n",
      "Thrive, chasing Grail with a #cancer blood test, finds tumors in seemingly healthy women https://t.co/BIZLvIZSk3\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "145\n",
      "-----\n",
      "Predictive biomarker for #immunotherapy in #NSCLC #LCSM #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "146\n",
      "-----\n",
      "At #AACR20 Dr Creelan presented data on adoptive TIL therapy for NSCLC.  This is a very interesting approach - surgery of a metastatic lesion, ex vivo TIL expansion, nivolumab, lymphodepletion and TIL reinfusion with further nivolumab  #LCSM https://t.co/ECHtoEoJTG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "147\n",
      "-----\n",
      "Gracell scores a first for CD7-directed Car-T therapy in T-cell leukaemia. Via @evaluatevantage https://t.co/54yX6Uqfia #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "148\n",
      "-----\n",
      "There was #cancer before the pandemic, there is cancer now, and there will be cancer after. Thankfully, some research continues. Progress toward off-the-shelf #CAR_T cells, from Shanghai #biotech, at #AACR20: https://t.co/YuVBfGVs5J\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "149\n",
      "-----\n",
      "Great to see new data presented at the #AACR20 early detection and #ctDNA session supporting the use of clonal variants to detect and monitor #MRD and disease recurrence in lung cancer.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "150\n",
      "-----\n",
      "Here is the data on patients enrolled on trial.  Interesting to note the high incidence of molecular alterations.  This exciting trial was supported by @SU2C #AACR20 #LCSM https://t.co/ZSWHknI66l\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "151\n",
      "-----\n",
      "At #AACR20 Dr Creelan presented data on adoptive TIL therapy for NSCLC.  This is a very interesting approach - surgery of a metastatic lesion, ex vivo TIL expansion, nivolumab, lymphodepletion and TIL reinfusion with further nivolumab  #LCSM https://t.co/ECHtoEoJTG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "152\n",
      "-----\n",
      "22% death rate in cancer patients with #COVID19 @GustaveRoussy experience #AACR2020 AACR\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "153\n",
      "-----\n",
      "Ben Creelan, MD @MoffittNews : Interesting Phase 1 trial shows durable CRs to adoptive cell transfer using TILs in #NSCLC. Many patients were low/no PDL1 and had oncogene drivers. Looking forward to seeing future work in this area.   #AACR20 #lcsm #lungcancer @EGFRResisters https://t.co/16GBuyBez9\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "154\n",
      "-----\n",
      "#AACR20 #LCSM #EGFR\n",
      "Disappointing results of #Poziotinib in 2L+ EGFR Exon20ins (n=115) by @LeXiuning\n",
      "ORR: 15% | mPFS: 4.2 m \n",
      "TRAEs ≥ 3: 63% (72/114) w/ 68% dose-reduction!\n",
      "Toxic profile w/ limited activity for being a good TKI. \n",
      "What to expect from Ph3? Not much else \n",
      "#OncoAlert https://t.co/ihvbaL7gZU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "155\n",
      "-----\n",
      "At #AACR20 Dr Creelan presented data on adoptive TIL therapy for NSCLC.  This is a very interesting approach - surgery of a metastatic lesion, ex vivo TIL expansion, nivolumab, lymphodepletion and TIL reinfusion with further nivolumab  #LCSM https://t.co/ECHtoEoJTG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "156\n",
      "-----\n",
      "Some patients did have further response after TIL infusion.  They also noted some responses after radiographic PD on nivolumab.  Dr Creelan also presented a rather dramatic case, indicated here #AACR20 #LCSM https://t.co/IOCcr89vSS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "157\n",
      "-----\n",
      "#COVID19 #AACR20 #LCSM\n",
      "TERAVOLT preliminary results by @marinagarassino. An amazing international effort to improve knowledge about #lungcancer &amp; COVID19.\n",
      "198 pts evaluated with 34.6% of death rate.\n",
      "Not specific anti-cancer treatment was associated w/ higher mortality #OncoAlert https://t.co/dWUKuoU1qi\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "158\n",
      "-----\n",
      "#COVID19 #AACR20 #LCSM\n",
      "TERAVOLT preliminary results by @marinagarassino. An amazing international effort to improve knowledge about #lungcancer &amp; COVID19.\n",
      "198 pts evaluated with 34.6% of death rate.\n",
      "Not specific anti-cancer treatment was associated w/ higher mortality #OncoAlert https://t.co/dWUKuoU1qi\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "159\n",
      "-----\n",
      "#OncoAlert #AACR20 Global registry of #COVIDー19 in patients with lung cancer led by @marinagarassino and @HornLeora, the #TERAVOLT registry: Thoracic Cancers International COVID-19 Collaboration. An impressive and rapidly executed, global registry. #LCSM https://t.co/UxjI9o6gcF\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "160\n",
      "-----\n",
      "Nicely presented data from @sloan_kettering by Dr. Kelly Bolton | Gene-specific effects of therapy on promoting pre-existing #CHIPsm in patients undergoing cancer therapy. Time to start thinking about prevention? #AACR20 #leusm\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "161\n",
      "-----\n",
      "Off-the-shelf CAR-T therapy helps leukemia patients in a small, first-in-human trial https://t.co/LCblW4C8JG via @sxbegle  #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "162\n",
      "-----\n",
      "Nicely presented data from @sloan_kettering by Dr. Kelly Bolton | Gene-specific effects of therapy on promoting pre-existing #CHIPsm in patients undergoing cancer therapy. Time to start thinking about prevention? #AACR20 #leusm https://t.co/Dl8mvIdjyB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "163\n",
      "-----\n",
      "At #AACR20 Dr Creelan presented data on adoptive TIL therapy for NSCLC.  This is a very interesting approach - surgery of a metastatic lesion, ex vivo TIL expansion, nivolumab, lymphodepletion and TIL reinfusion with further nivolumab  #LCSM https://t.co/ECHtoEoJTG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "164\n",
      "-----\n",
      "Targeting #EGFR exon 20 insertion with TAK788 leads to ORR of 43% #AACR20 https://t.co/fYp5lEkShc\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "165\n",
      "-----\n",
      "#NewsInBrief: COM701 Shows Antitumor Activity, +/− Nivolumab.  https://t.co/izNTTIutMb #AACR20 https://t.co/hI2aoEIeU2\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "166\n",
      "-----\n",
      "Predictive Biomarkers offer a noninvasive approach for prediction of therapeutic benefit from immune checkpoint inhibition in #lungcancer, per #AACR20 presentation by @max_diehn @AshAlizadeh on @SU2C @LUNGevity @LungAssociation #LungCancer Dream Team\n",
      "https://t.co/6tRnpjoAIl\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "167\n",
      "-----\n",
      "#OncoAlert #AACR20 Complications from #COVIDー19 in patients with thoracic cancers are striking. 80% with pneumonia and 27% with ARDS. 8% had multi-organ failure. 76% hospitalized. Mortality rate from this registry so far: 35% (66/191). Much higher than previous reports. #LCSM https://t.co/3oMj774oxW\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "168\n",
      "-----\n",
      "Bispecific CD19/CD22 CAR T Cells Active in Pediatric Relapsed ALL @NCIResearchCtr @AACR #AACR20 #leusm https://t.co/9i0ji0YNCf\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "169\n",
      "-----\n",
      "#OncoAlert #AACR20 Analyses to identify risk factors for severe events such as recent anti-cancer therapy (14d), radiographic findings. IO therapy not a clear risk. Numbers though are small and this is where large ongoing registries (such as #TERAVOLT) will help with perspective. https://t.co/XTfdNTdJqB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "170\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "171\n",
      "-----\n",
      "First report of TERAVOLT by @marinagarassino. N=200 (75% NSCLC, 81% smoker, age=68, 74% on active treatment). 80% with pneumonia/pneumonitis, 27% with ARDS. No spec Tx a/w higher mortality, but requires larger N. 35% death rate(!). Alarming rate of mortality. #AACR20 @OncoAlert https://t.co/2Z7l2DF6iN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "172\n",
      "-----\n",
      "#AACR20 #COVID19 Dr. Fabrice Barlesi on #COVID19nCancer at Gustave Roussy. Incidence #SARSCoV2 (12%), % asymptomatic (80%), ICU (11%), &amp; death (15%) similar to non-oncology population. Risk factors for poor outcome: ECOG&gt;1, heme malig, adv cancer w/ chemo (not other tx) in 3 mos. https://t.co/st9GCjGirh\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "173\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "174\n",
      "-----\n",
      "Larotrectinib shows 95% ORR in patients harboring NTRK1/2/3 gene fusions - would like to see such amazing waterfall plots for other targeted therapies. #AACR20 https://t.co/ufkGDvddCM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "175\n",
      "-----\n",
      "#OncoAlert\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "176\n",
      "-----\n",
      "#AACR20 Important to know the spectrum of #KRAS and now the specific codons. #Clinicaltrials 🆕 for the #KRASG12C #AMG510 and other 💊. #CRCSM #PANCSM #LCSM #PrecisionMedicine \n",
      "Importance of co-occurring mutations. Interesting co-mutation patterns &amp; dependencies. Type-specific🧬. https://t.co/lZvYQjr0Aw\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "177\n",
      "-----\n",
      "Coinciding with the #COVID19nCancer session at #AACR20, @CD_AACR has published the largest peer reviewed series (thus far) of #COVID19 in cancer patients (N=105 from China). \n",
      "Overall, a higher rate of complications is seen across the board. @tmprowell \n",
      "https://t.co/sgH7lEi0z6 https://t.co/32VGCKwx2u\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "178\n",
      "-----\n",
      "#OncoAlert #AACR20 Analyses to identify risk factors for severe events such as recent anti-cancer therapy (14d), radiographic findings. IO therapy not a clear risk. Numbers though are small and this is where large ongoing registries (such as #TERAVOLT) will help with perspective. https://t.co/XTfdNTdJqB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "179\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "180\n",
      "-----\n",
      "It’s day two of #AACR20. Today at 520 pm ET, @theNCI’s Deputy Director for Scientific Strategy and Development, Dr. Dinah Singer will present a special session, “NCI Activities: #COVID-19 and #CancerResearch.” Be sure to tune in. https://t.co/Axx9XlL1xs https://t.co/zFQODE0ezB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "181\n",
      "-----\n",
      "Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "182\n",
      "-----\n",
      "CONGRESS | #AACR20 | Kelly L Bolton, @sloan_kettering, discusses how oncologic therapy shapes the fitness landscape of clonal hematopoiesis (CH) in solid tumors. If clinically validated, CH may guide risk stratification of transformed myeloid neoplasms like AML &amp; MDS #leusm https://t.co/Nk5HfcJF9R\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "183\n",
      "-----\n",
      "cfDNA sequencing leveraging informative methylation patterns detected more than 50 cancer types across stages. Considering the potential value of early detection in deadly malignancies, further evaluation of this test is justified in prospective population-level studies.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "184\n",
      "-----\n",
      "#AACR20 💭I think integrating #ctDNA #liquidbiopsies is going to be the new paradigm shift in more efficient trial designs. If you chose 🩸🧬MRD➕subset of patients, especially for these adjuvant studies, sample size required would be a lot lower since event rate will be high📈. https://t.co/ltbTc4pISo\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "185\n",
      "-----\n",
      "There was #cancer before the pandemic, there is cancer now, and there will be cancer after. Thankfully, some research continues. Progress toward off-the-shelf #CAR_T cells, from Shanghai #biotech, at #AACR20: https://t.co/YuVBfGVs5J\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "186\n",
      "-----\n",
      "Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "187\n",
      "-----\n",
      "Talk from #TRACERx about the use ctDNA in early stage lung cancer to predict patient relapse after surgery, correlating it with minimum residual disease:\n",
      "⬆️ pre-op ctDNA shedding associated with longer MRD lead-times and shorter DFS times post-op\n",
      "#AACR20 #AACR2020 #lcsm https://t.co/eqtjL1ypV1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "188\n",
      "-----\n",
      "Toxicity of capmatinib is generally pretty mild, and not dissimilar from with crizotinib.  We gain CNS efficacy without cost in the form of toxicity.  Hopefully patients will have access to this agent soon. It is currently under priority review at the FDA #AACR20 #LCSM https://t.co/s4f8Gble9o\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "189\n",
      "-----\n",
      "#AACR20 Virtual Annual Meeting I: Early Detection and ctDNA Session. Nickolas Papadopoulos presents:  A first-of-its-kind prospective study of a multicancer blood test to screen and manage 10,000 women with no history of cancer. https://t.co/KeMHhirfgU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "190\n",
      "-----\n",
      "#OncoAlert #AACR20 Analyses to identify risk factors for severe events such as recent anti-cancer therapy (14d), radiographic findings. IO therapy not a clear risk. Numbers though are small and this is where large ongoing registries (such as #TERAVOLT) will help with perspective. https://t.co/XTfdNTdJqB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "191\n",
      "-----\n",
      "#AACR20 Hongbing Cai presents data showing cancer patients may be more vulnerable to SARS-COV-2 infection. Data were simultaneously published in Cancer Discovery. @CD_AACR https://t.co/ecP5FskLgQ https://t.co/UDX54MAHdS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "192\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "193\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "194\n",
      "-----\n",
      "#AACR20 Virtual Annual Meeting Program Chair Antoni Ribas opens the special Clinical Plenary Session on COVID-19 and Cancer. https://t.co/2c42aOUazm\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "195\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "196\n",
      "-----\n",
      "Exciting data presented by @Barzin_ at #AACR20 on the use of a novel ctDNA assay to predict outcomes for immunotherapy in NSCLC.  CAPP-Seq is more sensitive than many commercially available assays.  They coupled this with a bulkRNA sequencing called CIBERSORT #LCSM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "197\n",
      "-----\n",
      "Thanks @tmprowell for highlighting talk by Dr. Voight at #AACR20 on widening disparities in cancer caused by #COVID19.  @GUSurvivorship\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "198\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "199\n",
      "-----\n",
      "Thank you to the #brainmets working group: @tmprowell, @nlinmd, @EdKimMDLCI, @ASCO, @CancerResrch\n",
      "\n",
      "Esp important is the rec to incl those vulnerable #patients w/ lepto (LMD) in #ClinicalTrials as a separate cohort. \n",
      "\n",
      "Now - how to enforce these guidelines?!\n",
      "\n",
      "#BCSM #LCSM #MelSM https://t.co/P9wRgnT9Ta\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "200\n",
      "-----\n",
      "Durable Immunotherapy Response Estimation by immune profiling and ctDNA-On-treatment (DIRECT-On assay) is a simple blood test that can predict which pts respond to immunotherapy within first 6 months of starting immunotherapy @Barzin_ @Stanford @max_diehn #AACR2020 #AACR20 #LCSM https://t.co/9E8gRBzV8D\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "201\n",
      "-----\n",
      "Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the #COVID19 outbreak!\n",
      "⭕️Patients with hematological, lung, or with metastatic cancer had the highest frequency of severe event!\n",
      "@CD_AACR #AACR20 @OncoAlert @DrChoueiri \n",
      "https://t.co/EgMXlbmXq9 https://t.co/0IVZ4CE9ye\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "202\n",
      "-----\n",
      "#AACR20 Virtual Annual Meeting I: Early Detection and ctDNA Session. Nickolas Papadopoulos presents:  A first-of-its-kind prospective study of a multicancer blood test to screen and manage 10,000 women with no history of cancer. https://t.co/KeMHhirfgU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "203\n",
      "-----\n",
      "Missed #COVID19nCancer plenary in #AACR20 @AACR?\n",
      "Here’s a thread to catch up on all the fascinating global research presented by:\n",
      "@AACR @AACRPres #AntoniRibas #LiZhang @marinagarassino @barlesi #CarlosGomez #LouisVoigt #HongbingCai cc:@OncoAlert @COVID19nCCC @ASCO @ASH_hematology\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "204\n",
      "-----\n",
      "A personal slide mix on #STK11- #KEAP mutations in #NSCLC from #AACR20 . My interpretation:\n",
      "👉Co-occurrence with #KRAS shows resistance to IO BUT\n",
      "👉STK11/KEAP1 mut in KN42 benefit from pembro\n",
      "👉STK11/KEAP1 mut- KRAS wt- PDL1+ may respond to IO!\n",
      "#LCSM @lcsmchat #OncoAlert @myESMO https://t.co/UZw2e4aDOA\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "205\n",
      "-----\n",
      "Larotrectinib shows 95% ORR in patients harboring NTRK1/2/3 gene fusions - would like to see such amazing waterfall plots for other targeted therapies. #AACR20 https://t.co/ufkGDvddCM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "206\n",
      "-----\n",
      ".@Amgen strives to address the unmet need for #prostatecancer patients. This includes investigating potential therapeutic targets such as STEAP1 which is over-expressed in more than 80 percent of prostate cancers. See data presented earlier today at #AACR20 https://t.co/9eGGWlLpM6\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "207\n",
      "-----\n",
      "#AACR20 #COVID19 Dr. Louis Voigt w/ courageous talk \"Flattening the Curve, but Widening the Disparities\": #pandemic creates ideal conditions for emotion-driven decision-making &amp; dev from std of care due to lack of evid &amp; overwhelmed health system-&gt;⬆️#healthinequalities\n",
      "#thatsbias https://t.co/hY3ZyUNF9x\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "208\n",
      "-----\n",
      "#AACR20👇🏼#TwitterPoll ➡️ #COVID19 &amp; #Cancer #COVIDnCancer. \n",
      "Thoughts on minimizing surveillance visits or deciding on who could be spared or prioritized for chemo using #ctDNA #liquidbiopsies for #MinimalResidualDisease #MRD. Access programs available for #cancer ➕home-draw🩸🚑\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "209\n",
      "-----\n",
      "At #AACR20 Dr Creelan presented data on adoptive TIL therapy for NSCLC.  This is a very interesting approach - surgery of a metastatic lesion, ex vivo TIL expansion, nivolumab, lymphodepletion and TIL reinfusion with further nivolumab  #LCSM https://t.co/ECHtoEoJTG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "210\n",
      "-----\n",
      "And that's a wrap! Day 2 of #AACR20 done 🔴🟣🟢 Thanks for following along! #mmsm #lymsm #leusm\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "211\n",
      "-----\n",
      "Larotrectinib shows 95% ORR in patients harboring NTRK1/2/3 gene fusions - would like to see such amazing waterfall plots for other targeted therapies. #AACR20 https://t.co/ufkGDvddCM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "212\n",
      "-----\n",
      "They did repeated blood draws among patients receiving IO to classify those as patients that go on to have durable clinical benefit vs those that did not.  They found that high baseline ctDNA and lower percentage of CD8 T cells was associated with better survival #LCSM #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "213\n",
      "-----\n",
      "Durable Immunotherapy Response Estimation by immune profiling and ctDNA-On-treatment (DIRECT-On assay) is a simple blood test that can predict which pts respond to immunotherapy within first 6 months of starting immunotherapy @Barzin_ @Stanford @max_diehn #AACR2020 #AACR20 #LCSM https://t.co/9E8gRBzV8D\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "214\n",
      "-----\n",
      "STK11 and KEAP1 mutations in KEYNOTE-042. STK11 mutation a/w lower PD-L1 expression. Pembro a/w better outcomes compared with chemo, regardless of STK11 or KEAP1 mutation status. Very low ORR with chemo in STK11 mutation+ NSCLC.\n",
      "#AACR20 @OncoAlert https://t.co/Nqe7NetuCO\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "215\n",
      "-----\n",
      "First-in-human study of SC-004, an antibody-drug conjugate targeting CLDN6/9, in patients with epithelial ovarian cancers ⁦@ErikaHamilton9⁩ #AACR20 ⁦@AACR⁩  https://t.co/k014XH2F3d\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "216\n",
      "-----\n",
      "Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the #COVID19 outbreak!\n",
      "⭕️Patients with hematological, lung, or with metastatic cancer had the highest frequency of severe event!\n",
      "@CD_AACR #AACR20 @OncoAlert @DrChoueiri \n",
      "https://t.co/EgMXlbmXq9 https://t.co/0IVZ4CE9ye\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "217\n",
      "-----\n",
      "A discussion about the atezolizumab randomised phase 3 study in prostate cancer. What’s the future of immune therapy in this disease? #AACR20 #prostatecancer https://t.co/jzUSD0Atfg\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "218\n",
      "-----\n",
      "Exciting data presented by @Barzin_ at #AACR20 on the use of a novel ctDNA assay to predict outcomes for immunotherapy in NSCLC.  CAPP-Seq is more sensitive than many commercially available assays.  They coupled this with a bulkRNA sequencing called CIBERSORT #LCSM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "219\n",
      "-----\n",
      "Larotrectinib shows 95% ORR in patients harboring NTRK1/2/3 gene fusions - would like to see such amazing waterfall plots for other targeted therapies. #AACR20 https://t.co/ufkGDvddCM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "220\n",
      "-----\n",
      "Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the #COVID19 outbreak!\n",
      "⭕️Patients with hematological, lung, or with metastatic cancer had the highest frequency of severe event!\n",
      "@CD_AACR #AACR20 @OncoAlert @DrChoueiri \n",
      "https://t.co/EgMXlbmXq9 https://t.co/0IVZ4CE9ye\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "221\n",
      "-----\n",
      "#AACR20 #COVID19 Dr. Fabrice Barlesi on #COVID19nCancer at Gustave Roussy. Incidence #SARSCoV2 (12%), % asymptomatic (80%), ICU (11%), &amp; death (15%) similar to non-oncology population. Risk factors for poor outcome: ECOG&gt;1, heme malig, adv cancer w/ chemo (not other tx) in 3 mos. https://t.co/st9GCjGirh\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "222\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "223\n",
      "-----\n",
      "#OncoAlert #AACR20 In 28 patients with cancer and #COVID19, 36% required mechanical ventilation, 29% mortality with 21% still hospitalized. For those discharged, median hospitalization 18.4 days. For those with severe events, median 7 days from COVID diagnosis to event. https://t.co/Gq4j4ivica\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "224\n",
      "-----\n",
      ".@VirusesImmunity &amp; Anna Marie Pyle: A stem loop RNA that stimulates RIG-I activation delays tumor growth, extends survival, and prevents tumor recurrence. JEM’s cancer collection for #AACR20 (https://t.co/G1mQsSpTaZ) has summaries of articles in this PDF: https://t.co/Hec3sDfz71 https://t.co/opwHDK5OAQ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "225\n",
      "-----\n",
      "CONGRESS | #AACR20 | Kelly L Bolton, @sloan_kettering, discusses how oncologic therapy shapes the fitness landscape of clonal hematopoiesis (CH) in solid tumors. If clinically validated, CH may guide risk stratification of transformed myeloid neoplasms like AML &amp; MDS #leusm https://t.co/Nk5HfcJF9R\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "226\n",
      "-----\n",
      "Very excited to see our #metanalysis from @ASCO_pubs #JCOGO presented at #AACR20 by @marinagarassino @HornLeora et al. #TERAVOLT team! @tm_parekh @ASCO @AACR @COVID19nCCC https://t.co/iOFHphGBZj\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "227\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "228\n",
      "-----\n",
      "Larotrectinib shows 95% ORR in patients harboring NTRK1/2/3 gene fusions - would like to see such amazing waterfall plots for other targeted therapies. #AACR20 https://t.co/ufkGDvddCM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "229\n",
      "-----\n",
      "Outstanding thread from @ADesaiMD #COVID19 #AACR20 @COVID19nCCC https://t.co/HiIaD0nXYc\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "230\n",
      "-----\n",
      "Here is the data on patients enrolled on trial.  Interesting to note the high incidence of molecular alterations.  This exciting trial was supported by @SU2C #AACR20 #LCSM https://t.co/ZSWHknI66l\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "231\n",
      "-----\n",
      "At #AACR20 Dr Creelan presented data on adoptive TIL therapy for NSCLC.  This is a very interesting approach - surgery of a metastatic lesion, ex vivo TIL expansion, nivolumab, lymphodepletion and TIL reinfusion with further nivolumab  #LCSM https://t.co/ECHtoEoJTG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "232\n",
      "-----\n",
      "Some patients did have further response after TIL infusion.  They also noted some responses after radiographic PD on nivolumab.  Dr Creelan also presented a rather dramatic case, indicated here #AACR20 #LCSM https://t.co/IOCcr89vSS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "233\n",
      "-----\n",
      "#AACR20 David Thiel from @MayoClinic presents at the Early Detection and ctDNA session results from the study investigating the @GrailBio cfDNA methylation signatures test. The manuscript can be found here in Annals of Oncology:  https://t.co/8OjSaWeURz https://t.co/cfEcY8pxVd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "234\n",
      "-----\n",
      "A lot of people with a lot of hope are watching Valter Longo PhD’s work in this area closely.  The basic science is sound.  Very sound. https://t.co/m5MmX9im3E\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "235\n",
      "-----\n",
      "Predictive Biomarkers offer a noninvasive approach for prediction of therapeutic benefit from immune checkpoint inhibition in #lungcancer, per #AACR20 presentation by @max_diehn @AshAlizadeh on @SU2C @LUNGevity @LungAssociation #LungCancer Dream Team\n",
      "https://t.co/6tRnpjoAIl\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "236\n",
      "-----\n",
      "Presented by @DavidHongMD: Pts with #NTRK-mutant or amplified tumors do not respond to #larotrectinib. Are these activating mutations? If so, are they weaker than NTRK fusions? Do they affect drug binding? #AACR20 https://t.co/8SluwIlhRy\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "237\n",
      "-----\n",
      "Patients with cancer appear more vulnerable to SARS-COV-2. Paper pubished @CD_AACR #AACR20 #COVID19 📣 # https://t.co/vGBI59oWoK\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "238\n",
      "-----\n",
      "It’s day two of #AACR20. Today at 520 pm ET, @theNCI’s Deputy Director for Scientific Strategy and Development, Dr. Dinah Singer will present a special session, “NCI Activities: #COVID-19 and #CancerResearch.” Be sure to tune in. https://t.co/Axx9XlL1xs https://t.co/zFQODE0ezB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "239\n",
      "-----\n",
      "Predictive biomarker for #immunotherapy in #NSCLC #LCSM #AACR20 https://t.co/sIU60LX4Rt\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "240\n",
      "-----\n",
      "Great to see new data presented at the #AACR20 Early Detection and #ctDNA session supporting the use of clonal variants to detect and monitor #MRD and disease recurrence in lung cancer.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "241\n",
      "-----\n",
      "Tertiary lymphoid structure (TLS) formation in NSCLC may predict response to immunotherapy (durvalumab) thru interaction with tumor micro-environment. Dr. Sriram Sridhar from AstraZeneca #AACR2020 #AACR20 #LCSM https://t.co/ywMmlw63gL\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "242\n",
      "-----\n",
      "Dr. Garassino/TERAVOLT initial findings: unexpectedly high mortality among #lungcancer patients with #COVID19. 34.6% death rate in first dataset #AACR20 #lcsm @EGFRResisters https://t.co/YNVan2eZrQ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "243\n",
      "-----\n",
      "BIOL 315 - This is a great example of how scientific knowledge is continually revised! A new study finds Ras mutations are not as common (~1 in 5 cancers) as historically thought (~1 in 3).\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "244\n",
      "-----\n",
      "Early detection at #AACR20: David Thiel @MayoClinic speaks about test to predict cancer and organ of origin w/cfDNA. \"Intention is to use in addition to testing based on screening guidelines (not on its own)\" -- wondering why not for all patients? #lcsm @lungcancer @EGFRResisters https://t.co/uzEWy6WNWR\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "245\n",
      "-----\n",
      "Great chairing from Dr Fertig @FertigLab &amp; Dr Turajlic @SamraTurajlic at \"Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease\" #AACR20 Virtual #science Minisymp🙏Thanks @AACR for all efforts making this possible in challenging times! #StaySafe\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "246\n",
      "-----\n",
      "#AACR20 #COVID19 Dr. Fabrice Barlesi on #COVID19nCancer at Gustave Roussy. Incidence #SARSCoV2 (12%), % asymptomatic (80%), ICU (11%), &amp; death (15%) similar to non-oncology population. Risk factors for poor outcome: ECOG&gt;1, heme malig, adv cancer w/ chemo (not other tx) in 3 mos. https://t.co/st9GCjGirh\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "247\n",
      "-----\n",
      "At #AACR20 Dr Creelan presented data on adoptive TIL therapy for NSCLC.  This is a very interesting approach - surgery of a metastatic lesion, ex vivo TIL expansion, nivolumab, lymphodepletion and TIL reinfusion with further nivolumab  #LCSM https://t.co/ECHtoEoJTG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "248\n",
      "-----\n",
      "Recent study from @LivUni @FredNatLab \"The Frequency of Ras Mutations in Cancers\" found that ~19% of cancer patients harbor Ras mutations. Meaning everyone has to go back to their Intro Powerpoint slides and change from \"30% of all cancers.\" #AACR20 https://t.co/OVisW3z17D\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "249\n",
      "-----\n",
      "Here is the data on patients enrolled on trial.  Interesting to note the high incidence of molecular alterations.  This exciting trial was supported by @SU2C #AACR20 #LCSM https://t.co/ZSWHknI66l\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "250\n",
      "-----\n",
      "Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "251\n",
      "-----\n",
      "Cancer patients like triple-negative #breastcancer survivor @deb_silverman are among those most vulnerable to #COVID19: https://t.co/4M0pycC7i1 @washingtonpost #AACR20 #endcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "252\n",
      "-----\n",
      "#AACR20 Reminder that #WordsMatter. Just heard \"Many of our pts are metastatic.\" Pts don't metastasize. Tumors do. Pts are not their disease so: \"Many of our pts have metastatic dz.\" See our lang of respect guide for all speakers at #ASCO20: https://t.co/ne7tIMJLDC #advocacy https://t.co/ZmDYDXNbIP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "253\n",
      "-----\n",
      "New study by Crystal Mackall and colls shows intracerebroventricular- or intratumoral-administered #CARTcells exhibit greater therapeutic potency as compared to intravenous delivery, in atypical teratoid/rhabdoid tumor mouse models https://t.co/QnawGBnpQA #ChildhoodCancer #AACR20 https://t.co/WJWe6evIqB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "254\n",
      "-----\n",
      "Technical challenges exist in using #liquidbiopsies to screen everyone for cancer, in addition to cost issues.  #AACR20 #lcsm #lungcancer @EGFRResisters https://t.co/V3xu4uyIHW\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "255\n",
      "-----\n",
      "An important point raised in the early detection session today at the #AACR20 while going for ctDNA/methylation assays, we should be careful if the healthy individuals harbour a rare undetected tumor or a mutation of risk for the future!\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "256\n",
      "-----\n",
      "Some patients did have further response after TIL infusion.  They also noted some responses after radiographic PD on nivolumab.  Dr Creelan also presented a rather dramatic case, indicated here #AACR20 #LCSM https://t.co/IOCcr89vSS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "257\n",
      "-----\n",
      "New study by Crystal Mackall and colls shows intracerebroventricular- or intratumoral-administered #CARTcells exhibit greater therapeutic potency as compared to intravenous delivery, in atypical teratoid/rhabdoid tumor mouse models https://t.co/QnawGBnpQA #ChildhoodCancer #AACR20 https://t.co/WJWe6evIqB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "258\n",
      "-----\n",
      "A combination therapy targeting the WNT pathway resulted in 67% decrease in tumor activity for some patients with #solidtumors, according to a recent clinical trial led by our @FilipJankuMD: https://t.co/vFLbN5tEas #AACR20 #endcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "259\n",
      "-----\n",
      "Great discussion by Dr. Patricia LoRusso @YaleMed on the NTRK treatment landscape -1st and subsequent line treatment options for NTRK-fusion positive cancers. #AACR2020 #AACR20 #LCSM https://t.co/JI9EBc1qht\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "260\n",
      "-----\n",
      "#OncoAlert\n",
      "Very interesting #COVID19 paper in @CD_AACR. \n",
      "#Cancer patients do worse, unsurprisingly.\n",
      "However patients receiving #radiotherapy do not. Radiation may be less immune suppressive than systemic therapies I suspect (though that could depend on type/location of radiation)\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "261\n",
      "-----\n",
      "#AACR20. Valuable thread by my friend &amp; #bcsm #advocacy colleague. Drs. @nlinmd, @EdKimMDLCI, I, &amp; others wrote about how to include ppl w/ #brainmets in #clinicaltrials (https://t.co/MDrlBP0EOP), &amp; #cnsmetsworkshop2019 was devoted to this topic. #drugdevelopment #regulatory https://t.co/StY3nbC3Bj\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "262\n",
      "-----\n",
      "Dr Marina Garassino @marinagarassino presenting data from #TERAVOLT evaluating #COVID19 and lung cancer #LCSM \n",
      "Results overlapping with our own institutional experience recently spread via #SoMe #AACR20 @AACR @OncoAlert #OncoAlert @IASLC @gecp_org https://t.co/zcglqIyYow\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "263\n",
      "-----\n",
      "Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the #COVID19 outbreak!\n",
      "⭕️Patients with hematological, lung, or with metastatic cancer had the highest frequency of severe event!\n",
      "@CD_AACR #AACR20 @OncoAlert @DrChoueiri \n",
      "https://t.co/EgMXlbmXq9 https://t.co/0IVZ4CE9ye\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "264\n",
      "-----\n",
      "#OncoAlert\n",
      "Very interesting #COVID19 paper in @CD_AACR. \n",
      "#Cancer patients do worse, unsurprisingly.\n",
      "However patients receiving #radiotherapy do not. Radiation may be less immune suppressive than systemic therapies I suspect (though that could depend on type/location of radiation)\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "265\n",
      "-----\n",
      "#OncoAlert\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "266\n",
      "-----\n",
      "Promising research for #braincancer #coloncancer treatment! .@amritasule presented study results at #AACR20 showing #PARP and #ATR #DNA repair inhibitors together are more effective than a PARP inhibitor alone. @RanjitBindra @SmilowCancer @YaleMed @YNHH   https://t.co/XFB6b6peoz https://t.co/qfzig30WOb\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "267\n",
      "-----\n",
      "Some patients did have further response after TIL infusion.  They also noted some responses after radiographic PD on nivolumab.  Dr Creelan also presented a rather dramatic case, indicated here #AACR20 #LCSM https://t.co/IOCcr89vSS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "268\n",
      "-----\n",
      "Great discussion by @AbboshChris on using ctDNA to measure minimum residual disease (MRD) in adjuvant trials for early-stage lung cancer - to predict which pts will relapse after surgery. Results frm TRACERx @SwantonLab @SU2Cscience @LungAssociation #AACR2020 #AACR20 #LCSM https://t.co/DToCKYUfKg\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "269\n",
      "-----\n",
      "Check recent content @NatureCancer about #ctDNA and #LiquidBiopsy in cancer:\n",
      "\n",
      "- #Immunotherapy in SCLC and NSCLC, ITH, clinical implementation, and more!\n",
      "\n",
      "https://t.co/BSc74nrBFa\n",
      "https://t.co/0TgSQO7k9Y\n",
      "https://t.co/KIxFN8Gu2k\n",
      "https://t.co/HZlrrXXsN3\n",
      "\n",
      "#AACR20 https://t.co/80SQVa48Af\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "270\n",
      "-----\n",
      "Our Colleague @shilpaonc live from #AACR20 discussing her work on this first in human study of mRNA2416 given intratumorrally alone and in combination with durvalumab in patients with advanced cancers\n",
      "Edited: @weoncologists https://t.co/2rxks3qi8a\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "271\n",
      "-----\n",
      "Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "272\n",
      "-----\n",
      "The current gold standard for measuring TMB is WES, but targeted gene panels have shown to also estimate TMB. It's imperative that panel TMB values are reliable &amp; consistent to help predict patients who would benefit from immune checkpoint inhibitors. #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "273\n",
      "-----\n",
      "Evidence that supports TMB as a predictive biomarker is mounting, where studies in TMB-high tumors, such as melanoma or lung, reveal that elevated TMB have been associated with clinical benefit from #cancer immunotherapies. #AACR20 @d2merino https://t.co/xC1Qn0XzY9 https://t.co/pOfIKVU8s3\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "274\n",
      "-----\n",
      "Starting NOW: Phase 2 results from our TMB Harmonization Project is being presented @AACR's Virtual Annual Meeting. Be sure to follow the conversation w/ #AACR20 and learn more about our project here: https://t.co/xC1Qn0XzY9\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "275\n",
      "-----\n",
      "Starting NOW: Phase 2 results from our TMB Harmonization Project is being presented @AACR's Virtual Annual Meeting. Be sure to follow the conversation w/ #AACR20 and learn more about our project here: https://t.co/xC1Qn0XzY9\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "276\n",
      "-----\n",
      "CONGRESS | #AACR20 | Kelly L Bolton, @sloan_kettering, discusses how oncologic therapy shapes the fitness landscape of clonal hematopoiesis (CH) in solid tumors. If clinically validated, CH may guide risk stratification of transformed myeloid neoplasms like AML &amp; MDS #leusm https://t.co/Nk5HfcJF9R\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "277\n",
      "-----\n",
      "Good news, but Genentech, Inc. is only allowing women to be part of the trial. This is contrary FDA recommendations which suggests men be included in bc trials. #bcsm\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "278\n",
      "-----\n",
      "#OncoAlert\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "279\n",
      "-----\n",
      "#COVID19 #AACR20 #LCSM\n",
      "TERAVOLT preliminary results by @marinagarassino. An amazing international effort to improve knowledge about #lungcancer &amp; COVID19.\n",
      "198 pts evaluated with 34.6% of death rate.\n",
      "Not specific anti-cancer treatment was associated w/ higher mortality #OncoAlert https://t.co/dWUKuoU1qi\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "280\n",
      "-----\n",
      "Poziotinib Shows Mixed Findings in Exon 20-Mutant NSCLC @MDAndersonNews @AACR #lcsm #AACR20 https://t.co/2bTCacIpt4\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "281\n",
      "-----\n",
      "Presentan resultados de ensayo clínico CIMAvax en congreso de Asociación para la Investigación del Cáncer en #US. Resultados alentadores de combinar dos inmunoterapias novedosas. @centro_cim @RoswellPark https://t.co/ZjU38wpVMz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "282\n",
      "-----\n",
      "An amazing job with this Virtual #AACR20 , Kudos‼️  \n",
      "Thank you very much to all the hard working people at @AACR for making this possible‼️Way to set the bar🙌\n",
      "Best from @weoncologists &amp; all of us at @OncoAlert 🚨 https://t.co/R5MDUSCIQ9\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "283\n",
      "-----\n",
      "Our Colleague @shilpaonc live from #AACR20 discussing her work on this first in human study of mRNA2416 given intratumorrally alone and in combination with durvalumab in patients with advanced cancers\n",
      "Edited: @weoncologists https://t.co/2rxks3qi8a\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "284\n",
      "-----\n",
      "Are #COVID19 patients with thoracic #cancer less likely to be admitted to #ICU? Read more in the latest news from #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "285\n",
      "-----\n",
      "Two studies presented Monday at the Opening Clinical Plenary Session at the #AACR20 Virtual Meeting I examined different strategies for addressing these challenges to improve treatment for melanoma. https://t.co/sz9eBviGsy\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "286\n",
      "-----\n",
      "Live Notes, Real Time Conference Coverage 2020 #AACR #Virtual Meeting April 28, 2020 Session on #Novel #Targets and #Therapies 2:35 PM https://t.co/5usl7KYaL6 via @Pharma_BI @AACR @CureCancerNow @pharmanews @BiotechWorld #AACR20 @StephenJWillia2\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "287\n",
      "-----\n",
      "Our Colleague @shilpaonc live from #AACR20 discussing her work on this first in human study of mRNA2416 given intratumorrally alone and in combination with durvalumab in patients with advanced cancers\n",
      "Edited: @weoncologists https://t.co/2rxks3qi8a\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "288\n",
      "-----\n",
      "Our Colleague @shilpaonc live from #AACR20 discussing her work on this first in human study of mRNA2416 given intratumorrally alone and in combination with durvalumab in patients with advanced cancers\n",
      "Edited: @weoncologists https://t.co/2rxks3qi8a\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "289\n",
      "-----\n",
      "📢 Pr Fabrice @barlesi @GustaveRoussy a présenté en plénière #Covid19etCancer du congrès #AACR20 une analyse précoce de la situation et la manière dont Gustave Roussy s’est adapté avec agilité pour gérer l’épidémie de #covid19.\n",
      "\n",
      "Lire le communiqué : https://t.co/VPFdDJgHol\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "290\n",
      "-----\n",
      "Our secondary analysis objective was to use the clinical data to further investigate 3 calibration approaches that may help align TMB values across NGS panels. #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "291\n",
      "-----\n",
      "For Phase 2B of our TMB Harmonization Project, our primary analysis objective was to assess the empirical variability in the association between the panel TMB values &amp; WES TMB in the clinical samples. #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "292\n",
      "-----\n",
      "Talk from #TRACERx about the use ctDNA in early stage lung cancer to predict patient relapse after surgery, correlating it with minimum residual disease:\n",
      "⬆️ pre-op ctDNA shedding associated with longer MRD lead-times and shorter DFS times post-op\n",
      "#AACR20 #AACR2020 #lcsm https://t.co/eqtjL1ypV1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "293\n",
      "-----\n",
      "Starting NOW: Phase 2 results from our TMB Harmonization Project is being presented @AACR's Virtual Annual Meeting. Be sure to follow the conversation w/ #AACR20 and learn more about our project here: https://t.co/xC1Qn0XzY9\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "294\n",
      "-----\n",
      ".@d2merino on our TMB Harmonization Project: The primary objective is to align-on &amp; publish universal best practices for defining TMB, as well as proposing and executing analytic validation approaches including the alignment against external reference standards. #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "295\n",
      "-----\n",
      "The goals of Phase 2 of the TMB Harmonization Project include the creation of a universal reference standard to help calibrate or align TMB scores obtained from different NGS panels and better understand the sources of variability across panels. #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "296\n",
      "-----\n",
      "Phase 1 of the TMB Harmonization Project consisted of an in silico approach that used publicly available WES data from the TCGA project. 11 labs participated and a strong correlation between WES TMB and the panel TMB values was found. #AACR20 https://t.co/xC1Qn0XzY9 https://t.co/paEHUkD2Nf\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "297\n",
      "-----\n",
      "Are #COVID19 patients with thoracic #cancer less likely to be admitted to #ICU? Read more in the latest news from #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "298\n",
      "-----\n",
      "Evidence that supports TMB as a predictive biomarker is mounting, where studies in TMB-high tumors, such as melanoma or lung, reveal that elevated TMB have been associated with clinical benefit from #cancer immunotherapies. #AACR20 @d2merino https://t.co/xC1Qn0XzY9 https://t.co/pOfIKVU8s3\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "299\n",
      "-----\n",
      "Great discussion by @AbboshChris on using ctDNA to measure minimum residual disease (MRD) in adjuvant trials for early-stage lung cancer - to predict which pts will relapse after surgery. Results frm TRACERx @SwantonLab @SU2Cscience @LungAssociation #AACR2020 #AACR20 #LCSM https://t.co/DToCKYUfKg\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "300\n",
      "-----\n",
      "#OncoAlert #AACR20 In 28 patients with cancer and #COVID19, 36% required mechanical ventilation, 29% mortality with 21% still hospitalized. For those discharged, median hospitalization 18.4 days. For those with severe events, median 7 days from COVID diagnosis to event. https://t.co/Gq4j4ivica\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "301\n",
      "-----\n",
      "#OncoAlert #AACR20 Analyses to identify risk factors for severe events such as recent anti-cancer therapy (14d), radiographic findings. IO therapy not a clear risk. Numbers though are small and this is where large ongoing registries (such as #TERAVOLT) will help with perspective. https://t.co/XTfdNTdJqB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "302\n",
      "-----\n",
      "Our Colleague @shilpaonc live from #AACR20 discussing her work on this first in human study of mRNA2416 given intratumorrally alone and in combination with durvalumab in patients with advanced cancers\n",
      "Edited: @weoncologists https://t.co/2rxks3qi8a\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "303\n",
      "-----\n",
      "@AACR\n",
      "@CureCancerNow\n",
      "@pharmanews\n",
      "@BiotechWorld\n",
      "#AACR20\n",
      "@StephenJWillia2\n",
      "\n",
      "#Cancer: Novel #Targets and #Therapies - Outstanding Real time coverage by Dr. Williams https://t.co/afTW2jxA05\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "304\n",
      "-----\n",
      "Tertiary lymphoid structure (TLS) formation in NSCLC may predict response to immunotherapy (durvalumab) thru interaction with tumor micro-environment. Dr. Sriram Sridhar from AstraZeneca #AACR2020 #AACR20 #LCSM https://t.co/ywMmlw63gL\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "305\n",
      "-----\n",
      "Talk from #TRACERx about the use ctDNA in early stage lung cancer to predict patient relapse after surgery, correlating it with minimum residual disease:\n",
      "⬆️ pre-op ctDNA shedding associated with longer MRD lead-times and shorter DFS times post-op\n",
      "#AACR20 #AACR2020 #lcsm https://t.co/eqtjL1ypV1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "306\n",
      "-----\n",
      "Some patients did have further response after TIL infusion.  They also noted some responses after radiographic PD on nivolumab.  Dr Creelan also presented a rather dramatic case, indicated here #AACR20 #LCSM https://t.co/IOCcr89vSS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "307\n",
      "-----\n",
      "#OncoAlert\n",
      "Very interesting #COVID19 paper in @CD_AACR. \n",
      "#Cancer patients do worse, unsurprisingly.\n",
      "However patients receiving #radiotherapy do not. Radiation may be less immune suppressive than systemic therapies I suspect (though that could depend on type/location of radiation)\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "308\n",
      "-----\n",
      "Correct @pashtoonkasi  therapeutic trial for gBRCA1/2 only in POLO\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "309\n",
      "-----\n",
      "We evaluated 3 different calibration approaches and evaluated the extent to which these helped align panel TMB values in clinical samples. We found in most of the cases, the 2 TCGA calibration methods helped tighten the spread of panel TMB values #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "310\n",
      "-----\n",
      "As complex biomarkers, such as TMB, become more readily incorporated into #oncology care, scientific and regulatory approaches are necessary for alignment on optimal performance thresholds and standards development. #AACR20 https://t.co/xC1Qn0XzY9 https://t.co/Uy6V5vCNbU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "311\n",
      "-----\n",
      ".@DavidHongMD: site-agnostic Vivtrakvi (larotrectinib) works better for #cancers with NTRK gene fusions vs other mutations. #AACR20 https://t.co/nvBLhcLfXg\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "312\n",
      "-----\n",
      "Talk from #TRACERx about the use ctDNA in early stage lung cancer to predict patient relapse after surgery, correlating it with minimum residual disease:\n",
      "⬆️ pre-op ctDNA shedding associated with longer MRD lead-times and shorter DFS times post-op\n",
      "#AACR20 #AACR2020 #lcsm https://t.co/eqtjL1ypV1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "313\n",
      "-----\n",
      "Great discussion by Dr. Patricia LoRusso @YaleMed on the NTRK treatment landscape -1st and subsequent line treatment options for NTRK-fusion positive cancers. #AACR2020 #AACR20 #LCSM https://t.co/JI9EBc1qht\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "314\n",
      "-----\n",
      "Durable Immunotherapy Response Estimation by immune profiling and ctDNA-On-treatment (DIRECT-On assay) is a simple blood test that can predict which pts respond to immunotherapy within first 6 months of starting immunotherapy @Barzin_ @Stanford @max_diehn #AACR2020 #AACR20 #LCSM https://t.co/9E8gRBzV8D\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "315\n",
      "-----\n",
      ".@DavidHongMD: site-agnostic Vivtrakvi (larotrectinib) works better for #cancers with NTRK gene fusions vs other mutations. #AACR20 https://t.co/nvBLhcLfXg\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "316\n",
      "-----\n",
      "ctDNA measurement thru liquid biopsy over time (frm FLAURA study) predicts progression-free survival &amp; correlates w/ tumor size in EGFR-mutant NSCLC tx w/ osimertinib. Possibility fr monitoring during #COVID19? Dr. Martin Johnson frm Astra Zeneca #AACR2020 #AACR20 #LCSM https://t.co/5utKOMIMZc\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "317\n",
      "-----\n",
      "New study by Crystal Mackall and colls shows intracerebroventricular- or intratumoral-administered #CARTcells exhibit greater therapeutic potency as compared to intravenous delivery, in atypical teratoid/rhabdoid tumor mouse models https://t.co/QnawGBnpQA #ChildhoodCancer #AACR20 https://t.co/WJWe6evIqB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "318\n",
      "-----\n",
      ".@uclcancer’s @squezadd will be chairing the Predictive Biomarkers for Immunotherapeutics session at the #AACR20 Virtual Annual Meeting I. Join online tonight from 20:20 – 23:35 BST to hear about emerging clinical research in immunology. https://t.co/tVpACzxsXU https://t.co/fv4PExKwi2\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "319\n",
      "-----\n",
      "“The adjusted survival curve of severe events showed that cancer patients who had anticancer treatment in the past 14 days or patchy consolidation at admission were significantly associated with severe events,” Dr Zhang said. #AACR20\n",
      "https://t.co/XMJYCCXEoP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "320\n",
      "-----\n",
      "#OncoAlert #AACR20 More mature data emerging from China. This review by Dr. Zhang at Tongji in Wuhan discusses patients with cancer and #COVID19. Interesting to contrast these with data from US, Italy, Spain, France, etc - some trends just reflect patient populations served. https://t.co/5nxOc3BYb2\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "321\n",
      "-----\n",
      "#OncoAlert #AACR20 Analyses to identify risk factors for severe events such as recent anti-cancer therapy (14d), radiographic findings. IO therapy not a clear risk. Numbers though are small and this is where large ongoing registries (such as #TERAVOLT) will help with perspective. https://t.co/XTfdNTdJqB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "322\n",
      "-----\n",
      "@OncoAlert @BenWestphalen @weoncologists #AACR20 👆🏼#BRAF - one of my patients recently sent me this illustrating from a recent review the diversity of tumor types in which #BRAF mutations are seen as well as the spectrum of mutations (V600E 🆚 non-V600E); classifications of #BRAF mutations. #precisionmedicine https://t.co/Ls3p52ijEs\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "323\n",
      "-----\n",
      "Great discussion by @AbboshChris on using ctDNA to measure minimum residual disease (MRD) in adjuvant trials for early-stage lung cancer - to predict which pts will relapse after surgery. Results frm TRACERx @SwantonLab @SU2Cscience @LungAssociation #AACR2020 #AACR20 #LCSM https://t.co/DToCKYUfKg\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "324\n",
      "-----\n",
      "Thank you so much to the #AACR20 organizers for making this possible: kudos for organizing a seamless event even in the face of #COVID19 . Very thoughtful discussion, tons of participation from the audience and some very cool #cancer tweep connections. See y'all tomorrow! https://t.co/tUxR4msXCN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "325\n",
      "-----\n",
      "\"~19% of cancer patients harbor RAS mutations\" per recent study in #CancerResearch @AACR journal. Not so much the 30% quoted historically. Wide variability across cancers.... #AACR20 https://t.co/ylUH2mMMQW https://t.co/nr0TfPFGR9\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "326\n",
      "-----\n",
      "Hey @AACR, is the 5 pm Eastern time #AACR20 session on \"NCI Activities: COVID-19 and Cancer Research\" going to happen? Only hearing music and seeing AACR advert slides.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "327\n",
      "-----\n",
      "Waiting for the session to begin! amazing setup for the online meeting...#AACR20 We are presenting our breast atlas work @nicholas_navin @MDA_UTHGrad  @KessenbrockLab @DLawsonlab labs at 3:55EDT! https://t.co/MidhFjnlvt\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "328\n",
      "-----\n",
      "Talk from #TRACERx about the use ctDNA in early stage lung cancer to predict patient relapse after surgery, correlating it with minimum residual disease:\n",
      "⬆️ pre-op ctDNA shedding associated with longer MRD lead-times and shorter DFS times post-op\n",
      "#AACR20 #AACR2020 #lcsm https://t.co/eqtjL1ypV1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "329\n",
      "-----\n",
      "Loving the talk by Yvonne Chen giving a bird's-eye view of the pipeline and challenges for CAR-T clinical implementation #AACR20 #cancer #therapy https://t.co/9IG5JtN5Er\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "330\n",
      "-----\n",
      "Great presentation by Dr. Padmanee Sharma of @MDAndersonNews @AACR #AACR20 on why PD-1 and PD-L1 inhibitors performed poorly in #mCRPC to date and what the next steps should be https://t.co/0vT59YkLKy\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "331\n",
      "-----\n",
      "Fantastic thread about the #COVID19 and cancer #COVID19nCancer #AACR20 - thanks!\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "332\n",
      "-----\n",
      "CONGRESS | #AACR20 | Kelly L Bolton, @sloan_kettering, discusses how oncologic therapy shapes the fitness landscape of clonal hematopoiesis (CH) in solid tumors. If clinically validated, CH may guide risk stratification of transformed myeloid neoplasms like AML &amp; MDS #leusm https://t.co/Nk5HfcJF9R\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "333\n",
      "-----\n",
      "Fascinating talk by @barlesi @GustaveRoussy - Cancer patient outcomes with #COVID19, incl therapy, AEs and pediatric patients. Similar outcomes regardless of #COVID19 however need to pay attention to specific factors. \"Participation in CTs is essential\" #COVID19nCancer #AACR20 https://t.co/ZRZMZ5nxGa\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "334\n",
      "-----\n",
      "Join @uclcancer’s @AbboshChris tonight from 19:15 – 19:25 BST as he presents the latest data from the #CRUKFunded, @ucl-sponsored #TRACERx study at the #AACR20 Annual Meeting I. Join the session here: https://t.co/uwGlbLBI0d https://t.co/pD6Vxmr44w\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "335\n",
      "-----\n",
      "#Covid19: First results from TERAVOLT registry for thoracic cancers show high mortality rate of COVID-19 in pats w/ thoracic malignancies. Mortality rate of COVID-19 in this group does not appear 2 b linked to specific treatmt/comorbidity. Video: https://t.co/QlXez9T5FB #AACR20 https://t.co/wPkHD6ouqF\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "336\n",
      "-----\n",
      "Exciting data presented by @Barzin_ at #AACR20 on the use of a novel ctDNA assay to predict outcomes for immunotherapy in NSCLC.  CAPP-Seq is more sensitive than many commercially available assays.  They coupled this with a bulkRNA sequencing called CIBERSORT #LCSM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "337\n",
      "-----\n",
      "Same for me. If there's a plan for a delayed start can you please let us know @AACR?\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "338\n",
      "-----\n",
      "New hope for lung cancer patients. A Moffitt study shows personalized immunotherapy called TIL worked for at least 25% of patients in a clinical trial. Results were presented today at the American Association for Cancer Research Annual Meeting. #AACR20 https://t.co/acqM4YSNa9 https://t.co/3Ehc8JaZuw\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "339\n",
      "-----\n",
      "At #AACR20 Dr Creelan presented data on adoptive TIL therapy for NSCLC.  This is a very interesting approach - surgery of a metastatic lesion, ex vivo TIL expansion, nivolumab, lymphodepletion and TIL reinfusion with further nivolumab  #LCSM https://t.co/ECHtoEoJTG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "340\n",
      "-----\n",
      "Great chairing from Dr Fertig @FertigLab &amp; Dr Turajlic @SamraTurajlic at \"Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease\" #AACR20 Virtual #science Minisymp🙏Thanks @AACR for all efforts making this possible in challenging times! #StaySafe\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "341\n",
      "-----\n",
      "Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "342\n",
      "-----\n",
      "“The adjusted survival curve of severe events showed that cancer patients who had anticancer treatment in the past 14 days or patchy consolidation at admission were significantly associated with severe events,” Dr Zhang said. #AACR20\n",
      "https://t.co/XMJYCCXEoP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "343\n",
      "-----\n",
      "Predictive Biomarkers offer a noninvasive approach for prediction of therapeutic benefit from immune checkpoint inhibition in #lungcancer, per #AACR20 presentation by @max_diehn @AshAlizadeh on @SU2C @LUNGevity @LungAssociation #LungCancer Dream Team\n",
      "https://t.co/6tRnpjoAIl\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "344\n",
      "-----\n",
      "There was #cancer before the pandemic, there is cancer now, and there will be cancer after. Thankfully, some research continues. Progress toward off-the-shelf #CAR_T cells, from Shanghai #biotech, at #AACR20: https://t.co/YuVBfGVs5J\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "345\n",
      "-----\n",
      ".@DavidHongMD: site-agnostic Vivtrakvi (larotrectinib) works better for #cancers with NTRK gene fusions vs other mutations. #AACR20 https://t.co/nvBLhcLfXg\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "346\n",
      "-----\n",
      "Phase 1 of the TMB Harmonization Project consisted of an in silico approach that used publicly available WES data from the TCGA project. 11 labs participated and a strong correlation between WES TMB and the panel TMB values was found. #AACR20 https://t.co/xC1Qn0XzY9 https://t.co/paEHUkD2Nf\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "347\n",
      "-----\n",
      "Phase 1 of the TMB Harmonization Project consisted of an in silico approach that used publicly available WES data from the TCGA project. 11 labs participated and a strong correlation between WES TMB and the panel TMB values was found. #AACR20 https://t.co/xC1Qn0XzY9 https://t.co/paEHUkD2Nf\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "348\n",
      "-----\n",
      "Our Colleague @shilpaonc live from #AACR20 discussing her work on this first in human study of mRNA2416 given intratumorrally alone and in combination with durvalumab in patients with advanced cancers\n",
      "Edited: @weoncologists https://t.co/2rxks3qi8a\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "349\n",
      "-----\n",
      "As complex biomarkers, such as TMB, become more readily incorporated into #oncology care, scientific and regulatory approaches are necessary for alignment on optimal performance thresholds and standards development. #AACR20 https://t.co/xC1Qn0XzY9 https://t.co/Uy6V5vCNbU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "350\n",
      "-----\n",
      "Targeting #EGFR exon 20 insertion with TAK788 leads to ORR of 43% #AACR20 https://t.co/fYp5lEkShc\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "351\n",
      "-----\n",
      "As complex biomarkers, such as TMB, become more readily incorporated into #oncology care, scientific and regulatory approaches are necessary for alignment on optimal performance thresholds and standards development. #AACR20 https://t.co/xC1Qn0XzY9 https://t.co/Uy6V5vCNbU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "352\n",
      "-----\n",
      "Was such a good talk!!! (Full bias, but idc)\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "353\n",
      "-----\n",
      "Huge thanks to @AACR for the opportunity to present our work on genomic correlates of PD-L1 expression today at #AACR20 and to fellow authors @GLambertiMD @BiagioMd @GRecondoMD @meyersonlab @DrMarkAwad  as well as non-twitter folks for tremendous support and mentorship.\n",
      "1/3\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "354\n",
      "-----\n",
      "The NCI Activities: COVID-19 and Cancer Research session is starting now. #AACR20 Virtual Annual Meeting I.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "355\n",
      "-----\n",
      "Couldn’t have said it better, thank you!!\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "356\n",
      "-----\n",
      "The NCI Activities: COVID-19 and Cancer Research session is starting now. #AACR20 Virtual Annual Meeting I.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "357\n",
      "-----\n",
      "#OncoAlert #AACR20 Global registry of #COVIDー19 in patients with lung cancer led by @marinagarassino and @HornLeora, the #TERAVOLT registry: Thoracic Cancers International COVID-19 Collaboration. An impressive and rapidly executed, global registry. #LCSM https://t.co/UxjI9o6gcF\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "358\n",
      "-----\n",
      "ICYMI earlier, a look at #liquidbiopsy data at #AACR20:\n",
      "Thrive, chasing Grail with a #cancer blood test, finds tumors in seemingly healthy women https://t.co/BIZLvIZSk3\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "359\n",
      "-----\n",
      "To learn more about what we evaluated in Phase 1 of the TMB Harmonization Project, visit: https://t.co/us1TAD7MhV #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "360\n",
      "-----\n",
      "Our #AACR20 poster presentations are available on-demand. View research presentations by Yuman Fong, M.D., chair of the Department of Surgery at City of Hope, and medical oncologist Mihaela Cristea, M.D.\n",
      "\n",
      "Dr. Fong: https://t.co/taB7ae9TeQ\n",
      "Dr. Cristea: https://t.co/XdWaJgt4tP https://t.co/VqLdJWiDx7\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "361\n",
      "-----\n",
      "Due to the importance of TMB in patients' stratification in immunotherapy, this harmonization and standardization of TMB between WES and panel sequencing is definitely valuable to the field. #AACR20 \n",
      "https://t.co/VAeJPj9yqA https://t.co/HngrHVrnaL\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "362\n",
      "-----\n",
      "The NCI Activities: COVID-19 and Cancer Research session is starting now. #AACR20 Virtual Annual Meeting I.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "363\n",
      "-----\n",
      "Great chairing from Dr Fertig @FertigLab &amp; Dr Turajlic @SamraTurajlic at \"Evaluating Cancer Genomics from Normal Tissues through Evolution to Metastatic Disease\" #AACR20 Virtual #science Minisymp🙏Thanks @AACR for all efforts making this possible in challenging times! #StaySafe\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "364\n",
      "-----\n",
      "The NCI Activities: COVID-19 and Cancer Research session is starting now. #AACR20 Virtual Annual Meeting I.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "365\n",
      "-----\n",
      "Our Colleague @shilpaonc live from #AACR20 discussing her work on this first in human study of mRNA2416 given intratumorrally alone and in combination with durvalumab in patients with advanced cancers\n",
      "Edited: @weoncologists https://t.co/2rxks3qi8a\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "366\n",
      "-----\n",
      ".@Amgen strives to address the unmet need for #prostatecancer patients. This includes investigating potential therapeutic targets such as STEAP1 which is over-expressed in more than 80 percent of prostate cancers. See data presented earlier today at #AACR20 https://t.co/9eGGWlLpM6\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "367\n",
      "-----\n",
      "Our #AACR20 poster presentations are available on-demand. View research presentations by Yuman Fong, M.D., chair of the Department of Surgery at City of Hope, and medical oncologist Mihaela Cristea, M.D.\n",
      "\n",
      "Dr. Fong: https://t.co/taB7ae9TeQ\n",
      "Dr. Cristea: https://t.co/XdWaJgt4tP https://t.co/VqLdJWiDx7\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "368\n",
      "-----\n",
      "In the \"green room\" (it's pretty grey...) ahead of the @AACR #AACR20 presentation on the @CancerResrch #TMB Harmonization Project. Excited to be representing the collaborative work of such a great group of partners! Don't forget to tune in! Presentation starts at 4:55pm! https://t.co/ILJMIVTej1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "369\n",
      "-----\n",
      "#AACR20 #COVID19 Dr. Fabrice Barlesi on #COVID19nCancer at Gustave Roussy. Incidence #SARSCoV2 (12%), % asymptomatic (80%), ICU (11%), &amp; death (15%) similar to non-oncology population. Risk factors for poor outcome: ECOG&gt;1, heme malig, adv cancer w/ chemo (not other tx) in 3 mos. https://t.co/st9GCjGirh\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "370\n",
      "-----\n",
      "We invite all #AACR20 participants to discover our robust range of modalities designed to address tumor types with high unmet need represented in Amgen’s investigational #anticancer pipeline. Visit the newly refreshed https://t.co/nS2DiI3prf. #BiTEtechnology #ImmunoOncology https://t.co/B5i7tE8Db5\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "371\n",
      "-----\n",
      "We continue to learn about impact of #COVID19 on #cancer patients. A number of studies reported at @AACR today continue to expand our knowledge. Now we need a coherent picture. What is clear: many patients with #cancer develop serious illness because of their disease/treatment\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "372\n",
      "-----\n",
      "Why aren’t all medicines taken as pills? Teresa Klinowska, Global Project Leader in Oncology, explains some of the decisions that go into how medicines are developed. #SciencefromAtoZ #AACR20 https://t.co/yuoe3QQtf1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "373\n",
      "-----\n",
      "Targeting #EGFR exon 20 insertion with TAK788 leads to ORR of 43% #AACR20 https://t.co/fYp5lEkShc\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "374\n",
      "-----\n",
      "🤓 Patients with cancer appear more vulnerable to SARS-COV-2. Paper published @CD_AACR #AACR20 #COVID19 https://t.co/D6m1xoJzQk\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "375\n",
      "-----\n",
      "One major benefit of virtual  #AACR20 is that I never miss a session! After a busy morning, finally settling in to watch the 'Early Detection and ctDNA' session #LiquidBiopsy.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "376\n",
      "-----\n",
      "#AACR20 Reminder that #WordsMatter. Just heard \"Many of our pts are metastatic.\" Pts don't metastasize. Tumors do. Pts are not their disease so: \"Many of our pts have metastatic dz.\" See our lang of respect guide for all speakers at #ASCO20: https://t.co/ne7tIMJLDC #advocacy https://t.co/ZmDYDXNbIP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "377\n",
      "-----\n",
      "That was an excellent Presentation by a wonderful colleague, Dr\n",
      "Diana Merino Vega @d2merino\n",
      "tittled \"Allignment of TMB Measured on Clinical samples: Phase 2B of the Friends of Cancer Research TMB Harmonization Project, during the during the @AACR #AACR20 Virtual Mtg I. #AACRAMC https://t.co/bkPTp77a0q\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "378\n",
      "-----\n",
      "Thank you to the #brainmets working group: @tmprowell, @nlinmd, @EdKimMDLCI, @ASCO, @CancerResrch\n",
      "\n",
      "Esp important is the rec to incl those vulnerable #patients w/ lepto (LMD) in #ClinicalTrials as a separate cohort. \n",
      "\n",
      "Now - how to enforce these guidelines?!\n",
      "\n",
      "#BCSM #LCSM #MelSM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "379\n",
      "-----\n",
      "Can't do this at an in-person meeting! Hint to @AACR: please display current speaker &amp; session in the video player  #AACR20 https://t.co/pGYaPHgyRs\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "380\n",
      "-----\n",
      "Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "381\n",
      "-----\n",
      "Targeting #EGFR exon 20 insertion with TAK788 leads to ORR of 43% #AACR20 https://t.co/fYp5lEkShc\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "382\n",
      "-----\n",
      "Adding atezo to enza unfortunately showed no evidence of benefit. Kudos to patients / investigators /GNE for commiting to a ph 3 trial to get clear data. Need to turn up bunsen burners in the lab to make PrCa “hot”. @PCF_Science PCF_Science @DanaFarberNews @Uromigos @tompowles1 https://t.co/IlYpbggMvZ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "383\n",
      "-----\n",
      "Just Out📣at @NEJM 📰In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genes🧬w/a role in homologous recombination repair, olaparib was associated w/longer PFS‼️ #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "384\n",
      "-----\n",
      "Just Out📣at @NEJM 📰In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genes🧬w/a role in homologous recombination repair, olaparib was associated w/longer PFS‼️ #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "385\n",
      "-----\n",
      "Our @OncoAlert 🚨Colleague @CharuAggarwalMD 👩‍⚕️from @PennCancer  Virtually Live at #AACR20 discussing global🌏presentations dealing #COVID19 and #Cancer : #TERAVOLT from @marinagarassino 🇮🇹&amp; The French experience by @barlesi from @GustaveRoussy 🇫🇷\n",
      "Edited: @weoncologists https://t.co/yJXXuVGIJV\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "386\n",
      "-----\n",
      "The Opening Clinical Plenary Session of the #AACR20 Virtual Meeting I featured two studies that examined strategies to improve responses to BRAF and MEK inhibitors in patients with advanced melanoma. https://t.co/JOey5E72jS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "387\n",
      "-----\n",
      "Our @OncoAlert 🚨Colleague @CharuAggarwalMD 👩‍⚕️from @PennCancer  Virtually Live at #AACR20 discussing global🌏presentations dealing #COVID19 and #Cancer : #TERAVOLT from @marinagarassino 🇮🇹&amp; The French experience by @barlesi from @GustaveRoussy 🇫🇷\n",
      "Edited: @weoncologists https://t.co/yJXXuVGIJV\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "388\n",
      "-----\n",
      "New study by Crystal Mackall and colls shows intracerebroventricular- or intratumoral-administered #CARTcells exhibit greater therapeutic potency as compared to intravenous delivery, in atypical teratoid/rhabdoid tumor mouse models https://t.co/QnawGBnpQA #ChildhoodCancer #AACR20 https://t.co/WJWe6evIqB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "389\n",
      "-----\n",
      "Exciting to hear about new opportunities for researchers in the physical sciences and oncology to collaborate and disseminate exciting new avenues of translational research! #AACR20 https://t.co/rQQ5N0ZAmr\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "390\n",
      "-----\n",
      "Agree! Took me a bit to figure out the speaker when jumping from session to session! #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "391\n",
      "-----\n",
      "In the \"green room\" (it's pretty grey...) ahead of the @AACR #AACR20 presentation on the @CancerResrch #TMB Harmonization Project. Excited to be representing the collaborative work of such a great group of partners! Don't forget to tune in! Presentation starts at 4:55pm! https://t.co/ILJMIVTej1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "392\n",
      "-----\n",
      "We should be in San Diego today for the annual @AACR meeting. However we are pleased to say we will be at the Virtual Annual Meeting II in June 2020 with some new posters. For now, you can view previous posters here: \n",
      "https://t.co/Vy0TF2QkJ6\n",
      "#AACR20 https://t.co/Dg84e7w89m\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "393\n",
      "-----\n",
      "Here’s what would help patients: \n",
      "\n",
      "If in addition to a lengthy and detailed paper &amp; https://t.co/ebWn8BVV8u entry, trialists  had a clear 1-page infographic detailing which patients were enrolled, what each arm got &amp; what the average results were. \n",
      "\n",
      "1/2\n",
      "\n",
      "#AACR2020 @OncoAlert\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "394\n",
      "-----\n",
      "@theNCI is supporting #COVID19-related research efforts. Program announcements in this tweet. Please contact your program officer. #AACR2020 #AACR20 #LCSM https://t.co/1IKrsqoIJT\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "395\n",
      "-----\n",
      "Great discussion by @AbboshChris on using ctDNA to measure minimum residual disease (MRD) in adjuvant trials for early-stage lung cancer - to predict which pts will relapse after surgery. Results frm TRACERx @SwantonLab @SU2Cscience @LungAssociation #AACR2020 #AACR20 #LCSM https://t.co/DToCKYUfKg\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "396\n",
      "-----\n",
      "The NCI Activities: COVID-19 and Cancer Research session is starting now. #AACR20 Virtual Annual Meeting I.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "397\n",
      "-----\n",
      "#AACR20 Reminder that #WordsMatter. Just heard \"Many of our pts are metastatic.\" Pts don't metastasize. Tumors do. Pts are not their disease so: \"Many of our pts have metastatic dz.\" See our lang of respect guide for all speakers at #ASCO20: https://t.co/ne7tIMJLDC #advocacy https://t.co/ZmDYDXNbIP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "398\n",
      "-----\n",
      "Huge thanks to @AACR for the opportunity to present our work on genomic correlates of PD-L1 expression today at #AACR20 and to fellow authors @GLambertiMD @BiagioMd @GRecondoMD @meyersonlab @DrMarkAwad  as well as non-twitter folks for tremendous support and mentorship.\n",
      "1/3\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "399\n",
      "-----\n",
      "Here’s what would help patients: \n",
      "\n",
      "If in addition to a lengthy and detailed paper &amp; https://t.co/ebWn8BVV8u entry, trialists  had a clear 1-page infographic detailing which patients were enrolled, what each arm got &amp; what the average results were. \n",
      "\n",
      "1/2\n",
      "\n",
      "#AACR2020 @OncoAlert https://t.co/CsVDGEyIMd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "400\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "401\n",
      "-----\n",
      "Here’s what would help patients: \n",
      "\n",
      "If in addition to a lengthy and detailed paper &amp; https://t.co/ebWn8BVV8u entry, trialists  had a clear 1-page infographic detailing which patients were enrolled, what each arm got &amp; what the average results were. \n",
      "\n",
      "1/2\n",
      "\n",
      "#AACR2020 @OncoAlert https://t.co/CsVDGEyIMd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "402\n",
      "-----\n",
      "Great to see our Digital Editors still keeping their site members up to date with the latest research from #AACR20. Check out their coffee chat highlight from day 1 of the meeting\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "403\n",
      "-----\n",
      "Link to our recent paper. Great work by Liam Spurr @lfspurr, Giuseppe Lamberti @GLambertiMD with wonderful leadership by Andy Cherniack and Mark Awad.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "404\n",
      "-----\n",
      "Here’s what would help patients: \n",
      "\n",
      "If in addition to a lengthy and detailed paper &amp; https://t.co/ebWn8BVV8u entry, trialists  had a clear 1-page infographic detailing which patients were enrolled, what each arm got &amp; what the average results were. \n",
      "\n",
      "1/2\n",
      "\n",
      "#AACR2020 @OncoAlert\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "405\n",
      "-----\n",
      "This study greatly supports our ongoing practice of using immunotherapy or targeted therapy in lung cancer patients.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "406\n",
      "-----\n",
      "#OncoAlert #AACR20 Long awaited data from TAK-788 (now mobocertinib) in #EGFR exon 20 #NSCLC - this is clearly an unmet need with poor outcomes achieved using standard EGFR TKIs or immunotherapy. TAK-788 has some promising features to help in this setting #LCSM https://t.co/43HKq137Sr\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "407\n",
      "-----\n",
      "For the first time, a blood test has been shown to help detect many types of cancer in a study of thousands of people with no history or symptoms of the disease. #ResearchSavesLives https://t.co/Gf20bKaHgy\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "408\n",
      "-----\n",
      "Exciting Ph1 data by @DrScottTagawa of @weillcornell @nyphospital at #AACR20 @AACR  \n",
      "PSMA-targeted alpha emitter 225Ac-J591 in #mCRPC is safe and promising with 63.6% (14/22) PSA decline and 2 with response &gt;1 yr \n",
      "@Panos_Vlach @nhbander @cnsternberg @DrDavidNanus https://t.co/MrGYk9MPIP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "409\n",
      "-----\n",
      "Presentan resultados de ensayo clínico CIMAvax en congreso de Asociación para la Investigación del Cáncer en #US. Resultados alentadores de combinar dos inmunoterapias novedosas. @centro_cim @RoswellPark\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "410\n",
      "-----\n",
      "Outstanding summary for recent data discussing COVID-19 infection in cancer patients.@ADesaiMD #Covid_19 #AACR #cancer https://t.co/lfzjoTbVUU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "411\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "412\n",
      "-----\n",
      "#AACR20 Virtual Annual Meeting I: Grant A. McArthur presents primary results from the phase 3 IMspire150 trial. https://t.co/PkhvG3aZ7a\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "413\n",
      "-----\n",
      "The Opening Clinical Plenary Session of the #AACR20 Virtual Meeting I featured two studies that examined strategies to improve responses to BRAF and MEK inhibitors in patients with advanced melanoma. https://t.co/JOey5E72jS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "414\n",
      "-----\n",
      "The Opening Clinical Plenary Session of the #AACR20 Virtual Meeting I featured two studies that examined strategies to improve responses to BRAF and MEK inhibitors in patients with advanced melanoma. https://t.co/JOey5E72jS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "415\n",
      "-----\n",
      "@theNCI is making accommodations to ensure patients remain safe while participating in @theNCI -sponsored clinical trials #AACR2020 #AACR20 #LCSM https://t.co/OtN3Jwn3eC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "416\n",
      "-----\n",
      "Study on Thrive’s blood test for early #cancer screening presented today at #AACR2020 #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "417\n",
      "-----\n",
      "TAK-788 (#mobocertinib) in New Drugs on the Horizon at #AACR20. Just announced yesterday FDA Breakthrough designation for this drug for treating #exon20 #lungcancer patients, a subset of #NSCLC w/no approved treatment yet #AACR20 #lcsm @EGFRResisters @Exon20Group @TakedaOncology https://t.co/mgpGgUZPyd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "418\n",
      "-----\n",
      ".@DavidHongMD: site-agnostic Vivtrakvi (larotrectinib) works better for #cancers with NTRK gene fusions vs other mutations. #AACR20 https://t.co/nvBLhcLfXg\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "419\n",
      "-----\n",
      "The Opening Clinical Plenary Session of the #AACR20 Virtual Meeting I featured two studies that examined strategies to improve responses to BRAF and MEK inhibitors in patients with advanced melanoma. https://t.co/JOey5E72jS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "420\n",
      "-----\n",
      "@theNCI is making accommodations to ensure patients remain safe while participating in @theNCI -sponsored clinical trials #AACR2020 #AACR20 #LCSM https://t.co/OtN3Jwn3eC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "421\n",
      "-----\n",
      "Great introduction from Dr. Alberto Bardelli on the potential applications of #LiquidBiopsy. Researchers have really pushed the envelop on assay sensitivity &amp; specificity, enabling longitudinal studies, MRD surveillance, etc that were not possible only a few years ago. #AACR20 https://t.co/4neOZk9zRL\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "422\n",
      "-----\n",
      "TMB is an #immunotherapy biomarker with tumor type agnostic potential. The use of #TMB has been hindered by the fact that commercial labs measure TMB differently. Pleased to see the hard work of the TMB harmonization project presented today at #AACR20 and published in #JITC. https://t.co/w2AUTikbaM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "423\n",
      "-----\n",
      "Just Out📣at @NEJM 📰In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genes🧬w/a role in homologous recombination repair, olaparib was associated w/longer PFS‼️ #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "424\n",
      "-----\n",
      "2020 #AACR #Virtual Meeting April 28, 2020 Session on #Evaluating #Cancer #Genomics from #Normal #Tissues Through #Metastatic #Disease 3:50 PM https://t.co/5T3WeWi315 via @Pharma_BI @pharma_BI @AACR @CureCancerNow @pharmanews\n",
      "@BiotechWorld #AACR20 @StephenJWillia2\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "425\n",
      "-----\n",
      "Today’s #AACR20 presentation on #COVID19nCancer (and @CD_AACR paper) is the subject of a @lauriemcginley2 column. \n",
      "With a special cameo by @MDAndersonNews All Star physician scientist &amp; cancer survivor @deb_silverman #Bcsm @COVID19nCCC \n",
      "https://t.co/HiJ21w6Mq6 https://t.co/YIY9D3D3RU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "426\n",
      "-----\n",
      "New study by Crystal Mackall and colls shows intracerebroventricular- or intratumoral-administered #CARTcells exhibit greater therapeutic potency as compared to intravenous delivery, in atypical teratoid/rhabdoid tumor mouse models https://t.co/QnawGBnpQA #ChildhoodCancer #AACR20 https://t.co/WJWe6evIqB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "427\n",
      "-----\n",
      "Plenary session Day 2 Dr Zhang presents #Covid19 in patients in Wuhan China. #Lungcancer was most common at 25%  #AACR20 #LCSM https://t.co/PX4l5el3jx\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "428\n",
      "-----\n",
      "The Opening Clinical Plenary Session of the #AACR20 Virtual Meeting I featured two studies that examined strategies to improve responses to BRAF and MEK inhibitors in patients with advanced melanoma. https://t.co/JOey5E72jS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "429\n",
      "-----\n",
      "At #AACR20 Dr Creelan presented data on adoptive TIL therapy for NSCLC.  This is a very interesting approach - surgery of a metastatic lesion, ex vivo TIL expansion, nivolumab, lymphodepletion and TIL reinfusion with further nivolumab  #LCSM https://t.co/ECHtoEoJTG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "430\n",
      "-----\n",
      "I am not sure what to make of the multiple presentations at #AACR20 that ask for slides to not be posted.  I am looking out for it and not posting images of the slides, but its a bit odd in the setting of a meeting that is completely online with free universal access.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "431\n",
      "-----\n",
      "Blood test shows promise for predicting cancer, tissue of origin ahead of histologic diagnosis https://t.co/bWVy45aWw5 #AACR20 #cancerscreening @GrailBio https://t.co/T7uTitGkoB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "432\n",
      "-----\n",
      "#AACR20 Program and Abstracts available from @AACR at\n",
      "https://t.co/2AIxSYUrOf\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "433\n",
      "-----\n",
      "Blood test shows promise for predicting cancer, tissue of origin ahead of histologic diagnosis https://t.co/bWVy45aWw5 #AACR20 #cancerscreening @GrailBio https://t.co/T7uTitGkoB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "434\n",
      "-----\n",
      "#AACR20 Virtual Annual Meeting I: Early Detection and ctDNA Session. Nickolas Papadopoulos presents:  A first-of-its-kind prospective study of a multicancer blood test to screen and manage 10,000 women with no history of cancer. https://t.co/KeMHhirfgU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "435\n",
      "-----\n",
      "#COVID19 #AACR20 #LCSM\n",
      "TERAVOLT preliminary results by @marinagarassino. An amazing international effort to improve knowledge about #lungcancer &amp; COVID19.\n",
      "198 pts evaluated with 34.6% of death rate.\n",
      "Not specific anti-cancer treatment was associated w/ higher mortality #OncoAlert https://t.co/dWUKuoU1qi\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "436\n",
      "-----\n",
      "Dear Colleagues,\n",
      "Thank you for your use the #OncoAlert hashtag on your tweets during #AACR20 to keep colleagues worldwide informed‼️Please feel free to Tell a Friend about @OncoAlert 🚨and help us make the oncology world even smaller🌐We Are ALL OncoAlert‼️ https://t.co/umeMqU4rzj\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "437\n",
      "-----\n",
      "#Covid19: First results from TERAVOLT registry for thoracic cancers show high mortality rate of COVID-19 in pats w/ thoracic malignancies. Mortality rate of COVID-19 in this group does not appear 2 b linked to specific treatmt/comorbidity. Video: https://t.co/QlXez9T5FB #AACR20 https://t.co/wPkHD6ouqF\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "438\n",
      "-----\n",
      "Great discussion by Dr @jasonlukemd @UPMCHillmanCC on mech of immune-exclusion, T cell-inflamed tumors &amp; #immunotherapy #AACR20 @AACR Referenced paper for genomic changes &amp; immune infiltration @biorxivpreprint \n",
      "https://t.co/EyXwn5tQWx https://t.co/dbnDk7AoqO\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "439\n",
      "-----\n",
      "Presentan resultados de ensayo clínico CIMAvax en congreso de Asociación para la Investigación del Cáncer en #US. Resultados alentadores de combinar dos inmunoterapias novedosas. @centro_cim @RoswellPark\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "440\n",
      "-----\n",
      "Dinah Singer discusses @theNCI response to #COVID19. #AACR20 #coronavirus https://t.co/RD7Osgnm9D\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "441\n",
      "-----\n",
      "The @CancerResrch #TMB Harmonization Project aims to align across panel TMB values estimated with different commercial tests to ensure consistency across TMB values... this effort is key to help identify patients who are more likely to benefit from #immunotherapies #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "442\n",
      "-----\n",
      "@theNCI is supporting #COVID19-related research efforts. Program announcements in this tweet. Please contact your program officer. #AACR2020 #AACR20 #LCSM https://t.co/1IKrsqoIJT\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "443\n",
      "-----\n",
      ".@d2merino on our TMB Harmonization Project: The primary objective is to align-on &amp; publish universal best practices for defining TMB, as well as proposing and executing analytic validation approaches including the alignment against external reference standards. #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "444\n",
      "-----\n",
      "Dinah Singer discusses @theNCI response to #COVID19. #AACR20 #coronavirus https://t.co/wTLlwJNPfJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "445\n",
      "-----\n",
      "Dinah Singer discusses @theNCI response to #COVID19. #AACR20 #coronavirus https://t.co/RD7Osgnm9D\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "446\n",
      "-----\n",
      "Great discussion by Dr. Patricia LoRusso @YaleMed on the NTRK treatment landscape -1st and subsequent line treatment options for NTRK-fusion positive cancers. #AACR2020 #AACR20 #LCSM https://t.co/JI9EBc1qht\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "447\n",
      "-----\n",
      "Our @OncoAlert 🚨Colleague @LeciaSequist 👩‍⚕️of @MassGeneralNews Live from #AACR20 Discussing The Geometry Study and Zenith20. #LCSM @LungCancer \n",
      "Edited: @weoncologists https://t.co/U9ZPHynuZA\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "448\n",
      "-----\n",
      "cfDNA sequencing leveraging informative methylation patterns detected more than 50 cancer types across stages. Considering the potential value of early detection in deadly malignancies, further evaluation of this test is justified in prospective population-level studies.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "449\n",
      "-----\n",
      "Great discussion by @AbboshChris on using ctDNA to measure minimum residual disease (MRD) in adjuvant trials for early-stage lung cancer - to predict which pts will relapse after surgery. Results frm TRACERx @SwantonLab @SU2Cscience @LungAssociation #AACR2020 #AACR20 #LCSM https://t.co/DToCKYUfKg\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "450\n",
      "-----\n",
      "We announced new #MRD surveillance data from the #TRACERx collaboration with @uclcancer, @TheCrick &amp; @CR_UK at #AACR20. Read the release: https://t.co/9W4ezkbVKv #AACR2020 https://t.co/M2T6pUSaDN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "451\n",
      "-----\n",
      "Dinah Singer discusses @theNCI response to #COVID19. #AACR20 #coronavirus https://t.co/wTLlwJNPfJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "452\n",
      "-----\n",
      "The @CancerResrch #TMB Harmonization Project aims to align across panel TMB values estimated with different commercial tests to ensure consistency across TMB values... this effort is key to help identify patients who are more likely to benefit from #immunotherapies #AACR20 https://t.co/m1gUafB7d7\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "453\n",
      "-----\n",
      "High yield data today at #AACR20 coming from my mentors and colleagues here at @MoffittNews #LCSM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "454\n",
      "-----\n",
      "Talk from #TRACERx about the use ctDNA in early stage lung cancer to predict patient relapse after surgery, correlating it with minimum residual disease:\n",
      "⬆️ pre-op ctDNA shedding associated with longer MRD lead-times and shorter DFS times post-op\n",
      "#AACR20 #AACR2020 #lcsm https://t.co/eqtjL1ypV1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "455\n",
      "-----\n",
      "This👇. Absolutely this.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "456\n",
      "-----\n",
      "Dinah Singer discusses @theNCI response to #COVID19. #AACR20 #coronavirus https://t.co/RD7Osgnm9D\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "457\n",
      "-----\n",
      "Dinah Singer discusses @theNCI response to #COVID19. #AACR20 #coronavirus https://t.co/wTLlwJNPfJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "458\n",
      "-----\n",
      "🤓 Patients with cancer appear more vulnerable to SARS-COV-2. Paper published @CD_AACR #AACR20 #COVID19 https://t.co/D6m1xoJzQk\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "459\n",
      "-----\n",
      "Outstanding summary for recent data discussing COVID-19 infection in cancer patients.@ADesaiMD #Covid_19 #AACR #cancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "460\n",
      "-----\n",
      "Live Notes, Real Time Conference Coverage @AACR #AACR20 Virtual Meeting April 28, 2020 Session on @theNCI Activities: #COVID19 and #Cancer #Research 5:20 PM @theNCI @NIH are relaxing grant rules IMPORTANT INFO for researchers!  https://t.co/ERO4vVrlcK via @Pharma_BI #endcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "461\n",
      "-----\n",
      "#OncoAlert #AACR20 More mature data emerging from China. This review by Dr. Zhang at Tongji in Wuhan discusses patients with cancer and #COVID19. Interesting to contrast these with data from US, Italy, Spain, France, etc - some trends just reflect patient populations served. https://t.co/5nxOc3BYb2\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "462\n",
      "-----\n",
      "Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "463\n",
      "-----\n",
      "Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the #COVID19 outbreak!\n",
      "⭕️Patients with hematological, lung, or with metastatic cancer had the highest frequency of severe event!\n",
      "@CD_AACR #AACR20 @OncoAlert @DrChoueiri \n",
      "https://t.co/EgMXlbmXq9 https://t.co/0IVZ4CE9ye\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "464\n",
      "-----\n",
      "Just Out📣at @NEJM 📰In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genes🧬w/a role in homologous recombination repair, olaparib was associated w/longer PFS‼️ #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "465\n",
      "-----\n",
      "@OncoAlert @BenWestphalen @weoncologists #AACR20 👆🏼#BRAF - one of my patients recently sent me this illustrating from a recent review the diversity of tumor types in which #BRAF mutations are seen as well as the spectrum of mutations (V600E 🆚 non-V600E); classifications of #BRAF mutations. #precisionmedicine https://t.co/Ls3p52ijEs\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "466\n",
      "-----\n",
      "The study was released at the #AACR20 Virtual Annual Meeting I and published in our peer-reviewed journal, @CD_AACR. https://t.co/V42iKVGPEg https://t.co/aX2JDcd4ae\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "467\n",
      "-----\n",
      "Thoughtful presentation on cancer and #COVID19 by Dr. Louis Voight from MSKCC.\n",
      "\n",
      "\"Pandemic create perfect conditions for suboptimal care of deviation from standard care with major impact on the most vulnerable patients\"\n",
      "\n",
      "#AACR20 @OncoAlert https://t.co/ceAeNmzrUx\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "468\n",
      "-----\n",
      "Thank you to the #brainmets working group: @tmprowell, @nlinmd, @EdKimMDLCI, @ASCO, @CancerResrch\n",
      "\n",
      "Esp important is the rec to incl those vulnerable #patients w/ lepto (LMD) in #ClinicalTrials as a separate cohort. \n",
      "\n",
      "Now - how to enforce these guidelines?!\n",
      "\n",
      "#BCSM #LCSM #MelSM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "469\n",
      "-----\n",
      "Due to the importance of TMB in patients' stratification in immunotherapy, this harmonization and standardization of TMB between WES and panel sequencing is definitely valuable to the field. #AACR20 \n",
      "https://t.co/VAeJPj9yqA https://t.co/R2IfUE8I9f https://t.co/HngrHVrnaL\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "470\n",
      "-----\n",
      "We announced new #MRD surveillance data from the #TRACERx collaboration with @uclcancer, @TheCrick &amp; @CR_UK at #AACR20. Read the release: https://t.co/9W4ezkbVKv #AACR2020 https://t.co/M2T6pUSaDN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "471\n",
      "-----\n",
      "We invite all #AACR20 participants to discover our robust range of modalities designed to address tumor types with high unmet need represented in Amgen’s investigational #anticancer pipeline. Visit the newly refreshed https://t.co/nS2DiI3prf. #BiTEtechnology #ImmunoOncology https://t.co/B5i7tE8Db5\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "472\n",
      "-----\n",
      "Missed #COVID19nCancer plenary in #AACR20 @AACR?\n",
      "Here’s a thread to catch up on all the fascinating global research presented by:\n",
      "@AACR @AACRPres #AntoniRibas #LiZhang @marinagarassino @barlesi #CarlosGomez #LouisVoigt #HongbingCai cc:@OncoAlert @COVID19nCCC @ASCO @ASH_hematology\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "473\n",
      "-----\n",
      "2nd day #AACR2020 virtual conference.  Wonderful update of @theNCI Deputy Director Dr. Dinah Singer on NCI's effort to combat #COVID19. Cancer researchers are still working, NCI is open for business! https://t.co/LZDCEdGSl9\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "474\n",
      "-----\n",
      "I am not sure what to make of the multiple presentations at #AACR20 that ask for slides to not be posted.  I am looking out for it and not posting images of the slides, but its a bit odd in the setting of a meeting that is completely online with free universal access.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "475\n",
      "-----\n",
      "#AACR20 more on PARP⛔️ #BRCA #DNA-Repair 🧬\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "476\n",
      "-----\n",
      "New study by Crystal Mackall and colls shows intracerebroventricular- or intratumoral-administered #CARTcells exhibit greater therapeutic potency as compared to intravenous delivery, in atypical teratoid/rhabdoid tumor mouse models https://t.co/QnawGBnpQA #ChildhoodCancer #AACR20 https://t.co/WJWe6evIqB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "477\n",
      "-----\n",
      "As complex biomarkers, such as TMB, become more readily incorporated into #oncology care, scientific and regulatory approaches are necessary for alignment on optimal performance thresholds and standards development. #AACR20 https://t.co/xC1Qn0XzY9 https://t.co/Uy6V5vCNbU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "478\n",
      "-----\n",
      "As a phenomenal 1st part of #AACR20 wraps up, WE at @OncoAlert 🚨Congratulate &amp; thank @AACR for putting together a phenomenal meeting, you are all pioneers and the Oncology community will build from here.  Thanks to all of our colleagues for the support, stay safe &amp; stay strong‼️ https://t.co/T8Cg4ptdzN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "479\n",
      "-----\n",
      "Talk from #TRACERx about the use ctDNA in early stage lung cancer to predict patient relapse after surgery, correlating it with minimum residual disease:\n",
      "⬆️ pre-op ctDNA shedding associated with longer MRD lead-times and shorter DFS times post-op\n",
      "#AACR20 #AACR2020 #lcsm https://t.co/eqtjL1ypV1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "480\n",
      "-----\n",
      "Exciting data presented by @Barzin_ at #AACR20 on the use of a novel ctDNA assay to predict outcomes for immunotherapy in NSCLC.  CAPP-Seq is more sensitive than many commercially available assays.  They coupled this with a bulkRNA sequencing called CIBERSORT #LCSM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "481\n",
      "-----\n",
      "@halletjulie @HKennecke @marklewismd @realbowtiedoc @drdonsdizon @scottrberry @mraphaelmd @oncology_bg @profevasegelov @PamelaKunzMD News from AACR on COVID19 and cancer from @ADesaiMD  https://t.co/yszdQk930y\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "482\n",
      "-----\n",
      "Predictive Biomarkers offer a noninvasive approach for prediction of therapeutic benefit from immune checkpoint inhibition in #lungcancer, per #AACR20 presentation by @max_diehn @AshAlizadeh on @SU2C @LUNGevity @LungAssociation #LungCancer Dream Team\n",
      "https://t.co/6tRnpjoAIl\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "483\n",
      "-----\n",
      "It’s day two of #AACR20. Today at 520 pm ET, @theNCI’s Deputy Director for Scientific Strategy and Development, Dr. Dinah Singer will present a special session, “NCI Activities: #COVID-19 and #CancerResearch.” Be sure to tune in. https://t.co/Axx9XlL1xs https://t.co/zFQODE0ezB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "484\n",
      "-----\n",
      "As a phenomenal 1st part of #AACR20 wraps up, WE at @OncoAlert 🚨Congratulate &amp; thank @AACR for putting together a phenomenal meeting, you are all pioneers and the Oncology community will build from here.  Thanks to all of our colleagues for the support, stay safe &amp; stay strong‼️ https://t.co/T8Cg4ptdzN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "485\n",
      "-----\n",
      "The NCI Activities: COVID-19 and Cancer Research session is starting now. #AACR20 Virtual Annual Meeting I.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "486\n",
      "-----\n",
      "As a phenomenal 1st part of #AACR20 wraps up, WE at @OncoAlert 🚨Congratulate &amp; thank @AACR for putting together a phenomenal meeting, you are all pioneers and the Oncology community will build from here.  Thanks to all of our colleagues for the support, stay safe &amp; stay strong‼️ https://t.co/T8Cg4ptdzN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "487\n",
      "-----\n",
      "#AACR20 Virtual Annual Meeting I: Early Detection and ctDNA Session. Chris Abbosh presents: Phylogenetic tracking and minimal residual disease detection using ctDNA in early-stage NSCLC: A lung TRACERx study. https://t.co/dmVDkxM9tt\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "488\n",
      "-----\n",
      "#AACR20 💭I think integrating #ctDNA #liquidbiopsies is going to be the new paradigm shift in more efficient trial designs. If you chose 🩸🧬MRD➕subset of patients, especially for these adjuvant studies, sample size required would be a lot lower since event rate will be high📈. https://t.co/ltbTc4pISo\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "489\n",
      "-----\n",
      "@halletjulie @HKennecke @marklewismd @realbowtiedoc @drdonsdizon @scottrberry @mraphaelmd @oncology_bg @profevasegelov @PamelaKunzMD News from AACR on COVID19 and cancer from @ADesaiMD  https://t.co/yszdQk930y\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "490\n",
      "-----\n",
      "#AACR20 more on PARP⛔️ #BRCA #DNA-Repair 🧬 https://t.co/h9Q19aRF5I\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "491\n",
      "-----\n",
      "Collaboration #Cuba #US presenting encouraging results of #immunotherapy combination CIMAvax/nivolumab for the treatment of cancer. @centro_cim @RoswellPark\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "492\n",
      "-----\n",
      "Antoni Ribas (@UCLAJCCC) &amp; @AACRPres Elaine Mardis wrap up #AACR20 virtual meeting Part 1. ~60,000 \"attendees\"! Part 2 coming up June 22-24 https://t.co/zDjJsIDW26\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "493\n",
      "-----\n",
      "The Opening Clinical Plenary Session of the #AACR20 Virtual Meeting I featured two studies that examined strategies to improve responses to BRAF and MEK inhibitors in patients with advanced melanoma. https://t.co/JOey5E72jS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "494\n",
      "-----\n",
      "The @CancerResrch #TMB Harmonization Project aims to align across panel TMB values estimated with different commercial tests to ensure consistency across TMB values... this effort is key to help identify patients who are more likely to benefit from #immunotherapies #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "495\n",
      "-----\n",
      "Atezolizumab + enzalutamide not increasing OS or PFS (vs Enza alone) in prostate cancer (CRPC) - HR1.12. No subgroup appears to benefit and no long-term progressors. This seriously questions any role for ICIs in prostate cancer #AACR20 #prostatecancer https://t.co/VBx5PDu0bO\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "496\n",
      "-----\n",
      "Dinah Singer discusses @theNCI response to #COVID19. #AACR20 #coronavirus https://t.co/RD7Osgnm9D\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "497\n",
      "-----\n",
      "Dr. Singer of @theNCI at #AACR2020: new flexibilities for the cancer research committee during #Covid_19 including extended grant deadline and flexibility on extension. https://t.co/OkJpBaGRjQ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "498\n",
      "-----\n",
      "Dinah Singer discusses @theNCI response to #COVID19. #AACR20 #coronavirus https://t.co/wTLlwJNPfJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "499\n",
      "-----\n",
      "Antoni Ribas (@UCLAJCCC) &amp; @AACRPres Elaine Mardis wrap up #AACR20 virtual meeting Part 1. ~60,000 \"attendees\"! Part 2 coming up June 22-24 https://t.co/zDjJsIDW26\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "500\n",
      "-----\n",
      "Antoni Ribas (@UCLAJCCC) &amp; @AACRPres Elaine Mardis wrap up #AACR20 virtual meeting Part 1. ~60,000 \"attendees\"! Part 2 coming up June 22-24 https://t.co/zDjJsIDW26\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "501\n",
      "-----\n",
      "Positive results for PROfound trial..\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "502\n",
      "-----\n",
      "#AACR20 💭I think integrating #ctDNA #liquidbiopsies is going to be the new paradigm shift in more efficient trial designs. If you chose 🩸🧬MRD➕subset of patients, especially for these adjuvant studies, sample size required would be a lot lower since event rate will be high📈. https://t.co/ltbTc4pISo\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "503\n",
      "-----\n",
      "Thank you to all the registrants attending our first @AACR Virtual Annual Meeting. We are thrilled to bring this cutting-edge science to the cancer research community. #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "504\n",
      "-----\n",
      "#AACR20 more on PARP⛔️ #BRCA #DNA-Repair 🧬\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "505\n",
      "-----\n",
      "Targeting #EGFR exon 20 insertion with TAK788 leads to ORR of 43% #AACR20 https://t.co/fYp5lEkShc\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "506\n",
      "-----\n",
      "Outstanding summary for recent data discussing COVID-19 infection in cancer patients.@ADesaiMD #Covid_19 #AACR #cancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "507\n",
      "-----\n",
      "@LizCancerHealth @UCLAJCCC @AACRPres Amazing! Congratulations for this great move to make science accessible to everyone in very difficult moments. #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "508\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "-----\n",
      "Great discussion by @AbboshChris on using ctDNA to measure minimum residual disease (MRD) in adjuvant trials for early-stage lung cancer - to predict which pts will relapse after surgery. Results frm TRACERx @SwantonLab @SU2Cscience @LungAssociation #AACR2020 #AACR20 #LCSM https://t.co/DToCKYUfKg\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "509\n",
      "-----\n",
      "As a phenomenal 1st part of #AACR20 wraps up, WE at @OncoAlert 🚨Congratulate &amp; thank @AACR for putting together a phenomenal meeting, you are all pioneers and the Oncology community will build from here.  Thanks to all of our colleagues for the support, stay safe &amp; stay strong‼️ https://t.co/T8Cg4ptdzN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "510\n",
      "-----\n",
      "Thank you to all the registrants attending our first @AACR Virtual Annual Meeting. We are thrilled to bring this cutting-edge science to the cancer research community. #AACR20 https://t.co/VnfwnHqfVF\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "511\n",
      "-----\n",
      "It’s a wrap! Awesome 2 days of sessions. Thank you for the tweets-especially from our patients and SSP advocates. See you in June!  #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "512\n",
      "-----\n",
      "Just Out📣at @NEJM 📰In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genes🧬w/a role in homologous recombination repair, olaparib was associated w/longer PFS‼️ #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "513\n",
      "-----\n",
      "Live Notes, Real Time Conference Coverage 2020 @AACR #AACR20 Virtual Meeting April 28, 2020 Session on #COVID19 and #Cancer 9:00 AM https://t.co/K3tezUQLFz via @Pharma_BI @pharmanews @CureCancerNow @BiotechWorld @CNN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "514\n",
      "-----\n",
      "Are all #PARP inhibitors the same?? hitting a PARP more potent can give better clinical outcomes. #NewDrugs session at #AACR20 . #OncoAlert #pcsm #bcsm #ovariancancer #DDR #BRCA https://t.co/mTUA5LkQsJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "515\n",
      "-----\n",
      "#AACR20 @lfspurr from @DanaFarber and @broadinstitute presents on the genomic correlates of PD-L1 expression and response to immunotherapy in NSCLC. You can learn more in this manuscript published in Annals of Oncology: https://t.co/GDcAUJxack #LCSM @GLambertiMD @meyersonlab https://t.co/xahzpzw5EU\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "516\n",
      "-----\n",
      "#AACR20 Reminder that #WordsMatter. Just heard \"Many of our pts are metastatic.\" Pts don't metastasize. Tumors do. Pts are not their disease so: \"Many of our pts have metastatic dz.\" See our lang of respect guide for all speakers at #ASCO20: https://t.co/ne7tIMJLDC #advocacy https://t.co/ZmDYDXNbIP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "517\n",
      "-----\n",
      "#AACR20 David Thiel from @MayoClinic presents at the Early Detection and ctDNA session results from the study investigating the @GrailBio cfDNA methylation signatures test. The manuscript can be found here in Annals of Oncology:  https://t.co/8OjSaWeURz https://t.co/cfEcY8pxVd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "518\n",
      "-----\n",
      "Fighting stigma —  #AACR20 roundup: Tecentriq/Xtandi combo fails to show OS benefit, halting Roche's PD-L1 push ...: The Phase III study dubbed IMbassador enrolled 759 patients with ... Roche is sponsoring a small, open-label study to evaluate using… https://t.co/vUKzJdhc7g\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "519\n",
      "-----\n",
      "Check recent content @NatureCancer\n",
      " about #ctDNA and #LiquidBiopsy in cancer:\n",
      "\n",
      "- #Immunotherapy in SCLC and NSCLC, ITH, clinical implementation, and more!\n",
      "\n",
      "https://t.co/OMPFaRGU65\n",
      "https://t.co/SXvHYm5Hmw\n",
      "https://t.co/e26wYMedBV\n",
      "https://t.co/CErTHIOYvA\n",
      "\n",
      "#AACR20 https://t.co/agOl6k5Zfh\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "520\n",
      "-----\n",
      "Gracell scores a first for CD7-directed Car-T therapy in T-cell leukaemia. Via @evaluatevantage https://t.co/54yX6Uqfia #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "521\n",
      "-----\n",
      "Good news, but Genentech, Inc. is only allowing women to be part of the trial. This is contrary FDA recommendations which suggests men be included in bc trials. #bcsm\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "522\n",
      "-----\n",
      "Dear Colleagues,\n",
      "Thank you for a great couple of days of science, all of us at @OncoAlert 🚨are very grateful for your support &amp; for helping in keeping colleagues worldwide #OncoAlert!! Thank you #AACR20 &amp; look forward to Part 2⃣.\n",
      "Ps. Numbers don't lie, this was a success! Kudos! https://t.co/F4edm9zrVC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "523\n",
      "-----\n",
      "#AACR20 Reminder that #WordsMatter. Just heard \"Many of our pts are metastatic.\" Pts don't metastasize. Tumors do. Pts are not their disease so: \"Many of our pts have metastatic dz.\" See our lang of respect guide for all speakers at #ASCO20: https://t.co/ne7tIMJLDC #advocacy https://t.co/ZmDYDXNbIP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "524\n",
      "-----\n",
      "Dear Colleagues,\n",
      "Thank you for a great couple of days of science, all of us at @OncoAlert 🚨are very grateful for your support &amp; for helping in keeping colleagues worldwide #OncoAlert!! Thank you #AACR20 &amp; look forward to Part 2⃣.\n",
      "Ps. Numbers don't lie, this was a success! Kudos! https://t.co/F4edm9zrVC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "525\n",
      "-----\n",
      "Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "526\n",
      "-----\n",
      "Talk from #TRACERx about the use ctDNA in early stage lung cancer to predict patient relapse after surgery, correlating it with minimum residual disease:\n",
      "⬆️ pre-op ctDNA shedding associated with longer MRD lead-times and shorter DFS times post-op\n",
      "#AACR20 #AACR2020 #lcsm https://t.co/eqtjL1ypV1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "527\n",
      "-----\n",
      ":(\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "528\n",
      "-----\n",
      "The @CureMelanoma is grateful to @aacr for its great virtual meeting and the incredible #leadership of @CureMelanoma funded #melanoma #clinician #researcher and Dr. Toni Ribas\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "529\n",
      "-----\n",
      "That wraps up #AACR20 Virtual Annual Meeting I. Thank you to everyone who followed along these past two days and tweeted with us.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "530\n",
      "-----\n",
      "Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "531\n",
      "-----\n",
      "This is part of the cooperation with Cuban scientists mentioned in the PBS documentary about #Cuba cancer vaccine Cimavax. #CubaPorLaSalud, #CubaSalva, #CubavsBloqueo\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "532\n",
      "-----\n",
      "There was #cancer before the pandemic, there is cancer now, and there will be cancer after. Thankfully, some research continues. Progress toward off-the-shelf #CAR_T cells, from Shanghai #biotech, at #AACR20: https://t.co/YuVBfGVs5J\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "533\n",
      "-----\n",
      "That wraps up #AACR20 Virtual Annual Meeting I. Thank you to everyone who followed along these past two days and tweeted with us. https://t.co/x9uDOHXjhd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "534\n",
      "-----\n",
      "Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "535\n",
      "-----\n",
      "Dear Colleagues,\n",
      "Thank you for a great couple of days of science, all of us at @OncoAlert 🚨are very grateful for your support &amp; for helping in keeping colleagues worldwide #OncoAlert!! Thank you #AACR20 &amp; look forward to Part 2⃣.\n",
      "Ps. Numbers don't lie, this was a success! Kudos! https://t.co/F4edm9zrVC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "536\n",
      "-----\n",
      "Collaboration #Cuba #US presenting encouraging results of #immunotherapy combination CIMAvax/nivolumab for the treatment of cancer. @centro_cim @RoswellPark\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "537\n",
      "-----\n",
      "Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "538\n",
      "-----\n",
      "Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "539\n",
      "-----\n",
      ".@slschmid_lab used a technique to follow fast recycling endosomes in p53 cancer cells. JCB’s new cancer collection for #AACR20 (https://t.co/hgWqffwVlg) has short summaries of this and other articles here: https://t.co/4RX37r8ws2 https://t.co/W4ge0ShGRB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "540\n",
      "-----\n",
      "Bispecific CD19/CD22 CAR T Cells Active in Pediatric Relapsed ALL @NCIResearchCtr @AACR #AACR20 #leusm https://t.co/9i0ji0YNCf\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "541\n",
      "-----\n",
      "Starting NOW: Phase 2 results from our TMB Harmonization Project is being presented @AACR's Virtual Annual Meeting. Be sure to follow the conversation w/ #AACR20 and learn more about our project here: https://t.co/xC1Qn0XzY9\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "542\n",
      "-----\n",
      "CONGRESS | #AACR20 |  Results from a randomized study comparing DDGP regimen to SMILE in patients with newly diagnosed extranodal NK/T-cell lymphoma show no significant difference in CR and ORR rate between regimens #lymsm https://t.co/8Gn8C11Xdv\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "543\n",
      "-----\n",
      "Predictive Biomarkers offer a noninvasive approach for prediction of therapeutic benefit from immune checkpoint inhibition in #lungcancer, per #AACR20 presentation by @max_diehn @AshAlizadeh on @SU2C @LUNGevity @LungAssociation #LungCancer Dream Team\n",
      "https://t.co/6tRnpjoAIl\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "544\n",
      "-----\n",
      "#AACR20: @MarcoHHofmann, a member of our cancer research team presents preclinical data on how our pan-KRAS and MEK inhibitor combinations work across a broad range of mutations leading to tumor stasis or regression:\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "545\n",
      "-----\n",
      "It’s day two of #AACR20. Today at 520 pm ET, @theNCI’s Deputy Director for Scientific Strategy and Development, Dr. Dinah Singer will present a special session, “NCI Activities: #COVID-19 and #CancerResearch.” Be sure to tune in. https://t.co/Axx9XlL1xs https://t.co/zFQODE0ezB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "546\n",
      "-----\n",
      "Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "547\n",
      "-----\n",
      "Next \"new drug on the horizon\" is an oral SERD (Selective Estrogen Receptor Degrader), GDC-9545. Achieved same efficacy as other SERDs, but at a lower dose.\n",
      "\n",
      "Currently recruiting patients with #ER+ #MBC. \n",
      "\n",
      "#BCSM #AACR20 \n",
      "https://t.co/7aWgt2Bv60\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "548\n",
      "-----\n",
      "Gracell's allogneic anti-CD7 Car-T cells gave 100% CR in 5 T-cell ALL subjects (one CR MRD+ and short duration) #AACR20 https://t.co/HnBPpmlZ60\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "549\n",
      "-----\n",
      "Important data on cancer drug safety during COVID19 in France. IO and TKIs seem ok, chemo within 3 months a risk @DiSarfati\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "550\n",
      "-----\n",
      "At #AACR20 Dr Creelan presented data on adoptive TIL therapy for NSCLC.  This is a very interesting approach - surgery of a metastatic lesion, ex vivo TIL expansion, nivolumab, lymphodepletion and TIL reinfusion with further nivolumab  #LCSM https://t.co/ECHtoEoJTG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "551\n",
      "-----\n",
      "the Gracell data at #AACR20 on UCART-CD7 is nice but very early.  The knocked the CAR into the TCR which is good.\n",
      "\n",
      "CAR T cell persistence is limited &lt; 3-4 weeks.  \n",
      "\n",
      "Efficacy data is at 1 month only.\n",
      "\n",
      "(So risk of subsequent relapse not clear yet.)\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "552\n",
      "-----\n",
      "Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "553\n",
      "-----\n",
      "#AACR20 David Thiel from @MayoClinic presents at the Early Detection and ctDNA session results from the study investigating the @GrailBio cfDNA methylation signatures test. The manuscript can be found here in Annals of Oncology:  https://t.co/8OjSaWeURz https://t.co/cfEcY8pxVd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "554\n",
      "-----\n",
      "In the \"green room\" (it's pretty grey...) ahead of the @AACR #AACR20 presentation on the @CancerResrch #TMB Harmonization Project. Excited to be representing the collaborative work of such a great group of partners! Don't forget to tune in! Presentation starts at 4:55pm! https://t.co/ILJMIVTej1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "555\n",
      "-----\n",
      "Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "556\n",
      "-----\n",
      "Conclusion for TERAVOLT registry presentation on #AACR20 https://t.co/hR3R47wVNK\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "557\n",
      "-----\n",
      "#AACR20 Hongbing Cai presents data showing cancer patients may be more vulnerable to SARS-COV-2 infection. Data were simultaneously published in Cancer Discovery. @CD_AACR https://t.co/ecP5FskLgQ https://t.co/UDX54MAHdS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "558\n",
      "-----\n",
      "The first @AACR Annual Meeting and the first midnight conference I attended(time-zone differences). All the presentations I attended were awesome! This meeting was one of the best sides of the isolation. Thank you to everyone involved in the organisation #AACR20 https://t.co/VpseLN5Lse\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "559\n",
      "-----\n",
      "Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "560\n",
      "-----\n",
      "Gracell scores a first for CD7-directed Car-T therapy in T-cell leukaemia. Via @evaluatevantage https://t.co/54yX6Uqfia #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "561\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "562\n",
      "-----\n",
      "There was #cancer before the pandemic, there is cancer now, and there will be cancer after. Thankfully, some research continues. Progress toward off-the-shelf #CAR_T cells, from Shanghai #biotech, at #AACR20: https://t.co/YuVBfGVs5J\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "563\n",
      "-----\n",
      "There was #cancer before the pandemic, there is cancer now, and there will be cancer after. Thankfully, some research continues. Progress toward off-the-shelf #CAR_T cells, from Shanghai #biotech, at #AACR20: https://t.co/YuVBfGVs5J\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "564\n",
      "-----\n",
      "ICYMI earlier, a look at #liquidbiopsy data at #AACR20:\n",
      "Thrive, chasing Grail with a #cancer blood test, finds tumors in seemingly healthy women https://t.co/BIZLvIZSk3\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "565\n",
      "-----\n",
      "One more time for the folks in the back— #WordsMatter\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "566\n",
      "-----\n",
      "Live Notes, Real Time Conference Coverage @AACR #AACR20 Virtual Meeting April 28, 2020 Session on Evaluating #Cancer #Genomics from Normal Tissues Through Metastatic Disease 3:50 PM https://t.co/kNtPBXxvYp via @Pharma_BI #endcancer @sloan_kettering @MDAndersonNews @NCIGenomics\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "567\n",
      "-----\n",
      "At #AACR20 Dr Creelan presented data on adoptive TIL therapy for NSCLC.  This is a very interesting approach - surgery of a metastatic lesion, ex vivo TIL expansion, nivolumab, lymphodepletion and TIL reinfusion with further nivolumab  #LCSM https://t.co/ECHtoEoJTG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "568\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "569\n",
      "-----\n",
      "This👇. Absolutely this.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "570\n",
      "-----\n",
      "“These data strongly support the importance of clinical testing for NTRK gene fusions in order to identify those patients most likely to benefit from larotrectinib,” says @DavidHongMD. \n",
      "\n",
      "Learn more about his study presented today at #AACR20. https://t.co/2Gg4fqwJ0r #endcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "571\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "572\n",
      "-----\n",
      "Live Notes, Real Time Conference Coverage @AACR #AACR20 Virtual Meeting April 28, 2020 Session on Evaluating #Cancer #Genomics from Normal Tissues Through Metastatic Disease 3:50 PM https://t.co/kNtPBXxvYp via @Pharma_BI #endcancer @sloan_kettering @MDAndersonNews @NCIGenomics\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "573\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "574\n",
      "-----\n",
      "TIL Therapy Elicits Encouraging Activity in Advanced NSCLC https://t.co/7xPmSfSQZA #AACR20 #LCSM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "575\n",
      "-----\n",
      "“These data strongly support the importance of clinical testing for NTRK gene fusions in order to identify those patients most likely to benefit from larotrectinib,” says @DavidHongMD. \n",
      "\n",
      "Learn more about his study presented today at #AACR20. https://t.co/2Gg4fqwJ0r #endcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "576\n",
      "-----\n",
      "#AACR2020\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "577\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "578\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "579\n",
      "-----\n",
      "#AACR20 Reminder that #WordsMatter. Just heard \"Many of our pts are metastatic.\" Pts don't metastasize. Tumors do. Pts are not their disease so: \"Many of our pts have metastatic dz.\" See our lang of respect guide for all speakers at #ASCO20: https://t.co/ne7tIMJLDC #advocacy https://t.co/ZmDYDXNbIP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "580\n",
      "-----\n",
      "@halletjulie @HKennecke @marklewismd @realbowtiedoc @drdonsdizon @scottrberry @mraphaelmd @oncology_bg @profevasegelov @PamelaKunzMD News from AACR on COVID19 and cancer from @ADesaiMD  https://t.co/yszdQk930y\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "581\n",
      "-----\n",
      "I am not sure what to make of the multiple presentations at #AACR20 that ask for slides to not be posted.  I am looking out for it and not posting images of the slides, but its a bit odd in the setting of a meeting that is completely online with free universal access.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "582\n",
      "-----\n",
      "“These data strongly support the importance of clinical testing for NTRK gene fusions in order to identify those patients most likely to benefit from larotrectinib,” says @DavidHongMD. \n",
      "\n",
      "Learn more about his study presented today at #AACR20. https://t.co/2Gg4fqwJ0r #endcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "583\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "584\n",
      "-----\n",
      "There was #cancer before the pandemic, there is cancer now, and there will be cancer after. Thankfully, some research continues. Progress toward off-the-shelf #CAR_T cells, from Shanghai #biotech, at #AACR20: https://t.co/YuVBfGVs5J\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "585\n",
      "-----\n",
      "We just saw the data today at the #AACR20 virtual meeting showing = safety and efficacy of this different dosing for Pembro, and now its approved! Very timely given desire to decrease exposure to clinic/infusion centers during #COVID19.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "586\n",
      "-----\n",
      "Link to our recent paper. Great work by Liam Spurr @lfspurr, Giuseppe Lamberti @GLambertiMD with wonderful leadership by Andy Cherniack and Mark Awad. https://t.co/WIg6vm0JX4\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "587\n",
      "-----\n",
      "“These data strongly support the importance of clinical testing for NTRK gene fusions in order to identify those patients most likely to benefit from larotrectinib,” says @DavidHongMD. \n",
      "\n",
      "Learn more about his study presented today at #AACR20. https://t.co/2Gg4fqwJ0r #endcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "588\n",
      "-----\n",
      "Ben Creelan, MD @MoffittNews : Interesting Phase 1 trial shows durable CRs to adoptive cell transfer using TILs in #NSCLC. Many patients were low/no PDL1 and had oncogene drivers. Looking forward to seeing future work in this area.   #AACR20 #lcsm #lungcancer @EGFRResisters https://t.co/16GBuyBez9\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "589\n",
      "-----\n",
      "#Metabolism (Oncometabolites) and #DDR as targets to treat #cancer . #AACR20 #OncoAlert https://t.co/58jvSF5Skd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "590\n",
      "-----\n",
      "CONGRESS | #AACR20 | ABBV-184 is a survivin-specific TCR x CD3 bispecific therapeutic being investigated in patients with AML and lung cancer. The phase I trial is currently enrolling patients 🧬 #leusm https://t.co/lZKK15Qnmt\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "591\n",
      "-----\n",
      "$IOVA off 8%. Surely it’s time for the loonies to start accusing the #AACR20 discussant of being a filthy short seller.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "592\n",
      "-----\n",
      "Apresentado no #AACR20, o estudo fase II SWOG S1320 mostrou que a administração contínua das terapias-alvo dabrafenibe e trametinibe teve impacto na SLP de pts com melanoma irressecável com mutação BRAF V600E/K - https://t.co/eAW1ZFIkJi @AACR #ONCONEWS #MELANOMA #ONCONEWSnoAACR20 https://t.co/qtgTfWwrds\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "593\n",
      "-----\n",
      "Postcard #2 from #AACR20 with some commentary on new in cell therapies: https://t.co/M8o9a9qPtM\n",
      "Some interesting and different highlights today, which are not w/o controversy either! https://t.co/z2eP6h42KF\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "594\n",
      "-----\n",
      "Ben Creelan, MD @MoffittNews : Interesting Phase 1 trial shows durable CRs to adoptive cell transfer using TILs in #NSCLC. Many patients were low/no PDL1 and had oncogene drivers. Looking forward to seeing future work in this area.   #AACR20 #lcsm #lungcancer @EGFRResisters https://t.co/16GBuyBez9\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "595\n",
      "-----\n",
      "Just in time for #AACR20: the @CellPressNews Picture Show focused on Cancer Killers includes work on oncolytic viral therapy from my team with longtime collaborator @SoCalYuman @COH_SurgOnc (3 videos + last 2 images) https://t.co/BpGT9ksD6a #ImmunoOnc https://t.co/dB8sSQOxDs\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "596\n",
      "-----\n",
      "Talk from #TRACERx about the use ctDNA in early stage lung cancer to predict patient relapse after surgery, correlating it with minimum residual disease:\n",
      "⬆️ pre-op ctDNA shedding associated with longer MRD lead-times and shorter DFS times post-op\n",
      "#AACR20 #AACR2020 #lcsm https://t.co/eqtjL1ypV1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "597\n",
      "-----\n",
      "#AACR20 Reminder that #WordsMatter. Just heard \"Many of our pts are metastatic.\" Pts don't metastasize. Tumors do. Pts are not their disease so: \"Many of our pts have metastatic dz.\" See our lang of respect guide for all speakers at #ASCO20: https://t.co/ne7tIMJLDC #advocacy https://t.co/ZmDYDXNbIP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "598\n",
      "-----\n",
      "That wraps up #AACR20 Virtual Annual Meeting I. Thank you to everyone for following along and tweeting with us. https://t.co/9L1H0PhT4Y\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "599\n",
      "-----\n",
      "Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "600\n",
      "-----\n",
      "Live Notes, Real Time Conference Coverage @AACR #AACR20 Virtual Meeting April 28, 2020 Session on Evaluating #Cancer #Genomics from Normal Tissues Through Metastatic Disease 3:50 PM https://t.co/kNtPBXxvYp via @Pharma_BI #endcancer @sloan_kettering @MDAndersonNews @NCIGenomics\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "601\n",
      "-----\n",
      "Missed #COVID19nCancer plenary in #AACR20 @AACR?\n",
      "Here’s a thread to catch up on all the fascinating global research presented by:\n",
      "@AACR @AACRPres #AntoniRibas #LiZhang @marinagarassino @barlesi #CarlosGomez #LouisVoigt #HongbingCai cc:@OncoAlert @COVID19nCCC @ASCO @ASH_hematology\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "602\n",
      "-----\n",
      "Presentan resultados de ensayo clínico CIMAvax en congreso de Asociación para la Investigación del Cáncer en #US. Resultados alentadores de combinar dos inmunoterapias novedosas. @centro_cim @RoswellPark https://t.co/ZjU38wpVMz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "603\n",
      "-----\n",
      "Clinical Factors Predict Deterioration Among Patients With Cancer, COVID-19 @barlesi @GustaveRoussy @AACR #coronavirus #COVID19 #AACR20 https://t.co/FDtUuutt8w\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "604\n",
      "-----\n",
      "Conclusion for TERAVOLT registry presentation on #AACR20 https://t.co/hR3R47wVNK\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "605\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "606\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "607\n",
      "-----\n",
      "Dr. David Thiel presenting the Circulating Cell-Free Genome Atlas Study being run by GRAIL. ctDNA, matched tissue samples, methylation analyses, CCGA has it all! I am *very* excited to see these data. #AACR20 https://t.co/KH3jo91f3a\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "608\n",
      "-----\n",
      "The Opening Clinical Plenary Session of the #AACR20 Virtual Meeting I featured two studies that examined strategies to improve responses to BRAF and MEK inhibitors in patients with advanced melanoma. https://t.co/JOey5E72jS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "609\n",
      "-----\n",
      "Live Notes, Real Time Conference Coverage  @AACR #AACR20 Virtual Meeting April 28, 2020 Session on Novel #Cancer #Targets and #Therapies 2:35 PM https://t.co/pxcROUrhR9 via @Pharma_BI @pharmanews @pharmalot @BiotechWorld @Bioitworld #pharma360\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "610\n",
      "-----\n",
      "The Opening Clinical Plenary Session of the #AACR20 Virtual Meeting I featured two studies that examined strategies to improve responses to BRAF and MEK inhibitors in patients with advanced melanoma. https://t.co/JOey5E72jS\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "611\n",
      "-----\n",
      "#AACR20 David Thiel from @MayoClinic presents at the Early Detection and ctDNA session results from the study investigating the @GrailBio cfDNA methylation signatures test. The manuscript can be found here in Annals of Oncology:  https://t.co/8OjSaWeURz https://t.co/cfEcY8pxVd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "612\n",
      "-----\n",
      "Great discussion by @AbboshChris on using ctDNA to measure minimum residual disease (MRD) in adjuvant trials for early-stage lung cancer - to predict which pts will relapse after surgery. Results frm TRACERx @SwantonLab @SU2Cscience @LungAssociation #AACR2020 #AACR20 #LCSM https://t.co/DToCKYUfKg\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "613\n",
      "-----\n",
      "Thank you @aacr for a fab #aacr20! What an achievement to take the annual meeting online and have such amazing participation. So refreshing to travel to a conference again, even if only virtually 😊 Can’t wait for round 2 in June 👏🏻👏🏻👏🏻\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "614\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "615\n",
      "-----\n",
      "Just out📣at @TheLancetOncol 📰by @OncoAlert 🚨colleague @FAndreMD &amp;team. MonarcHER sees combo abemaciclib,fulvestrant, &amp;trastuzumab improved PFS Vs. SOC #chemotherapy +trastuzumab, w/a tolerable safety‼️#breastcancer #aacr20 #bcsm https://t.co/ZLtdVsul0O https://t.co/gi8FMoJcrv\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "616\n",
      "-----\n",
      "Mortality unexpectedly high among people with lung cancer, COVID-19 #AACR20 #LCSM #lungcancer https://t.co/VMzoQWJG3K\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "617\n",
      "-----\n",
      "Promising research for #braincancer #coloncancer treatment! .@amritasule presented study results at #AACR20 showing #PARP and #ATR #DNA repair inhibitors together are more effective than a PARP inhibitor alone. @RanjitBindra @SmilowCancer @YaleMed @YNHH   https://t.co/XFB6b6peoz https://t.co/qfzig30WOb\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "618\n",
      "-----\n",
      "Targeting #EGFR exon 20 insertion with TAK788 leads to ORR of 43% #AACR20 https://t.co/fYp5lEkShc\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "619\n",
      "-----\n",
      "Thanks to our #AACR20 Influencers and everyone who tweeted about @AACR Virtual Annual Meeting I!  See you again June 22-24 for Virtual Meeting II.\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "620\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "621\n",
      "-----\n",
      "That wraps up #AACR20 Virtual Annual Meeting I. Thank you to everyone for following along and tweeting with us. https://t.co/9L1H0PhT4Y\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "622\n",
      "-----\n",
      "#AACR20 Reminder that #WordsMatter. Just heard \"Many of our pts are metastatic.\" Pts don't metastasize. Tumors do. Pts are not their disease so: \"Many of our pts have metastatic dz.\" See our lang of respect guide for all speakers at #ASCO20: https://t.co/ne7tIMJLDC #advocacy https://t.co/ZmDYDXNbIP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "623\n",
      "-----\n",
      "That wraps up #AACR20 Virtual Annual Meeting I. Thank you to everyone for following along and tweeting with us. https://t.co/9L1H0PhT4Y\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "624\n",
      "-----\n",
      "Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "625\n",
      "-----\n",
      "#AACR20 COM701 #Immunotherapy data - always intriguing to see the ✅tumors respond to therapy when they theoretically won’t. 👇🏼Data on an MSS KRAS-mutant #CRCSM with sustained PR. Also saw a pancreas cancer #PANCSM patient listed on ongoing treatment(?MSI). #OncoAlert https://t.co/4J10DvZDzJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "626\n",
      "-----\n",
      "#AACR20 #ctDNA #LiquidBiopsies key is that if fusions are detected is helpful - ⛔️doesn’t exclude its presence. Interpret with disease context. #OncoAlert\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "627\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "628\n",
      "-----\n",
      "Antoni Ribas (@UCLAJCCC) &amp; @AACRPres Elaine Mardis wrap up #AACR20 virtual meeting Part 1. ~60,000 \"attendees\"! Part 2 coming up June 22-24 https://t.co/zDjJsIDW26\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "629\n",
      "-----\n",
      "Data  at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that #COVID19 prevalence among cancer patients is a) 12%  b) mortality is close to 15% (similar to general population c)Factors correlated with worst outcome: hemopathy, PS2+, recent chemotherapy https://t.co/Ga25jTRfyz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "630\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "631\n",
      "-----\n",
      "Presentan resultados de ensayo clínico CIMAvax en congreso de Asociación para la Investigación del Cáncer en #US. Resultados alentadores de combinar dos inmunoterapias novedosas. @centro_cim @RoswellPark\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "632\n",
      "-----\n",
      "Dr. Grace Dy is presenting new data today from Roswell Park's CIMAvax/nivolumab study. The combination’s activation of B and T cells is encouraging compared to checkpoint blockade #immunotherapy alone. #AACR20 https://t.co/Ufvqat0YzA https://t.co/NtjKeAxZfu\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "633\n",
      "-----\n",
      "Dr. Chris Abbosh's introduction very nicely framed the importance of intervention at the MRD stage. #LiquidBiopsy could allow us to shift the therapeutic window to when disease burden is earlier + guide targeted therapy selection. #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "634\n",
      "-----\n",
      "The use of #ctDNA early detection and prediction of #cancer is gaining momentum. Find out the latest results presented at #AACR20 on @OncologyCentral now:\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "635\n",
      "-----\n",
      "Thank you to @AACR for creating this wonderful forum. We think the first virtual #AACR20 was a success. See you for part 2 in June!\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "636\n",
      "-----\n",
      "This was the structural disclosure many were waiting for at #AACR20 @AACR: Matthew LaMarche of @NovartisScience raising the curtain for clinical SHP2 inhibitor #TNO155. Structurally quite distinct from previous tool SHP099 in order to address phototox &amp; off-target liabilities https://t.co/iOeyie4nia\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "637\n",
      "-----\n",
      "As a phenomenal 1st part of #AACR20 wraps up, WE at @OncoAlert 🚨Congratulate &amp; thank @AACR for putting together a phenomenal meeting, you are all pioneers and the Oncology community will build from here.  Thanks to all of our colleagues for the support, stay safe &amp; stay strong‼️ https://t.co/T8Cg4ptdzN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "638\n",
      "-----\n",
      "IMspire150 just presented at #AACR20 in metastatic #melanoma. Important PFS data up to 12m which may help individualize selection of initial therapies for BRAFmut pts. Longer FU to access who are the long responders (PD1 driven only? or synergistic effect?) is needed. https://t.co/I5gJ5C0BVr\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "639\n",
      "-----\n",
      "Kudos to @barlesi of @GustaveRoussy et al for this detailed analysis of cancer patients with #COVID19 @AACR #AACR20 @lalbiges @jsoria @FAndreMD https://t.co/jHBGoQr5a6\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "640\n",
      "-----\n",
      "That wraps up #AACR20 Virtual Annual Meeting I. Thank you to everyone for following along and tweeting with us. https://t.co/9L1H0PhT4Y\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "641\n",
      "-----\n",
      "#OncoAlert #AACR20 More mature data emerging from China. This review by Dr. Zhang at Tongji in Wuhan discusses patients with cancer and #COVID19. Interesting to contrast these with data from US, Italy, Spain, France, etc - some trends just reflect patient populations served. https://t.co/5nxOc3BYb2\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "642\n",
      "-----\n",
      "As a phenomenal 1st part of #AACR20 wraps up, WE at @OncoAlert 🚨Congratulate &amp; thank @AACR for putting together a phenomenal meeting, you are all pioneers and the Oncology community will build from here.  Thanks to all of our colleagues for the support, stay safe &amp; stay strong‼️ https://t.co/T8Cg4ptdzN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "643\n",
      "-----\n",
      "ICYMI earlier, a look at #liquidbiopsy data at #AACR20:\n",
      "Thrive, chasing Grail with a #cancer blood test, finds tumors in seemingly healthy women https://t.co/BIZLvIZSk3\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "644\n",
      "-----\n",
      "$IOVA at #AACR20. Ben Creelan says only subjects who had progressed on 4 cycles of Opdivo (+ 2 scans) were lymphodepleted and got TILs https://t.co/aGD1kqxJwI\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "645\n",
      "-----\n",
      "#AACR20 Reminder that #WordsMatter. Just heard \"Many of our pts are metastatic.\" Pts don't metastasize. Tumors do. Pts are not their disease so: \"Many of our pts have metastatic dz.\" See our lang of respect guide for all speakers at #ASCO20: https://t.co/ne7tIMJLDC #advocacy https://t.co/ZmDYDXNbIP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "646\n",
      "-----\n",
      "#AACR20 Reminder that #WordsMatter. Just heard \"Many of our pts are metastatic.\" Pts don't metastasize. Tumors do. Pts are not their disease so: \"Many of our pts have metastatic dz.\" See our lang of respect guide for all speakers at #ASCO20: https://t.co/ne7tIMJLDC #advocacy https://t.co/ZmDYDXNbIP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "647\n",
      "-----\n",
      "#COVID19: Practical and Immuno-Oncology Insight in Melanoma and Beyond https://t.co/KrCealmKIn #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "648\n",
      "-----\n",
      "Tertiary Lymphoid Structures as biomarkers of response to immunotherapy, live now #AACR20 ! https://t.co/MTsmp8ezB4\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "649\n",
      "-----\n",
      "Check out this video by the amazing Dr. @CharuAggarwalMD. \n",
      "\n",
      "#OncoAlert \n",
      "#AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "650\n",
      "-----\n",
      "Exciting to see assay benchmarking as a function of total cfDNA input receive increasing focus in #LiquidBiopsy field. Variant allele frequency does not tell the whole story &amp; these kinds of data are critical for selecting the correct test type for a certain sample. #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "651\n",
      "-----\n",
      "#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "652\n",
      "-----\n",
      "STK11 &amp; KEAP1 MT in #NSCLC pts receiving #Pembro on #KN42. Authors conclude that IO was superior to chemo in these subsets. Imp' to note: \n",
      "1. #KRASMT not reported\n",
      "2. How do these pts do with chemo+IO?\n",
      "3. Overall prevalence of these MT seem low\n",
      "#AACR20 @AACR #LCSM @OncoAlert https://t.co/FRCZqybOP8\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "653\n",
      "-----\n",
      "Just Out📣at @NEJM 📰In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genes🧬w/a role in homologous recombination repair, olaparib was associated w/longer PFS‼️ #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "654\n",
      "-----\n",
      "#AACR20 🩸🧬🧪ability to predict PFS. With the short t-1/2, of great value to consider. #LiquidBiopsies #ctDNA https://t.co/op3g36bnUr\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "655\n",
      "-----\n",
      "Thank you to the #brainmets working group: @tmprowell, @nlinmd, @EdKimMDLCI, @ASCO, @CancerResrch\n",
      "\n",
      "Esp important is the rec to incl those vulnerable #patients w/ lepto (LMD) in #ClinicalTrials as a separate cohort. \n",
      "\n",
      "Now - how to enforce these guidelines?!\n",
      "\n",
      "#BCSM #LCSM #MelSM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "656\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "657\n",
      "-----\n",
      "Nicely presented data from @sloan_kettering by Dr. Kelly Bolton | Gene-specific effects of therapy on promoting pre-existing #CHIPsm in patients undergoing cancer therapy. Time to start thinking about prevention? #AACR20 #leusm\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "658\n",
      "-----\n",
      "#AACR20. Valuable thread by my friend &amp; #bcsm #advocacy colleague. Drs. @nlinmd, @EdKimMDLCI, I, &amp; others wrote about how to include ppl w/ #brainmets in #clinicaltrials (https://t.co/MDrlBP0EOP), &amp; #cnsmetsworkshop2019 was devoted to this topic. #drugdevelopment #regulatory https://t.co/StY3nbC3Bj\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "659\n",
      "-----\n",
      "Postcard #2 from #AACR20 with some commentary on new in cell therapies: https://t.co/M8o9a9qPtM\n",
      "Some interesting and different highlights today, which are not w/o controversy either! https://t.co/z2eP6h42KF\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "660\n",
      "-----\n",
      "Thank you @aacr for a fab #aacr20! What an achievement to take the annual meeting online and have such amazing participation. So refreshing to travel to a conference again, even if only virtually 😊 Can’t wait for round 2 in June 👏🏻👏🏻👏🏻 https://t.co/jM27zaNaRG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "661\n",
      "-----\n",
      "#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "662\n",
      "-----\n",
      "Thank you @aacr for a fab #aacr20! What an achievement to take the annual meeting online and have such amazing participation. So refreshing to travel to a conference again, even if only virtually 😊 Can’t wait for round 2 in June 👏🏻👏🏻👏🏻 https://t.co/jM27zaNaRG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "663\n",
      "-----\n",
      "Regarding response assessment, ctDNA exhibit more eminent clinical application. Exploratory analysis from FLAURA correlate ctDNA clearance w/ ⬆️PFS. Could a individualized approach w/ early ctDNA reassessment guide the decision of escalating or de-escalating treatment? #AACR20 https://t.co/qgv3RC5eq1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "664\n",
      "-----\n",
      "#Covid19 and #Cancer lecture in #AACR20 . #OncoAlert\n",
      "✅No anti-cancer treatment associated with higher mortality\n",
      "✅Patients treateted with ICI wer NOT more succeptible to infection\n",
      "✅patchy consolidation risk factor for severe events\n",
      "✅don´t forget cancer tx. https://t.co/zVXpumDKIv\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "665\n",
      "-----\n",
      "Evidence that supports TMB as a predictive biomarker is mounting, where studies in TMB-high tumors, such as melanoma or lung, reveal that elevated TMB have been associated with clinical benefit from #cancer immunotherapies. #AACR20 @d2merino https://t.co/xC1Qn0XzY9 https://t.co/pOfIKVU8s3\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "666\n",
      "-----\n",
      "#Covid19: First results from TERAVOLT registry for thoracic cancers show high mortality rate of COVID-19 in pats w/ thoracic malignancies. Mortality rate of COVID-19 in this group does not appear 2 b linked to specific treatmt/comorbidity. Video: https://t.co/QlXez9T5FB #AACR20 https://t.co/wPkHD6ouqF\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "667\n",
      "-----\n",
      "Presentan resultados de ensayo clínico CIMAvax en congreso de Asociación para la Investigación del Cáncer en #US. Resultados alentadores de combinar dos inmunoterapias novedosas. @centro_cim @RoswellPark https://t.co/ZjU38wpVMz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "668\n",
      "-----\n",
      "Collaboration #Cuba #US presenting encouraging results of #immunotherapy combination CIMAvax/nivolumab for the treatment of cancer. @centro_cim @RoswellPark\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "669\n",
      "-----\n",
      "Atezolizumab + enzalutamide not increasing OS or PFS (vs Enza alone) in prostate cancer (CRPC) - HR1.12. No subgroup appears to benefit and no long-term progressors. This seriously questions any role for ICIs in prostate cancer #AACR20 #prostatecancer https://t.co/VBx5PDu0bO\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "670\n",
      "-----\n",
      "The @CureMelanoma is grateful to @aacr for its great virtual meeting and the incredible #leadership of @CureMelanoma funded #melanoma #clinician #researcher Dr. Toni Ribas\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "671\n",
      "-----\n",
      "#AACR20 Important to know the spectrum of #KRAS and now the specific codons. #Clinicaltrials 🆕 for the #KRASG12C #AMG510 and other 💊. #CRCSM #PANCSM #LCSM #PrecisionMedicine \n",
      "Importance of co-occurring mutations. Interesting co-mutation patterns &amp; dependencies. Type-specific🧬. https://t.co/lZvYQjr0Aw\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "672\n",
      "-----\n",
      "Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "673\n",
      "-----\n",
      "another dataset suggesting patients with hematologic malignancies have higher risk from #COVID19\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "674\n",
      "-----\n",
      "#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "675\n",
      "-----\n",
      "Next \"new drug on the horizon\" is an oral SERD (Selective Estrogen Receptor Degrader), GDC-9545. Achieved same efficacy as other SERDs, but at a lower dose.\n",
      "\n",
      "Currently recruiting patients with #ER+ #MBC. \n",
      "\n",
      "#BCSM #AACR20 \n",
      "https://t.co/7aWgt2Bv60\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "676\n",
      "-----\n",
      "# ICI biomarker\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "677\n",
      "-----\n",
      "Ben Creelan, MD @MoffittNews : Interesting Phase 1 trial shows durable CRs to adoptive cell transfer using TILs in #NSCLC. Many patients were low/no PDL1 and had oncogene drivers. Looking forward to seeing future work in this area.   #AACR20 #lcsm #lungcancer @EGFRResisters https://t.co/16GBuyBez9\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "678\n",
      "-----\n",
      "@AmgenOncology @AACR A round of applause #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "679\n",
      "-----\n",
      "Thanks #AACR20 - It has been fantastic, I'm amazed of how such gigantic conference has adapted so quickly to the difficulties! I'm grateful for the new interactions and for the outlook of the field, the cancer research community stands strong! See you again in June! 😍\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "680\n",
      "-----\n",
      "Tune in today at #AACR20 Virtual Annual Meeting. Olivia Lee will be presenting her work at 4:25 PM on the genomic characterization of brain metastases across four different types of cancer, breast, lung, renal cell carcinoma, and melanoma. https://t.co/k7B9k6wbVe #NCI_ITEB https://t.co/XLQCf7XKaf\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "681\n",
      "-----\n",
      "Live #AACR20 Tweet by @ivybelkins \"Ben Creelan : Interesting Phase 1 trial shows durable CRs to adoptive cell transfer using TILs in #NSCLC. Many patients were low/no PDL1 and had oncogene drivers. Looking forward to seeing future work in this area\" @OncoAlert #LCSM #lungcancer https://t.co/CgbODPTlxo\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "682\n",
      "-----\n",
      "Another great talk at the #AACR20 Predictive Biomarkers for Immunotherapeutics session on the use of #ctDNA to predict outcomes from immunotherapies earlier than scans based on RECIST criteria. We are also exploring this through a #TumorINFORMED approach. https://t.co/5E4pY8R5fW\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "683\n",
      "-----\n",
      "Another great talk at the #AACR20 Predictive Biomarkers for Immunotherapeutics session on the use of #ctDNA to predict outcomes from immunotherapies earlier than scans based on RECIST criteria. We are also exploring this through a #TumorINFORMED approach. https://t.co/5E4pY8R5fW\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "684\n",
      "-----\n",
      "👏👏👏👏👏👏\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "685\n",
      "-----\n",
      "Nice presentation by Dr Sridhar (AstraZeneca) showing that tertiary lymphoid structures (assessed by gene signatures expression) are associated with response to anti-PD-L1 durvalumab in #NSCLC and UC, extending our results from soft tissue sarcoma and melanoma. #AACR20 https://t.co/ZWZ30ATRIF\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "686\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "687\n",
      "-----\n",
      "#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience https://t.co/IsqKfLCWo0\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "688\n",
      "-----\n",
      "Check out this video by the amazing Dr. @CharuAggarwalMD. \n",
      "\n",
      "#OncoAlert \n",
      "#AACR20 https://t.co/yT24gXd2OP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "689\n",
      "-----\n",
      "another dataset suggesting patients with hematologic malignancies have higher risk from #COVID19 https://t.co/MYzKfDjmng\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "690\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "691\n",
      "-----\n",
      "I love @itsnot_pink\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "692\n",
      "-----\n",
      "Thanks to our #AACR20 Influencers and everyone who tweeted about @AACR Virtual Annual Meeting I!  See you again June 22-24 for Virtual Meeting II. https://t.co/lYpbPajfXK\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "693\n",
      "-----\n",
      "Talk from #TRACERx about the use ctDNA in early stage lung cancer to predict patient relapse after surgery, correlating it with minimum residual disease:\n",
      "⬆️ pre-op ctDNA shedding associated with longer MRD lead-times and shorter DFS times post-op\n",
      "#AACR20 #AACR2020 #lcsm https://t.co/eqtjL1ypV1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "694\n",
      "-----\n",
      "Toni Ribas just announced a dedicated symposium on #COVID19nCancer in July by @AACR. \n",
      "#AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "695\n",
      "-----\n",
      "That wraps up #AACR20 Virtual Annual Meeting I. Thank you to everyone for following along and tweeting with us. https://t.co/9L1H0PhT4Y\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "696\n",
      "-----\n",
      "We just saw the data today at the #AACR20 virtual meeting showing = safety and efficacy of this different dosing for Pembro, and now its approved! Very timely given desire to decrease exposure to clinic/infusion centers during #COVID19. https://t.co/abkNgEzU9l\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "697\n",
      "-----\n",
      "“These data strongly support the importance of clinical testing for NTRK gene fusions in order to identify those patients most likely to benefit from larotrectinib,” says @DavidHongMD. \n",
      "\n",
      "Learn more about his study presented today at #AACR20. https://t.co/2Gg4fqwJ0r #endcancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "698\n",
      "-----\n",
      "Great discussion by Dr @jasonlukemd @UPMCHillmanCC on mech of immune-exclusion, T cell-inflamed tumors &amp; #immunotherapy #AACR20 @AACR Referenced paper for genomic changes &amp; immune infiltration @biorxivpreprint \n",
      "https://t.co/EyXwn5tQWx https://t.co/dbnDk7AoqO\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "699\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "700\n",
      "-----\n",
      "That wraps up #AACR20 Virtual Annual Meeting I. Thank you to everyone for following along and tweeting with us. https://t.co/9L1H0PhT4Y\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "701\n",
      "-----\n",
      "Dear Colleagues,\n",
      "Thank you for a great couple of days of science, all of us at @OncoAlert 🚨are very grateful for your support &amp; for helping in keeping colleagues worldwide #OncoAlert!! Thank you #AACR20 &amp; look forward to Part 2⃣.\n",
      "Ps. Numbers don't lie, this was a success! Kudos! https://t.co/F4edm9zrVC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "702\n",
      "-----\n",
      "Interesting strategy to confuse your competitors exemplified today in the New Drugs on the Horizon Session Part 2. Just show different structures for your clinical asset on different slides... (The structure shown on the one pager for TAK-788 is actually osimertinib 😆) #AACR20 https://t.co/9BzGbRQbhk\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "703\n",
      "-----\n",
      "@OncoAlert @BenWestphalen @weoncologists #AACR20 👆🏼#BRAF - one of my patients recently sent me this illustrating from a recent review the diversity of tumor types in which #BRAF mutations are seen as well as the spectrum of mutations (V600E 🆚 non-V600E); classifications of #BRAF mutations. #precisionmedicine https://t.co/Ls3p52ijEs\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "704\n",
      "-----\n",
      "Join the second session of #AACR20 on June 22-24 to hear more about how @UCCancerCenter researchers #AnswerCancer\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "705\n",
      "-----\n",
      "At #AACR20 Dr Creelan presented data on adoptive TIL therapy for NSCLC.  This is a very interesting approach - surgery of a metastatic lesion, ex vivo TIL expansion, nivolumab, lymphodepletion and TIL reinfusion with further nivolumab  #LCSM https://t.co/ECHtoEoJTG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "706\n",
      "-----\n",
      "CONGRESS | #AACR20 | Caron A Jacobson, @DanaFarber, presents results from ZUMA-6: axi-cel + atezolizumab for refractory DLBCL. ORR was 75% with a 46% CR rate and no significant increase in incidence of AEs #lymsm https://t.co/nARISEHLLb\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "707\n",
      "-----\n",
      "We are proud of our partners @MoffittNews for the advances they are making in immunotherapy treatments!\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "708\n",
      "-----\n",
      "Join the second session of #AACR20 on June 22-24 to hear more about how @UCCancerCenter researchers #AnswerCancer https://t.co/R7dl9qCs0S\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "709\n",
      "-----\n",
      "Predictive biomarker for #immunotherapy in #NSCLC #LCSM #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "710\n",
      "-----\n",
      "STOP patient shaming! If you must say “prevention”, consider using the more accurate phrase of “risk reduction.”\n",
      "\n",
      "As a vegetarian for 20 yrs, avid half marathoner, no history of #breastcancer, &amp; diagnosed #metastatic at 34- my cancer was not preventable.\n",
      "\n",
      "#BCSM #LCSM #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "711\n",
      "-----\n",
      "Read @TrendsinPharma \"The Interplay of the Extracellular Matrix and Stromal Cells as a Drug Target in Stroma-Rich Cancers\" by Muranen (@tarumurmur) and colleagues - https://t.co/SoHGL2ngoO - #CellPressOncology #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "712\n",
      "-----\n",
      "Now that we have technologies sensitive enough to catch relapse at the earliest stages, how do we interpret &amp; use the data generated? Really interesting work from AstraZeneca using longitudinal ctDNA dynamics to model and predict progression-free survival in NSCLC. #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "713\n",
      "-----\n",
      "New study by Crystal Mackall and colls shows intracerebroventricular- or intratumoral-administered #CARTcells exhibit greater therapeutic potency as compared to intravenous delivery, in atypical teratoid/rhabdoid tumor mouse models https://t.co/QnawGBnpQA #ChildhoodCancer #AACR20 https://t.co/WJWe6evIqB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "714\n",
      "-----\n",
      "We are proud of our partners @MoffittNews for the advances they are making in immunotherapy treatments! https://t.co/KOaugMsafY\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "715\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "716\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "717\n",
      "-----\n",
      "Missed #COVID19nCancer plenary in #AACR20 @AACR?\n",
      "Here’s a thread to catch up on all the fascinating global research presented by:\n",
      "@AACR @AACRPres #AntoniRibas #LiZhang @marinagarassino @barlesi #CarlosGomez #LouisVoigt #HongbingCai cc:@OncoAlert @COVID19nCCC @ASCO @ASH_hematology\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "718\n",
      "-----\n",
      "TAK-788 (#mobocertinib) in New Drugs on the Horizon at #AACR20. Just announced yesterday FDA Breakthrough designation for this drug for treating #exon20 #lungcancer patients, a subset of #NSCLC w/no approved treatment yet #AACR20 #lcsm @EGFRResisters @Exon20Group @TakedaOncology https://t.co/mgpGgUZPyd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "719\n",
      "-----\n",
      "Quite accurate- a statement @genomeboy1\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "720\n",
      "-----\n",
      "Tuned back into #AACR20 &amp; immediately learned something: \n",
      "Q: \"How do you determine cfDNA-shedder from cfDNA-non-shedder if without in-situ tumor data?\"\n",
      "A: \"It may not be a shedder/non-shedder question, it may be level of sensitivity of the test.\" \n",
      "cc: #lcsm #bcsm #crcsm #gyncsm\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "721\n",
      "-----\n",
      "Presentan resultados de ensayo clínico CIMAvax en congreso de Asociación para la Investigación del Cáncer en #US. Resultados alentadores de combinar dos inmunoterapias novedosas. @centro_cim @RoswellPark\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "722\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "723\n",
      "-----\n",
      ".@Amgen strives to address the unmet need for #prostatecancer patients. This includes investigating potential therapeutic targets such as STEAP1 which is over-expressed in more than 80 percent of prostate cancers. See data presented earlier today at #AACR20 https://t.co/9eGGWlLpM6\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "724\n",
      "-----\n",
      "As an aside, it's *very* exciting to see ctDNA assays being rationally and intentionally integrated into clinical trials.  Allows research to focus on the biology w/o struggling with tech limitations, etc in post-hoc analysis. #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "725\n",
      "-----\n",
      "Dinah Singer discusses @theNCI response to #COVID19. #AACR20 #coronavirus https://t.co/RD7Osgnm9D\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "726\n",
      "-----\n",
      "Dinah Singer discusses @theNCI response to #COVID19. #AACR20 #coronavirus https://t.co/wTLlwJNPfJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "727\n",
      "-----\n",
      "Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "728\n",
      "-----\n",
      "Coinciding with the #COVID19nCancer session at #AACR20, @CD_AACR has published the largest peer reviewed series (thus far) of #COVID19 in cancer patients (N=105 from China). \n",
      "Overall, a higher rate of complications is seen across the board. @tmprowell \n",
      "https://t.co/sgH7lEi0z6 https://t.co/32VGCKwx2u\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "729\n",
      "-----\n",
      "Coinciding with the #COVID19nCancer session at #AACR20, @CD_AACR has published the largest peer reviewed series (thus far) of #COVID19 in cancer patients (N=105 from China). \n",
      "Overall, a higher rate of complications is seen across the board. @tmprowell \n",
      "https://t.co/sgH7lEi0z6 https://t.co/32VGCKwx2u\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "730\n",
      "-----\n",
      "Those are two acronyms that on first glance cause me to cringr\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "731\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "732\n",
      "-----\n",
      "#Covid19: First results from TERAVOLT registry for thoracic cancers show high mortality rate of COVID-19 in pats w/ thoracic malignancies. Mortality rate of COVID-19 in this group does not appear 2 b linked to specific treatmt/comorbidity. Video: https://t.co/QlXez9T5FB #AACR20 https://t.co/wPkHD6ouqF\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "733\n",
      "-----\n",
      "As an #IM resident I am pleased to watch #AACR20 live stream virtual meeting while preparing my shift fighting #COVID19 🥊 Thank to all who is making this happen @AACR @Rick__Buck @AACRPres &amp; who increased awareness @cancerassassin1 @Aiims1742 @DrSGraff @tmprowell  @OncoAlert 👏🏻 https://t.co/Dj9U74w9Tm\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "734\n",
      "-----\n",
      "Atezolizumab + enzalutamide not increasing OS or PFS (vs Enza alone) in prostate cancer (CRPC) - HR1.12. No subgroup appears to benefit and no long-term progressors. This seriously questions any role for ICIs in prostate cancer #AACR20 #prostatecancer https://t.co/VBx5PDu0bO\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "735\n",
      "-----\n",
      "#AACR20 #COVIDnCancer - must work together and share experiences https://t.co/kMuMN4f65s\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "736\n",
      "-----\n",
      "Predictive biomarker for #immunotherapy in #NSCLC #LCSM #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "737\n",
      "-----\n",
      "Collaboration #Cuba #US presenting encouraging results of #immunotherapy combination CIMAvax/nivolumab for the treatment of cancer. @centro_cim @RoswellPark https://t.co/ZjU38wpVMz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "738\n",
      "-----\n",
      "Dr. Abbosh and Dr. Johnson use the nomenclature \"ctDNA shedders\" versus \"ctDNA non-shedders\" to differentiate between samples that test pos vs neg at baseline. Not sure how I feel about this as it entrains biological resp w/ LOD of the assay. What do others think? #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "739\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "740\n",
      "-----\n",
      "Larotrectinib shows 95% ORR in patients harboring NTRK1/2/3 gene fusions - would like to see such amazing waterfall plots for other targeted therapies. #AACR20 https://t.co/ufkGDvddCM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "741\n",
      "-----\n",
      "2020 #AACR #Virtual Meeting April 28, 2020 Symposium: New #Cancer #Drugs on the #Horizon Part 3 12:30-1:25 PM https://t.co/5unWXkynbW via @Pharma_BI @StephenJWillia2 \n",
      "@AACR @CureCancerNow @pharmanews @BiotechWorld\n",
      "@HopkinsMedicine #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "742\n",
      "-----\n",
      "#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "743\n",
      "-----\n",
      "New study by Crystal Mackall and colls shows intracerebroventricular- or intratumoral-administered #CARTcells exhibit greater therapeutic potency as compared to intravenous delivery, in atypical teratoid/rhabdoid tumor mouse models https://t.co/QnawGBnpQA #ChildhoodCancer #AACR20 https://t.co/WJWe6evIqB\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "744\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "745\n",
      "-----\n",
      "There was #cancer before the pandemic, there is cancer now, and there will be cancer after. Thankfully, some research continues. Progress toward off-the-shelf #CAR_T cells, from Shanghai #biotech, at #AACR20: https://t.co/YuVBfGVs5J\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "746\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "747\n",
      "-----\n",
      "#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "748\n",
      "-----\n",
      "Great coverage by Dr. Stephen J Williams\n",
      "@pharma_BI\n",
      "@AACR\n",
      "@CureCancerNow\n",
      "@pharmanews\n",
      "@BiotechWorld\n",
      "@HopkinsMedicine\n",
      "#AACR20\n",
      "@StephenJWillia2 https://t.co/vFFJH5myoz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "749\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "750\n",
      "-----\n",
      "Please join us June 22-24 for #AACR20 Virtual Annual Meeting II. There will be thousands of proffered papers covering the spectrum of cancer research presented in minisymposia and in an e-poster platform. https://t.co/uizEwfiVlG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "751\n",
      "-----\n",
      "Menin-MLL1 antagonists -- the hottest new kids on the targeted therapy block arrive at #AACR20 \n",
      "\n",
      "$SNDX +66%\n",
      "\n",
      "$KURA +33%\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "752\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "753\n",
      "-----\n",
      "Non-small cell lung cancers can acquire resistance to immunotherapy by producing soluble versions of PD-L1 that can prevent immune checkpoint blockade. JEM’s collection for #AACR20 (https://t.co/G1mQsS8hMp) has new short summaries of articles in this PDF: https://t.co/Hec3sCXXIr https://t.co/UCKI2AUIav\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "754\n",
      "-----\n",
      "Atezolizumab + enzalutamide not increasing OS or PFS (vs Enza alone) in prostate cancer (CRPC) - HR1.12. No subgroup appears to benefit and no long-term progressors. This seriously questions any role for ICIs in prostate cancer #AACR20 #prostatecancer https://t.co/VBx5PDu0bO\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "755\n",
      "-----\n",
      "Real Time Conference Coverage 2020 #AACR #Virtual Meeting April 28, 2020 Session on @NCI Activities: #COVID-19 and #Cancer #Research 5:20 PM https://t.co/73IEKNzUzQ via @Pharma_BI @pharma_BI\n",
      "@AACR @CureCancerNow @pharmanews @BiotechWorld\n",
      "@theNCI #AACR20 @StephenJWillia2\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "756\n",
      "-----\n",
      "Such an amazing presentation by an even more amazing postdoc mentor!\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "757\n",
      "-----\n",
      "The latest The Breast Cancer Daily! https://t.co/36TGpQlztz Thanks to @NJHenpointe #cancer #aacr20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "758\n",
      "-----\n",
      "The cyclic structure of Lorlatinib's makes for impressive performance as a tyrosine kinase inhibitor. TKIs are a major and growing area of drug development, accounting for ~20% (&gt;$9 billion) of the current oncology market. #AACR20 https://t.co/2Dj817cpHl\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "759\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "760\n",
      "-----\n",
      "Nice thread on the #ctDNA session at virtual #AACR20- thanks @pratt_ed #liquidbiopsy #earlydetection\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "761\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "762\n",
      "-----\n",
      "#AACR20 Virtual Annual Meeting I: Adoptive Cell Transfer Therapy Session. Ben Creelan presents results from a phase I trial. Durable complete responses to adoptive cell transfer using tumor infiltrating lymphocytes (TIL) in non-small cell lung cancer (NSCLC). https://t.co/CzRhFEQL6I\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "763\n",
      "-----\n",
      "Our @OncoAlert 🚨Colleague @CharuAggarwalMD 👩‍⚕️from @PennCancer  Virtually Live at #AACR20 discussing global🌏presentations dealing #COVID19 and #Cancer : #TERAVOLT from @marinagarassino 🇮🇹&amp; The French experience by @barlesi from @GustaveRoussy 🇫🇷\n",
      "Edited: @weoncologists https://t.co/yJXXuVGIJV\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "764\n",
      "-----\n",
      "#AACR20. Great news for people living with #cancer during #COVID19 #pandemic: pembrolizumab 400 mg every 6 wks granted accelerated approval by FDA today for all existing indications. #advocacy #PatientExperience\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "765\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "766\n",
      "-----\n",
      "#OncoAlert #AACR20 Long awaited data from TAK-788 (now mobocertinib) in #EGFR exon 20 #NSCLC - this is clearly an unmet need with poor outcomes achieved using standard EGFR TKIs or immunotherapy. TAK-788 has some promising features to help in this setting #LCSM https://t.co/43HKq137Sr\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "767\n",
      "-----\n",
      "At #AACR20 Dr Creelan presented data on adoptive TIL therapy for NSCLC.  This is a very interesting approach - surgery of a metastatic lesion, ex vivo TIL expansion, nivolumab, lymphodepletion and TIL reinfusion with further nivolumab  #LCSM https://t.co/ECHtoEoJTG\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "768\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "769\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "770\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "771\n",
      "-----\n",
      "Current session Covid-19 &amp; Cancer Clinical trials\n",
      "#AACR20 #coronavirus #gmfbrainbuddies https://t.co/wyk4ckgG0A\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "772\n",
      "-----\n",
      "Still not where we need to be in stufying pts w #brainmets despite so much effort. We need pharma &amp; coop groups to include these pts! #btsm\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "773\n",
      "-----\n",
      "#AACR20 💭I think integrating #ctDNA #liquidbiopsies is going to be the new paradigm shift in more efficient trial designs. If you chose 🩸🧬MRD➕subset of patients, especially for these adjuvant studies, sample size required would be a lot lower since event rate will be high📈. https://t.co/ltbTc4pISo\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "774\n",
      "-----\n",
      "#AACR20👇🏼#TwitterPoll ➡️ #COVID19 &amp; #Cancer #COVIDnCancer. \n",
      "Thoughts on minimizing surveillance visits or deciding on who could be spared or prioritized for chemo using #ctDNA #liquidbiopsies for #MinimalResidualDisease #MRD. Access programs available for #cancer ➕home-draw🩸🚑\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "775\n",
      "-----\n",
      "Dear Colleagues,\n",
      "Thank you for a great couple of days of science, all of us at @OncoAlert 🚨are very grateful for your support &amp; for helping in keeping colleagues worldwide #OncoAlert!! Thank you #AACR20 &amp; look forward to Part 2⃣.\n",
      "Ps. Numbers don't lie, this was a success! Kudos! https://t.co/F4edm9zrVC\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "776\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "777\n",
      "-----\n",
      "That wraps up #AACR20 Virtual Annual Meeting I. Thank you to everyone for following along and tweeting with us. https://t.co/9L1H0PhT4Y\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "778\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "779\n",
      "-----\n",
      "#AACR20👇🏼#TwitterPoll ➡️ #COVID19 &amp; #Cancer #COVIDnCancer. \n",
      "Thoughts on minimizing surveillance visits or deciding on who could be spared or prioritized for chemo using #ctDNA #liquidbiopsies for #MinimalResidualDisease #MRD. Access programs available for #cancer ➕home-draw🩸🚑\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "780\n",
      "-----\n",
      "👇🏼🩸🧪🧬 #ctDNA #LiquidBiopsies #AACR20 https://t.co/s5vsBWexSJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "781\n",
      "-----\n",
      "This was the structural disclosure many were waiting for at #AACR20 @AACR: Matthew LaMarche of @NovartisScience raising the curtain for clinical SHP2 inhibitor #TNO155. Structurally quite distinct from previous tool SHP099 in order to address phototox &amp; off-target liabilities https://t.co/iOeyie4nia\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "782\n",
      "-----\n",
      "Still not where we need to be in stufying pts w #brainmets despite so much effort. We need pharma &amp; coop groups to include these pts! #btsm\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "783\n",
      "-----\n",
      "Both Dr. Bauer &amp; Dr. Abbosh showed that ctDNA can be used to monitor emergent subclones, including those associated with chemoresistance. It will be interesting to see if #LiquidBiopsy can assist therapy selection to minimize resistance and/or control tumor genotype #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "784\n",
      "-----\n",
      "Thank you organizers of #AACR20 for an excellent virtual meeting, allowing us to access the greatest and latest research on #ctDNA in #cancer. Can’t wait to find out what’s in store for the second half of virtual #AACR2020 in June!\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "785\n",
      "-----\n",
      "You don't see the happy dance I do everytime I come across a new clinical trial for #MBC.  Currently recruiting if anyone meets the criteria...\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "786\n",
      "-----\n",
      "Just Out📣at @NEJM 📰In metastatic castration-resistant #prostatecancer that had disease progression while on enzalutamide or abiraterone &amp;had alterations in genes🧬w/a role in homologous recombination repair, olaparib was associated w/longer PFS‼️ #AACR20 https://t.co/UlM259rDgi https://t.co/xSv9nSagiN\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "787\n",
      "-----\n",
      "Menin-MLL1 antagonists -- the hottest new kids on the targeted therapy block arrive at #AACR20 \n",
      "\n",
      "$SNDX +66%\n",
      "\n",
      "$KURA +33%\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "788\n",
      "-----\n",
      "COVID19 and Cancer: 25% Lung Cancer #AACR20 https://t.co/rfpmaUQuUc\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "789\n",
      "-----\n",
      "Live Notes, Real Time Conference Coverage @AACR #AACR20 Virtual Meeting April 28, 2020 Session on #COVID-19 and #Cancer #China #France #Italy 9:00 AM @CureCancerNow #endcancer @sloan_kettering @marinagarissino @barlesi https://t.co/K3tezV8mx7 via @Pharma_BI\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "790\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "791\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "792\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "793\n",
      "-----\n",
      "I am pretty sure that this is the future of cancer screening early detection and more cures @GrailBio @MayoClinicCIM @MayoCancerCare\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "794\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "795\n",
      "-----\n",
      "Data presented at plenary session #AACR20 from @GustaveRoussy by @barlesi shows that use of targeted agents or immunotherapy are not correlated with worst #COVID19 outcome among cancer patients in contrast with chemotherapy https://t.co/z0VqqIJrMJ\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "796\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "797\n",
      "-----\n",
      "Presentan resultados de ensayo clínico CIMAvax en congreso de Asociación para la Investigación del Cáncer en #US. Resultados alentadores de combinar dos inmunoterapias novedosas. @centro_cim @RoswellPark https://t.co/ZjU38wpVMz\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "798\n",
      "-----\n",
      "#AACR20 Reminder that #WordsMatter. Just heard \"Many of our pts are metastatic.\" Pts don't metastasize. Tumors do. Pts are not their disease so: \"Many of our pts have metastatic dz.\" See our lang of respect guide for all speakers at #ASCO20: https://t.co/ne7tIMJLDC #advocacy https://t.co/ZmDYDXNbIP\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "799\n",
      "-----\n",
      "An important point made during Q&amp;A of Dr. Bauer's talk: tumor evolution is *not* unidirectional. There is evidence of tumor reversion to earlier genotypes in order to circumvent 2nd line+ therapies. #AACR20 Two examples in BCa ▶️\n",
      "https://t.co/eUicrhQsVA\n",
      "https://t.co/v3aSZUxTXf\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "800\n",
      "-----\n",
      "Larotrectinib shows 95% ORR in patients harboring NTRK1/2/3 gene fusions - would like to see such amazing waterfall plots for other targeted therapies. #AACR20 https://t.co/ufkGDvddCM\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "801\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "802\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "803\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba https://t.co/go7X6uDbsd\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "804\n",
      "-----\n",
      "In a large Swedish cohort (&gt;3,000), 1.1% of early ER+ breast cancer presented de novo ESR1 mutations (E380Q most frequent), before any treatment. Patients had 4-fold higher relapse risk, 2-fold worse OS. Thanks Dr. Malin Dahlgren #AACR20 #bcsm Should we screen for this mut?\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "805\n",
      "-----\n",
      "Dr Marina Garassino @marinagarassino presenting data from #TERAVOLT evaluating #COVID19 and lung cancer #LCSM \n",
      "Results overlapping with our own institutional experience recently spread via #SoMe #AACR20 @AACR @OncoAlert #OncoAlert @IASLC @gecp_org https://t.co/zcglqIyYow\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "806\n",
      "-----\n",
      "35% décès des patients avec cancer du poumon hospitalisés avec COVID. On se doit de tout faire pour protéger ces patients. #AACR20\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "807\n",
      "-----\n",
      "Instituto Roswell Park de #EEUU, asociado con @BioCubaFarma para investigación, desarrollo y producción de medicamentos, presenta prometedores resultados de ensayo clínico en congreso sobre oncología. Otra demostración del prestigio de nuestra industria farmaceutica. #SomosCuba\n",
      "\n",
      "\n",
      "\n",
      "\n",
      "808\n",
      "-----\n",
      "#OncoAlert #AACR20 Analyses to identify risk factors for severe events such as recent anti-cancer therapy (14d), radiographic findings. IO therapy not a clear risk. Numbers though are small and this is where large ongoing registries (such as #TERAVOLT) will help with perspective. https://t.co/XTfdNTdJqB\n",
      "\n",
      "\n",
      "\n",
      "\n"
     ]
    }
   ],
   "source": [
    "my_dict=[]\n",
    "index_list=[]\n",
    "name_list=[]\n",
    "date_list=[]\n",
    "val=1\n",
    "for x in data:\n",
    "    print(str(val)+'\\n-----')\n",
    "    if 'retweeted_status' not in x:\n",
    "        if 'extended_tweet' not in x:\n",
    "            y=x['text']\n",
    "            print(y)\n",
    "        else:\n",
    "            y=x['extended_tweet']['full_text']\n",
    "            print(y)\n",
    "    else:\n",
    "        if 'extended_tweet' not in x['retweeted_status']:\n",
    "            y=x['retweeted_status']['text']\n",
    "            print(y)\n",
    "        else:\n",
    "            y=x['retweeted_status']['extended_tweet']['full_text']\n",
    "            print(y)\n",
    "    print('\\n\\n\\n')\n",
    "    my_dict.append(y)\n",
    "    index_list.append(val)\n",
    "    name_list.append(x['user']['name'])\n",
    "    date_list.append(x['created_at'])\n",
    "    val+=1\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 50,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd\n",
    "columns=[\"Index\",\"Date\",\"Name\",\"Tweet\"]\n",
    "my_df=pd.DataFrame(columns=columns)\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 54,
   "metadata": {},
   "outputs": [],
   "source": [
    "my_df['Index']=index_list\n",
    "my_df['Date']=date_list\n",
    "my_df['Name']=name_list\n",
    "my_df['Tweet']=my_dict"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 60,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Index</th>\n",
       "      <th>Date</th>\n",
       "      <th>Name</th>\n",
       "      <th>Tweet</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>Tue Apr 28 19:43:03 +0000 2020</td>\n",
       "      <td>Yale OCR</td>\n",
       "      <td>Promising research for #braincancer #coloncanc...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2</td>\n",
       "      <td>Tue Apr 28 19:43:07 +0000 2020</td>\n",
       "      <td>Sanjay Popat</td>\n",
       "      <td>#OncoAlert #AACR20 Chemotherapy within the pas...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>3</td>\n",
       "      <td>Tue Apr 28 19:43:10 +0000 2020</td>\n",
       "      <td>Dr. Arturo Loaiza-Bonilla, MD MSEd</td>\n",
       "      <td>#AACR20 🩸🧬🧪ability to predict PFS. With the sh...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>4</td>\n",
       "      <td>Tue Apr 28 19:43:36 +0000 2020</td>\n",
       "      <td>Paula Mulvenna</td>\n",
       "      <td>Live #AACR20 Tweet by @LizCancerHealth  \"Hongb...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>5</td>\n",
       "      <td>Tue Apr 28 19:43:52 +0000 2020</td>\n",
       "      <td>Pashtoon Kasi MD, MS</td>\n",
       "      <td>#AACR20 💭I think integrating #ctDNA #liquidbio...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>...</th>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "      <td>...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>803</th>\n",
       "      <td>804</td>\n",
       "      <td>Wed Apr 29 00:32:36 +0000 2020</td>\n",
       "      <td>Mauricio Z. Baptista</td>\n",
       "      <td>In a large Swedish cohort (&amp;gt;3,000), 1.1% of...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>804</th>\n",
       "      <td>805</td>\n",
       "      <td>Wed Apr 29 00:32:49 +0000 2020</td>\n",
       "      <td>Clarisse Audigier-Valette</td>\n",
       "      <td>Dr Marina Garassino @marinagarassino presentin...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>805</th>\n",
       "      <td>806</td>\n",
       "      <td>Wed Apr 29 00:33:26 +0000 2020</td>\n",
       "      <td>Clarisse Audigier-Valette</td>\n",
       "      <td>35% décès des patients avec cancer du poumon h...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>806</th>\n",
       "      <td>807</td>\n",
       "      <td>Wed Apr 29 00:34:00 +0000 2020</td>\n",
       "      <td>Margarita</td>\n",
       "      <td>Instituto Roswell Park de #EEUU, asociado con ...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>807</th>\n",
       "      <td>808</td>\n",
       "      <td>Wed Apr 29 00:34:30 +0000 2020</td>\n",
       "      <td>Clarisse Audigier-Valette</td>\n",
       "      <td>#OncoAlert #AACR20 Analyses to identify risk f...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>808 rows × 4 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     Index                            Date  \\\n",
       "0        1  Tue Apr 28 19:43:03 +0000 2020   \n",
       "1        2  Tue Apr 28 19:43:07 +0000 2020   \n",
       "2        3  Tue Apr 28 19:43:10 +0000 2020   \n",
       "3        4  Tue Apr 28 19:43:36 +0000 2020   \n",
       "4        5  Tue Apr 28 19:43:52 +0000 2020   \n",
       "..     ...                             ...   \n",
       "803    804  Wed Apr 29 00:32:36 +0000 2020   \n",
       "804    805  Wed Apr 29 00:32:49 +0000 2020   \n",
       "805    806  Wed Apr 29 00:33:26 +0000 2020   \n",
       "806    807  Wed Apr 29 00:34:00 +0000 2020   \n",
       "807    808  Wed Apr 29 00:34:30 +0000 2020   \n",
       "\n",
       "                                   Name  \\\n",
       "0                              Yale OCR   \n",
       "1                          Sanjay Popat   \n",
       "2    Dr. Arturo Loaiza-Bonilla, MD MSEd   \n",
       "3                        Paula Mulvenna   \n",
       "4                  Pashtoon Kasi MD, MS   \n",
       "..                                  ...   \n",
       "803                Mauricio Z. Baptista   \n",
       "804           Clarisse Audigier-Valette   \n",
       "805           Clarisse Audigier-Valette   \n",
       "806                           Margarita   \n",
       "807           Clarisse Audigier-Valette   \n",
       "\n",
       "                                                 Tweet  \n",
       "0    Promising research for #braincancer #coloncanc...  \n",
       "1    #OncoAlert #AACR20 Chemotherapy within the pas...  \n",
       "2    #AACR20 🩸🧬🧪ability to predict PFS. With the sh...  \n",
       "3    Live #AACR20 Tweet by @LizCancerHealth  \"Hongb...  \n",
       "4    #AACR20 💭I think integrating #ctDNA #liquidbio...  \n",
       "..                                                 ...  \n",
       "803  In a large Swedish cohort (&gt;3,000), 1.1% of...  \n",
       "804  Dr Marina Garassino @marinagarassino presentin...  \n",
       "805  35% décès des patients avec cancer du poumon h...  \n",
       "806  Instituto Roswell Park de #EEUU, asociado con ...  \n",
       "807  #OncoAlert #AACR20 Analyses to identify risk f...  \n",
       "\n",
       "[808 rows x 4 columns]"
      ]
     },
     "execution_count": 60,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "my_df"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [],
   "source": [
    "my_df.to_csv('umair.csv', encoding='utf-8', index=False)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.7.5"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
